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suggest a risk factor close to 6 for non-cardia cancer. This study also 
found the highest risk, 10 or more years, after infection6. The most 
impressive study is a Japanese one, after resection of (very) early 
cancer, 0/280 uninfected versus 36 of 1246 infected patients developed 
gastric cancer7,8. Data from nonrandomised eradication studies 
suggest that between 40 and 80% of cancers can be prevented9. A 
number of randomised studies have recently been reviewed and a 
meta-analysis has been done on those data10. Of these 7 studies 6 
were Asian. This might influence the applicability of the conclusion 
to the Western situation, but there is no clear evidence that this is 
the case for non-cardia especially intestinal histology cancer. Over 
6500 patients were randomised; in the combined control groups the 
cancer incidence was found to be 1.7%, in the eradication group the 
incidence was reduced to 1.1%. The low cancer rate explains why the 
individual studies did not result in significant differences. In terms 
of risk reduction this meta-analysis found 35% reduction, with a 95% 
confidence interval of 57-2%.
Clearly there does not seem to be much perspective for a definitive 
randomised study as sham eradication would not be acceptable. 
There are some side effects from antibiotic eradication, such as 
resistance of the target and other microbes, allergy and colitis in 
patients. In addition an eradication procedure leaves the possibility 
of re-infection. In the western population data on children indicate 
an incidence of 2% reinfection11. In the light of the obvious failure of 
the immunological system to clear the infection, this low percentage 
is amazing. Such re-infections can occur with the subtype of relative 
antibiotic resistant H. Pylori strains, but more often are the result 
of recrudescence (recolonization with the same strain)12. Because 
of side effects of antibiotics and these recurrences, the development 
of a vaccine, as has been done with Human Papillomavirus (hpv) 
seems a logical step, and might be cost-effective even in developed 
countries13,14. However progress in immunization against H. Pylori is 
awaiting the availability of all relevant antigens. Furthermore the site 
of response, the gastric mucosa and its strong acidity is not a common 
environment for vaccination15.
In conclusion the available data suggest that up to 80% of distal gas-
tric cancers are attributable to H. Pylori and therefore preventable. 
While in the past this would have required endoscopy it has now 
been established that serological detection is adequate16. The cost of 
this procedure would be minimal compared to almost all screening 
and intervention programs, the potential rewards would only be 




For most patients with gastric cancer cure remains elusive. Therefore 
better preventive, diagnostic and therapeutic options are a priority 
as gastric cancer remains the second leading cause of cancer related 
death worldwide1, only surpassed by lung cancer. 
The development of gastric cancer is considered to be an interplay 
of bacterial, environmental and host factors. Known risk factors for 
developing gastric cancer such as high salt intake, smoking and 
Helicobacter Pylori (H. Pylori) infection are diminishing due to 
lifestyle modifications. In case of H. Pylori infection however preva-
lence is still as high as 60% in Asia and approximately 30-40% in the 
Western European population2. Other risk factors, such as obesity 
and gastro-oesophageal reflux become more prevalent and change 
the spectrum of gastric cancers, resulting in more proximal tumours. 
These differences in incidence of environmental risk factors explain 
part of the geographic variations in gastric cancer3. 
For the following decades is has to be expected that the majority of 
patients, especially in the western world, still will present with an 
advanced stage of disease. In an attempt to improve outcome several 
combined treatment modalities in adjuvant and neoadjuvant setting 
have been applied. Although progress has been made, due to these 
interventions, outcome still is poor, urging the need for predictive 
markers to permit tailored therapy.
Therefore this review focuses on some perspectives in the prevention 
and treatment of gastric cancer.
Prevention
A potentially large step can be made if the data on the perspective 
of eradication of H. Pylori, which is still highly prevalent worldwide, 
live up to expectation. H. Pylori infection is considered to be acquired 
in early childhood. Due to migration, H. Pylori infection will become 
more equally distributed between currently so called low incidence 
(developed) and high incidence (undeveloped) countries4. 
A large database supports the concept of H. Pylori as an essential 
step in the development of distal gastric cancer. In essence the 
studies can be divided in observational studies, case control studies 
and eradication studies. Case control studies give increase of gastric 
cancer incidence around 1.8 fold5. Comments on this analysis usually 
express the opinion that this is an underestimation of the real 
incidence because signs of infections are missed if time between 
infection and diagnosis of cancer increases. A combined analysis of 
nested case control studies, 12 studies in over 1200 cancer patients 
10
Staging
Most patients, especially in the western world, will not present with 
an early stage of disease. In the setting of more advanced disease the 
therapeutic options are either to operate or not. Local or systemic 
progression will prevent curative surgery.  The established diagnos-
tic modality of choice for local staging is the endoscopic ultrasound 
(eus). Sensitivity and specificity for assessing serosal involvement 
varies between 77.8%-100% and 67.9%-100%, respectively29. However 
this technique also has limitations like inadequate staging in case of 
stenosis, limited penetration to access distant spread and the need to 
be invasive with use of sedation. Promising alternatives are multi-
detector row computed tomography (mdct) using virtual gastroscopy, 
and parallel imaging magnetic resonance imaging (pi mri). In a 
recent review the diagnostic accuracy in local staging and assessing 
serosal involvement was similar between eus, mdct and pi mri29. 
However it is to be expected that with further improvement of mdct 
and or pi mri these techniques could overcome eus. For the detection 
of distant metastasis Computed Tomography (ct) is standard. As 
already is the case in other cancers further improvement is expected 
by using Positron Emission Tomography (pet)-ct images30. New trac-
ers, like 3-deoxy-3-18F-fluorothymidine (flt) tracer might prove to 
be a superior combination with ct. A study by Hermann, in patients 
with gastric cancer (60% signet cell carcinoma) showed that com-
pared to fdg this tracer has a higher sensitivity in detecting gastric 
cancer31. The highest accuracy to detect peritoneal involvement 
remains diagnostic laparoscopy as sensitivity of both ct scan and pet 
scan still are low32,33.
Surgical Treatment
In selected cases, patients with tumours confined to the mucosa or 
superficial submucosa are amenable for minimal invasive resection 
techniques. Much experience with endoscopic mucosal resection 
(emr) exist in the Asian world, were many people are diagnosed with 
early gastric cancer. More recently the en bloc curative resection rate 
and recurrence free rate by using endoscopic submucosal dissection 
(esd), instead of emr, was reported to be higher, at the expense of 
more bleeding and perforations34. Laparoscopic gastrectomy may 
cause less morbidity and is claimed to achieve acceptable oncological 
long term results compared to conventional surgery by some35,36.
For the following decade however conventional surgery will remain 
standard of care to achieve cure in patients with gastric cancer. The 
five-year survival rate after curatively intended surgery still is disap-
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smoking habits, but should come close to those of hpv vaccination 
schemes.
Early detection
Some patient groups remain at risk for developing gastric cancer, 
with or without eradication of Helicobacter Pylori. Patients with 
chronic atrophic gastritis, a precursor lesion of intestinal type cancer, 
which can develop in patients with pernicious anaemia, are by some 
authorities advised to have endoscopic screening17. This is also 
sometimes recommended to patients after partial gastrectomy or in 
populations at risk such as those with familial adenomatous polyposis 
or hereditary nonpolyposis colorectal cancer18-20. 
Nationwide screening in high gastric cancer incidence areas, such as 
northeast Asia, is assumed to be cost-effective by some21. Moreover 
the early detection of gastric cancer is considered to explain the de-
cline of mortality by a few observational and uncontrolled trials22-24. 
However selection bias, lead and length time bias in these studies 
must be acknowledged. These nationwide screening programs mostly 
include barium x-ray, sometimes combined with H. Pylori and serum 
pepsinogeen testing. In case of abnormalities these tests are followed 
by endoscopy25.
Endoscopy will remain the method of choice for primary diagnosis. 
Some improvements have been made in diagnostic optics aiming at 
detection of mucosal abnormalities, like chromoendoscopy, magni-
fication narrow band imaging and confocal laser endomicroscopy26. 
New non-invasive methods to detect digestive tract carcinoma are 
being developed. In colorectal cancer the use of faecal occult blood 
test (fobt) is common but its use is limited because of false positive 
results due to occult bleeding of benign sources. Further research in 
tumour specific changes in faeces dna in colorectal cancer recently 
led to the discovery of aberrant methylation of rassf2 and sfrp2 
promotors, also in patients with gastric cancer27. These kind of 
assays are promising non-invasive techniques for early detection of 
cancer in the digestive tract. 
The small group of patients with hereditary diffuse gastric cancers 
because of a germline cdh1 mutation is today more readily recognised. 
These cdh1 mutation carriers have a high life time risk of developing 
gastric cancer estimated >80% and therefore pre-emptive total gast-
rectomy is often warranted. Although often not detected at screen-
ing, in most cases intramucosal foci of adenocarcinoma are found in 
the operation specimen and patients are curatively treated28.
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is a combination of platinum and fluoropyrimidine derivates with 
epirubicin. Compared to mono chemotherapy a better response 
rate and a modest survival benefit are achieved, at the expensive of 
increased toxicity45.
New systemic treatment options 
Pre-operative treatment 
In the magic trial 86% of the patients completed the first preoperative 
3 cycles, however only 55% of the patients started and 42% could 
complete the post-operative chemotherapy43. The ffcd 9703 trial 
supports the importance of the preoperative treatment as 2-3 cycles 
of preoperative 5- fluorouracil/cisplatin improves disease-free and 
overall survival in patients with resectable adenocarcinoma of gastric 
and lower oesophagus46. Therefore a logic strategy to improve the 
overall survival might be to optimize the preoperative chemothera-
peutic regimen, but this should not result in a more toxic regimen. 
Based on potent chemotherapeutic drugs the most effective regimen 
in the metastatic setting was an ecf based regimen as is showed in 
the systematic review of Wagner45. This regimen is evaluated in the 
magic study with a response rate combined with stable disease of 
~55 %, meaning that progressive disease after 2-3 cycles will occur in 
~45% of the patients and delayed surgery might affect these patients 
with an incomplete resection43. In conclusion, more active preopera-
tive regimens are necessary.  One option is the addition of preopera-
tive radiotherapy as is shown to be active in oesophageal cancer47. 
This regimen is currently evaluated in patients with gastric cancer 
in a phase I/II study in our centre (Metc 2006/162). Another option 
to achieve a more active preoperative regimen will be the addition 
of new targeted agents, for example trastuzumab in patients with a 
Her-2 positive gastric cancer (~20% of the patients). The addition of 
this agent showed to be active in patients with metastatic gastric 
cancer with a response rate of 47%48. Lapatinib can target besides 
the Her-2 receptor the epidermal growth factor receptor (egfr). No 
clinical data so far with lapatinib are available, but several phase II 
studies are ongoing and a phase III study with oxaliplatin/capacit-
abine +/- lapatinib has been initiated49. Bevacizumab a monoclonal 
antibody with a defined activity in tumours as metastatic colorectal 
cancer and breast cancer also seems to be an attractive new agent in 
patients with gastric cancer. In the perioperative setting ecf +/- 
bevacizumab is evaluated in a phase II/III setting. However until now 
the phase III study (avagast) did not demonstrate an increased disease 
free survival when adding bevacizumab to capecitabine or 5-fu and 
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pointingly low, 40% or less, compared to 70% or more in patients 
with early stage gastric cancer37,38.
Recently an update on extensive lymph node dissection of the Dutch 
gastric cancer trial was published39. The controversy on survival 
benefit of extended lymphadenectomy seems closed, as results now 
indicated a significant survival advantage, be it at the cost of increased 
morbidity. Probably surgical experience is a major gateway to im-
provement in this respect.
Standard systemic therapy 
Due to the disappointing results of surgery alone to establish cure, 
efforts have been made to improve outcome by adding neo- and or 
adjuvant chemotherapy and/or radiation therapy. 
In Japan especially, adjuvant chemotherapy is routinely administrated, 
however results of randomized studies showed conflicting results40,41. 
New information on targeting agents however may revive this concept. 
Based on a large American Intergroup trial, demonstrating a signifi-
cant survival benefit of adjuvant chemoradiotherapy, this strategy 
is currently used in the usa as standard treatment42. But in many 
other parts of the world this treatment schedule is not followed, as no 
survival advantage was demonstrated in patients receiving optimal 
surgery. In these countries, peri-operative chemotherapy based on 
the magic trial is considered to be the preferred treatment strategy 
in patients with resectable gastric cancer43. Peri-operative chemo-
therapy consisted of three cycles epirubicin, cisplatin and infusional 
5-fluorouracil (ecf) preoperatively and three cycles ecf postopera-
tively. This resulted in a five-year survival of 36% in the ecf group 
compared to 23% in the surgery-only group. Today this strategy is 
slightly converted to the epirubicin, oxaliplatin, capecitabine (eox) 
regimen, after the data of the real-2 study showed in the metastatic 
setting comparable results of eox and ecf. eox is therefore often seen 
as an alternative standard outpatient peri-operative chemotherapeutic 
regimen without need for continuous infusion44. For the future it 
seems unlikely that changes between currently available drugs will 
improve results. 
The standard treatment in patients with inoperable gastric cancer 
and a good performance is palliative chemotherapy which can in-
crease the median overall survival with 3-6 months compared to the 
best support of care45. Accepted chemotherapeutic drugs are platinum 
derivates (cisplatin,oxaliplatin), fluoropyrimidines (5fu, capecitabine, S1, 
uft), anthracyclines (doxorubicin, epirubicin), taxotere and irinotecan. 
The most common used regimen in patients with a good performance 
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Adjuvant chemotherapy for a 3 cm tumour in the breast with 3 
positive lymph nodes leads to a reduction of the risk of death of 
approximately 30% and of relapse of 40%. In colon cancer this reduc-
tion is 50% respectively 60%. However the risk reduction of neo-
adjuvant chemotherapy in gastric cancer is only 13% for death and 
28% for relapse43. Adjuvant treatment has even lower effects. As a 
consequence adjuvant treatment for gastric cancer is limited to the 
pre operative setting while it is standard practise in the post operative 
setting of treatment of early colon or breast cancer.
Probably these data mean that only certain cell types in gastric cancer 
are sensitive to chemotherapy. It would save numerous events of 
toxicity if a selection could be made of patients who would be likely 
to benefit from treatment based on sensitivity for chemotherapy.
Predictive testing has long been a holy grail in medical oncology. 
Although cell growth systems exposed to chemotherapy, like the 
Salmon assay55, had some merits in predicting failure of treatment, 
these systems never have had an impact on clinical practise. There 
has been a long history of research into prediction of tumour response 
by analysis of cellular markers considered to be related to the action 
of chemotherapeutic drugs.  The impact of finding such markers 
would be considerable, at first they could be used to deselect patients 
for toxic interventions, but the perspective of finding active drugs or 
combinations is alluring.
In gastric cancer a wide spectrum of drugs is used, leading to count-
less combinations of which no superior regimen has emerged.
A common final pathway of cancer cell death is apoptosis, controlled 
by the P53 gene product. Numerous studies have tried to relate 
tumour sensitivity to the amount or activity of this protein. However 
the real importance of the gene for particular clinical situations re-
mains enigmatic. Recently an analysis at the level of polymorphisms 
suggested again that a less effective P53 protein could indeed be 
related to less effect of the treatment in gastric cancer56. In many 
earlier studies interpretation may be hampered by a merely quanti-
tative analysis of the protein.
Activity of platinum derived drugs has commonly been associated 
with the presence of detoxifying enzymes such as the glutathione 
transferring proteins. This enzyme has a long history in research 
aimed at prediction or manipulation of response to platinum. Again 
recent studies incorporating polymorphism analysis suggested a 
relation between effect of platinum based regimens in gastric cancer 
and ineffective conjugation57. Comparable data were generated by 
the group of Goekkart58. Still the results of this new approach await 
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cisplatin in patients with inoperable gastric cancer50. 
Cetuximab, an antibody directed against the egfr receptor demon-
strated to be effective in head and neck cancer and colorectal cancer. 
In colorectal cancer this antibody is clinically effective in 50 percent 
of the tumours with a wild-type K-ras. Almost all patients with gastric 
cancer posses a wild-type K-ras. A phase II study in combination with 
standard chemotherapy in patients with advanced gastric cancer in 
46 patients showed a response rate of 65% (95% Convidence Interval 
(ci), 50–79%) including four complete responses51. Based on these 
promising findings, phase III clinical trials have been initiated in 
patients with advanced gastric cancer. 
Post-operative treatment 
To improve the post-operative setting, an adjuvant treatment should 
be relatively non-toxic, to enable start probably within 6 weeks after 
surgery, as in many tumour types a delayed adjuvant treatment 
showed to be less effective52. Many randomized trials, with and 
without adjuvant combination chemotherapy, in patients with 
resected gastric cancer did not give an unambiguous answer in its 
effect on survival. The trials performed in Asia are mainly positive 
and the trials performed in others countries grossly showed no effect 
on survival40,53. Some factors responsible for these finding are the 
relative small studies, and the fact that in many trials the planned 
dose could postoperatively not be administrated. Based on this last 
mentioned item relative non-toxic effective regimens are needed to 
improve the adjuvant treatment. In this context trastuzumab as a 
targeted drug might be interesting as this showed to be effective in 
the metastastic setting in patients with Her2 positive tumours and 
already proved to prolong survival as adjuvant treatment in patients 
with breast cancer48. Another promising approach is to start with 
3 courses of ecf followed by surgery and adding relative non-toxic 
new targeted drugs in the adjuvant setting. This strategy is currently 
applied in a study with preoperative oxaliplatin/5fu/erlotinib and 
radiotherapy followed by surgery and adjuvant erlotinib54.
Future perspectives toward selection of patients for (specific) 
systemic therapy by molecular paradigms
Compared to other common tumours such as colon cancer or breast 
cancer, chemotherapy effects on gastric cancer are limited. This can 
be illustrated by using common systems of analysis of risk of death 
or disease progression for these tumours, and the reduction of these 
risks due to chemotherapy (www.adjuvantonline.com, www.mskcc.org). 
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cancer cells. The role model for these markers is the cKit mutation in 
gastro-intestinal stroma cell tumours. A most relevant recent develop-
ment is the clinical evidence of activity of trastuzumab in Her-2/Neu 
overexpressing gastric cancers.  Overexpression is present in 20% of 
gastric tumours, mainly of the intestinal type68. The presence of this 
marker was associated with a worse prognosis69,70. In these studies 
this marker is usually considered as a prognostic marker, however 
many patients received chemotherapy in the course of their disease.  
This consideration is relevant as this amplification will in the future 
determine the selection of patients for trastuzumab therapy.
The identification of new targets to develop new drugs is essential 
to improve the outcome of gastric cancer. Based on our current 
cellular and environmental knowledge targets can be divided at the 
level of: the dna, cell cycle, epigenetically, growth signalling pathway 
and the cellular environment with angiogenesis and immunology. At 
the dna level and cell cycle level drugs as cisplatin and taxotere are 
well known.  A new target is parp an enzyme called poly(adp-ribose)
polymerase-1, which helps in detection and repair of dna strand 
breaks. Inhibitors of parp showed promising efficacy in patients 
with brca breast cancer71 and studies are currently being performed 
in other solid cancers as gastric cancer. At the epigenetic level an 
increased expression of histone deacetylase (hdac) is found in gastric 
cancer72. Vorinostat a drug targeting hdac is currently evaluated in 
gastric cancer73. At the growth signalling pathway many drugs are 
evaluated. In gastric cancer hsp90, a chaperone of many signalling 
pathway molecules as Her2/Neu, egfr and igfr1, is elevated. auy922, 
a hsp90 inhibitor is evaluated in a phase II study in gastric cancer74. 
Angiogenesis as a relative new well known target in the last 10 years 
is evaluated in gastric cancer in more than 2000 studies (www.trial.
gov). A less known target in gastric cancer is the immunological 
environment. Due to H. Pylori this can be impaired, as Anderson in 
2006 showed that ctla-4 engagement induces and maintains func-
tional inactivation of H. Pylori-specific T cells75. Therefore antibodies 
as ipilimumab inhibiting the inhibiting effect of ctla4 might be 
effective in gastric cancer. Promising results with ctla-4 inhibition 
in patients with metastatic melanoma were recently published76. 
Studies in gastric cancer blocking the ctla4 are ongoing. 
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confirmation as older studies have resulted in conflicting data59.
Doxorubicin like drugs are dependent in their effect on the presence 
of topoisomerase 2 (topo2), and will be hampered by overexpression 
of the P glycoprotein (PgP). An overexpression or amplification of 
topo2 were associated with a highly significant survival advantage 
in a study using high dose 5fu as a second line “rescue” treatment,  
even if it remained unclear if topoisomerase directed drugs were 
used  in addition60. However other studies do not readily confirm 
this result61.  In an earlier review Pommier concluded that no defini-
tive value to topoisomerase levels as predictor could be ascribed62. 
Probably a confounding factor in all of these studies is that changes 
in topo2 genes are often part of a complex in changes in the Erbb2 
complex, where amplification or overexpression can lead to deletion 
as well as overexpression of topo2. In those situations the Erbb2 status 
might surmount any effects of topo2 status. Related to topoisomerase 
expression in cancer cells is the over expression of PgP affecting drug 
efflux from the cell. Choi found however no relation with survival 
or time to progression after adjuvant chemotherapy with PgP over-
expression63. 
Many protein markers or their genes have been in studied in relation 
to 5fu or its many derivatives. One of the most obvious candidates is 
dihydropyrimidine dehydrogenase (dpd) as its (relative) absence 
modulates the levels of active metabolites of 5fu. However dpd 
deficiency does not increase 5fu efficiency in coloncancer patients64. 
As dpd deficiency is not easily missed clinically, an impact in gastric 
cancer treatment seems unlikely. The same lack of correlation is 
found for another key enzyme of 5fu activity; Thymidilate Synthase 
(ts)65,66. No clear verdict is also possible concerning oratate phos-
phoribosyltransferase (oprt) as most data are limited to in vitro 
studies, or in the case of a positive study correlated with the use of 
S1 particular to the Japanese situation67.
In retrospect the studies aimed at predictors of response to chemo-
therapy have largely been unsuccessful. With most of the markers 
described above these results might be related to the usually purely 
quantitative analysis of the proteins involved. The studies using 
polymorphism analysis might give a new impulse in this field. A 
second problem particular in case of gastric cancer is that the effect 
of chemotherapy is limited and not related to a limited group of 
drugs. In this situation very large numbers of treatments have to be 
analysed to find meaningful correlations. Prediction of response in 
solid tumour oncology has entered a new era with the introduction 
of drugs that are directly aimed at effects of genetic changes in 
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mastectomy needs to be considered. The relation-
ship between cl/p and cdh1 needs further study 
to inform future parents from hereditary diffuse 
gastric cancer (hdgc) families adequately.
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Abstract
Background and aims: cdh1 mutation carriers 
have a strongly increased risk of developing gastric 
cancer (gc) and lobular breast cancer (lbc). 
Methods: Clinical data of gc cases and surgical and 
histological data of prophylactic gastrectomies and 
mastectomies of all 10 Dutch cdh1 mutation fami-
lies were collected. Results: Ten different cdh1 
mutations were found. The pedigrees comprised 36 
gc cases mean age 40 years (range 20-72 years), and 
1 lbc case. Twenty-nine/37 carriers alive, aged 18-61 
years, underwent prophylactic gastrectomy. Invasive 
gc-foci and premalignant abnormalities were 
detected in 2 and 25 patients, respectively. In 4 
patients gc/Signet Ring Cells (src)-foci were diag-
nosed at preoperative gastroscopy. Longstanding 
presence of srcs without progression to invasive 
carcinoma was shown in 2 others. Multifocal lbc/
lcis was found in the two prophylactic mastectomy 
specimens. Clefts of lip and/or palate (cl/p) were re-
ported in 7 individuals from 3 families. Conclusions: 
The age at onset and aggressiveness of gc is highly 
variable, which has to be included in counselling on 
planning prophylactic gastrectomies. The incidence 
of lbc is expected to increase and prophylactic 
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Methods
Individuals from families with multiple gcs and/or gc at young age 
were referred to our clinical genetics centers. Family details were 
obtained and led to the suspicion of hdgc in a subset of families. In 
index cases from these families mutation analysis of the cdh1 gene 
was performed by pcr amplification of all coding exons including 
intron/exon boundaries, followed by direct sequencing using the 
bigdye terminator v1.1 cycle sequencing kit (pe Biosystems, Foster 
City, ca) and by mlpa analysis using the P08mlpa kit (mrc-Holland, 
Amsterdam, The Netherlands) in one laboratory.
In families with confirmed hdgc by detection of pathogenic cdh1 
mutations, relatives of index patients were counseled on hdgc and 
were offered presymptomatic dna-analysis. 
Based on current knowledge asymptomatic mutation carriers were 
advised to undergo a prophylactic gastrectomy. A Swiss roll technique 
was used to study the complete mucosa of the gastrectomy specimens 
and all abnormalities were mapped23. (Figure 1a and 1b) Complete 
clinical data of all proven/supposed mutation carriers in these 
families were collected and histological specimens of therapeutic 
and prophylactic gastrectomy specimens were reviewed by expert 
pathologists. 
Specifically alterations as decribed in the context of cdh1 mutation 
carriers were recorded; the presence of invasive carcinoma defined 
as infiltration in the gastric wall beyond the level of the muscularis 
mucosae, of clusters of signet ring cells (srcs) in the lamina propria 
< 3mm (also designated as in situ src carcinoma)13, of intraepithelial 
srcs with pagetoid spread either in the surface epithelial lining or 
extending deeper in the gastric crypt epithelium and any additional 
mucosal changes were recorded. Furthermore, details were collected 
about the surgical procedures and complications of the individuals 
who underwent prophylactic gastrectomy.
Results
Description of the 10 CDH1 mutation families
In family A, 2 cousins died of gc at ages 23 and 34 years, while their 
parents were healthy at that time at an age >60 years. Several distant 
relatives had died of gc at a mean young age. After a pathogenic 
cdh1 mutation was found in this family, 11/32 tested relatives were 
identified as mutation carriers of whom 9 underwent a prophylactic 
gastrectomy. Three mutation carriers in this family were born with 
a cleft lip and palate, an isolated cleft palate and a subtle lip defect 
(forme fruste of cleft lip) respectively.
Introduction
While the incidence of gastric cancer (gc) has declined during the 
last decades, it remains the second cause of cancer related death 
worldwide1. In contrast to the intestinal type of gc (igc), diffuse gc 
(dgc) has no clear defined risk factors and its incidence has been 
stable2, suggesting that genetic factors play a more dominant role in 
dgc.
The far majority of dgcs is characterized by loss of expression of 
E-cadherin. E-cadherin is a key cell surface protein involved in inter-
cellular connection and maintenance of epithelial integrity and is 
encoded by the tumor suppressor gene cdh13,4. dgcs have a greater 
tendency to diffusely invade the gastric wall and often present at an 
advanced stage.
A minority of dgcs (1-3%) is seen in families with autosomal dominant 
gc susceptibility5. Germline E-cadherin inactivating mutations in the 
cdh1 gene are responsible for the development of dgc in approximately 
30% of families with the hereditary diffuse gastric cancer syndrome 
(hdgc). Diagnostic criteria for hdgc are formulated by the Interna-
tional Gastric Cancer Linkage Consortium6. Germline cdh1 mutations 
have first been described in 1998 by Guilford et al. in 3 Maori kindreds 
with multiple dgcs at very young age7. Subsequently different 
germline mutations have been identified in families with different 
ethnic backgrounds worldwide8-12. The lifetime risk (ltr) for gc 
in hdgc kindreds is high and is estimated >80%13. Because of this 
high risk and the restricted value of current surveillance modalities, 
prophylactic gastrectomy is recommended as the treatment of choice 
in cdh1 mutation carriers in preventing advanced gc. In almost all 
resected stomachs of asymptomatic cdh1 mutation carriers multiple 
foci of signet ring cells (srcs) were found14-16. Female carriers are 
known to have an additional high risk of developing lobular breast 
cancer (lbc) with ltr of 60% by the age of 80 years, rising from age 
406,13,17-20, whereas other tumor sites like colon and prostate might 
also be associated with hdgc21,22.
In the Netherlands, cdh1 mutation analysis is available in a clinical 
setting since 1998. We report on the geno-/phenotypical data of all, 
in total 10, Dutch families with different pathogenic germline muta-
tions in the cdh1 gene and summarize the pathological findings after 
prophylactic gastrectomy and prophylactic mastectomy in mutation 
carriers in these families. We also discuss the issue of counseling on 
associated malignancies and prophylactic options and our finding of 
cleft lip with/without palate (cl/p) in a subset of patients.
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deceased brother) showed presence of src-foci in these biopsies. This 
niece underwent a prophylactic gastrectomy at age 23. Both gastrec-
tomy specimens showed multiple src-foci in the lamina propria, but 
no invasive carcinoma. Both patients were shown to be carrier of a 
cdh1 missense mutation, which has recently proved to be a patho-
genic mutation. Both parents of our first index patient died at ages 
>80 years without a history of malignancies.
In family H, a 41 years old female was shown to have a cdh1 muta-
tion after her diagnosis of metastasized gc. Her father died of gc at 
age 28. Thus far, her 21 years old daughter and a 39 years old sister 
tested positive for the cdh1 mutation.
In family I, a cdh1 mutation was found in a 55-years old man of 
Hindustan origin, who was recently diagnosed with dgc. One 
half-sister was treated for dgc, 2 years before at age 36. A second 
half-sister and the son of a half-brother died of dgc at age 20 and 26 
respectively. Their 75-years old mother, who turned out to be muta-
tion carrier, was never diagnosed with cancer. The cdh1 mutation 
was also found in the index patient’s affected half-sister alive and in 
a second healthy, 50-years old half-sister. One first and one second 
degree relative of his mother were reported to have had bc and her 3 
brothers died before age 50 of a ‘disease in the belly accompanied by 
vomiting blood’.
A pathogenic cdh1 mutation was established in dna of a 27-years old 
man with dgc in family J. His both parents were alive without a his-
tory of malignancies at ages 72 and 55 and cancer was not reported 
in their siblings. One distant relative was treated for testicular cancer 
at age 40 and died of gc at age 82. At this moment, no relatives have 
been tested for the cdh1 mutation. 
Genotypic/phenotypic data of the 10 CDH1 mutation families
Ten different, of which 5 newly described, cdh1 mutations were de-
tected. Details of the functional arrays of the c.1748T>G missense mu-
tation will be published in a series of functional studies elsewhere.
gc occurred in 36 patients (m/f: 13/23). Mean age at diagnosis was 
40 years (range 20-72 yrs), with 27 gcs diagnosed before the age of 
50 years and 10 of them before 30 years of age. Twenty-four of 26 
confirmed gcs were classified as dgc, 2 of them had clear features of 
an intestinal/mucinous gc. In 19 cases, including the igcs, srcs were 
reported. 
Dutch CDH1 mutation families Chapter 2
33
In family B, a cdh1 mutation was found after gc occurred in 4 family 
members at ages between 43 to 56 years. Subsequently, 16/25 relatives 
tested positive for this mutation, of whom 14 underwent a prophy-
lactic gastrectomy.
A female patient in family C died of gc at age 27, while her father 
and 2 of his second degree relatives died of gc at ages between 50 
and 60 years. Two sisters were shown to be carrier of a cdh1 muta-
tion and underwent prophylactic gastrectomy. One of them was 
diagnosed with T2N0M0 dgc and has no evidence of disease 7 years 
after surgery. cl/p was reported in 3 members of this family.
dgc was diagnosed in 2 sisters in family D from Turkish descent, at 
ages 37 and 39 years. Lung cancer and laryngeal cancer were reported 
in their father and his brother, both at age 60. The cdh1 mutation 
detected in dna of the index patients was also found in 2 children of 
one of them. Prophylactic gastrectomy is still under consideration.
In family E, a 42-years old man was diagnosed with gc after testing 
positive for a cdh1 mutation and, despite gastrectomy and chemo-
therapy, he died 19 months after initial diagnosis. dna analysis was 
performed because of his family history with a sister, mother and 
grandmother dead of gc at ages 26, 43 and 37 years. His 68 years old 
and asymptomatic maternal uncle was tested positive for the cdh1 
mutation.
A mother and daughter and a distant relative in family F died of 
gc at ages 35, 41 and 72 years. After her diagnosis of lbc at age 44, a 
second daughter was shown to be carrier of a cdh1 mutation, which 
was also found in a third healthy daughter. Both underwent prophy-
lactic gastrectomy, combined with prophylactic mastectomy (contral-
ateral/bilateral). A 20-years old granddaughter proved to be a muta-
tion carrier and gave birth to a son with a clp. The boy’s parents 
recently requested counseling on pre-implantation genetic diagnosis 
(pgd) of the cdh1 mutation for future pregnancies.
A 40-years old female member of the Creole family G finally agreed 
to the proposal of a prophylactic gastrectomy 10 years after the 
finding of src-foci in her stomach. Gastric surveillance had been 
performed because of her family history with 1 brother and 2 sisters 
dead from gc at ages 32, 22 and 21. Revised histological examination 
of gastric biopsies taken 7 years before in her niece (daughter of her 
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Other malignancies than gc are listed in table 1. cl/p was reported in 
7 individuals, of which 4 mutation carriers and 3 untested with ≤ 50% 
risk (Table 1).
DNA testing and follow-up of mutation carriers
Fifty-eight individuals are known carriers of one of the cdh1 mutations, 
50 by direct testing in blood or archival tissue specimens, 8 indirectly 
as derived from the pedigree. Of the 39 asymptomatic carriers alive, 
29 opted for prophylactic gastrectomy at a mean age of 36 years (18-
61 yrs), combined with prophylactic mastectomy in 2 cases (Table 2).
Prophylactic gastrectomies: clinical and surgical details
Prophylactic total gastrectomy, with Roux-en-Y-reconstruction, was 
performed by laparotomy in 23/29 and by laparoscopic procedure in 
6/29 cases. Treatment related morbidity was recorded as suture leak-
age (n=3), in one patient complicated by mediastinitis, and bronchop-
neumonia (n=2), one resulting in ards. Four patients required secon-
dary surgical procedures. Three patients underwent re-intervention 
respectively by endoscopic coagulation and laparotomic resection to 
complete removal of residual proximal gastric mucosa.
Hospitalization admission time varied from 5 to 26 days (mean: 11 days).
Prophylactic gastrectomies: histological findings
All slides of 28 available gastrectomy specimens were revised for this 
study. (Pre)malignant changes were seen in 27 of these specimens, 
consisting of invasive carcinoma in 2 patients, intramucosal carcino-
mas in 20 patients, and intra-epithelial clusters of srcs in 1 patient. In 
6 patients, only very subtle changes were seen with slightly atypi-
cal surface epithelial cells with cytoplasmic vacuoles. In 1 patient no 
gastric abnormalities were observed besides gastritis and intestinal 
metaplasia at age 42.
The presence or absence of srcs and/or residual gastric mucosa in 
the resection margins was not systematically documented. (Table 3).
Prophylactic mastectomies: histological findings
Multiple foci of lobular carcinoma in situ (lcis) and a 0.5 mm sized 
focus of invasive lobular carcinoma were detected in the contralateral 
mastectomy specimen of the patient who was treated for lbc before. 
Her sister’s mastectomy specimens showed bilateral widespread lcis.
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Table 1.
Genotypic/phenotypic data of the 10 CDH1 mutation families
fam Mutation (prev. reported by)  exon GC sex: n (age) age GC (yrs)mean (range)   other tumours(age)   individuals > 18 yrs with no malignancy.   CL/P
                mut*  50% mut 
A 	 c.1404del	(p.Ser469fs)	 	 	10	 M:	3	(25,44,63)	 	 	 	 	 	 GIST	in	duodenum	(42)	 	 	 	 	 	 3	(mut)	
	 	 	 	 	 	 F:	6	(23,31,34,39,65,65)	 	 	 	 	 BC	(>75)	
	 	 	 	 	 	 	 	 43	(23-65)		 	 	 	 	 	 	 	11	 	 	4	
B 	 c.1565+2dup24	 	 	 11	 	M:	1	(47)	 	 	 	 	 	 	 Abd	(50);	PC	(57)	F:	3	(43,43,55)	
	 	 	 	 	 	 	 	 	 	 	 	 	 U	(47)	Me	(43)
	 	 	 	 	 	 	 	 	47	(43-55)		 	 	 	 	 	 	 16	 	 12
 C	 c.1135_1137+5delins525	 	 	8	 M:	3	(52,	58,	58)		 	 	 	 	 	 	 	 	 	 	 	 	 	 2(≤ 50%)	
	 	 	 	 	 	 F:	1	(27)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	(mut)	
	 	 	 	 	 	 	 	 40	(27-52)		 	 	 	 	 	 	 	1	 	 3	
D 	 c.2195G>A	(p.Arg732Gln)	Missense8	 	14	 M:	 	 	 	 	 	 	 Lu	(60);	La	(60)	
	 	 	 	 	 	 F:	2	(37,39)	 	38	(37-39)		 	 	 	 	 	 	 2	 	 7	
E	 c.1476_1477del	(p.Arg492fs)26	 	 10	 M:	1	(42)	
	 	 	 	 	 	 F:	3	(26,37,43)	
	 	 	 	 	 	 	 	 37	(26-43)		 	 	 	 	 	 	 1	 	 	2	
F	 c.489C>A	(p.Cys163X)	 	4	 M:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 1	(≤	50%)	
	 	 	 	 	 	 F:	3	(35,41,72)	 	 	 	 	 	 	LBC	(44)
	 	 	 	 	 	 	 	 	 	 	 	 	 GIST	in	stomach	(43)	
	 	 	 	 	 	 	 	 49	(35-72)		 	 	 	 	 	 	 2	 	 4	
G 	 c.1748T>G	(p.Leu583Arg)	Missense	 	12	 M:	1	(32)	
	 	 	 	 	 	 F:	2	(21,22)	
	 	 	 	 	 	 	 	 29	(21-40)	 	 	 	 	 	 	 	 	2	 	 9	
H	 	c.187C>T	(p.Arg63X)22	 	 3	 M:	1	(28)	
	 	 	 	 	 	 F:	1	(41)	
	 	 	 	 	 	 	 	 35	(28-41)	 	 	 	 	 	 	 	 	 	 4	
I	 c.811_812delins12	(p.Val271fs)	 	 6	 M:	2	(26,55)		 	 	 	 	 	 	BC	(50)
	 	 	 	 	 	 	 	 	 	 	 	 	 BC	(age?)	
	 	 	 	 	 	 F:	2	(23,36)	 35	(23-55)		 	 	 	 	 	 	 2	 	 13
 J 	 c.55_74del	(p.Ser19fs)	 	 	1	 M:	1	(27)	
	 	 	 	 	 	 F:	
	 	 	 	 	 	 	 	 27	
total	 	 	 	 	 	 36	(M/F:	13/23)	 40	(20-72)		 	 	 	 12	 	 	 37*	 	 58	 	 	 	7	
M: male; F: female; GC: gastric cancer (symptomatic/at endoscopy/after prophylactic gastrctomy);     BC: breast cancer; LBC: lobular breast cancer; Abd: ‘cancer in the abdomen’ (unspecified); 
PC: pancreatic cancer; U: uterine cancer; Me: melanoma; Lu: lung cancer; La: laryngeal cancer;     CL/P: cleft lip and/or palate; mut: mutation; yrs: years
*	in	27	of	these	patients	prophylactic	gastrectomy	was	performed,	in	2	of	them	both	gastrectomy	and	mastectomy.
Table 3.
Prophylactic gastrectomies: histological findings
 Indiv M/F age Histology     (pre)-malignant foci (n)
A1	 M	 49	 clusters	of	SRCs	in	lamina	propria	 	 2
A2	 M	 46	 clusters	of	SRCs	in	lamina	propria	 	 17
A3	 M	 45	 clusters	of	SRCs	in	lamina	propria	
	 	 	 Helicobacter	Pylori-gastritis	 	 	 1
A4	 M	 43	 clusters	of	SRCs	in	lamina	propria	
	 	 	 Helicobacter	Pylori-gastritis
	 	 	 intestinal	metaplasia	 	 	 4
A5	 F	 42	 clusters	of	SRCs	in	lamina	propria
	 	 	 intestinal	metaplasia/	Barrett	 	 	 1
A6	 M	 20	 clusters	of	SRCs	in	lamina	propria	 	 6
A7	 M	 18	 clusters	of	SRCs	in	lamina	propria	 	 1
A8	 F	 18	 clusters	of	SRCs	in	lamina	propria	 	 12
A9	 F	 18	 clusters	of	SRCs	in	lamina	propria	
	 	 	 intra-epithelial	SRCs		 	 	 3
B1	 M	 61	 vacuolization	of	surface	epthelium
	 	 	 atrophic	gastritis	intestinal	metaplasia
	 	 	 foveal	hyperplasia	fundic	gland	polyps
	 	 	 pancreatic	metaplasia	leiomyomas	 	 <10
B2	 M	 55	 clusters	of	SRCs	in	lamina	propria	 	 4
B3	 F	 50	 clusters	of	SRCs	in	lamina	propria	 	 1
B4	 M	 42	 chronic	gastritis	intestinal	metaplasia
	 	 	 lymphoid	aggregation	 	 	 0
B5	 F	 40	 intra-epithelial	SRCs
	 	 	 vacuolization	of	surface	epithelium
	 	 	 intestinal	metaplasia
	 	 	 multiple	fundic	gland	polyps	 	 	 <10
B6	 F	 31	 intra-epithelial	SRCs
	 	 	 vacuolization	of	surface	epithelium	
	 	 	 mild	gastritis	areas	of	subepithelial	edema	 >30
B7	 F	 30	 vacuolization	of	surface	epithelium
	 	 	 fundic	gland	polyps
	 	 	 ectopic	gastric	mucosa	in	duodenum	 	 <5
B8	 F	 31	 clusters	of	SRCs	in	lamina	propria
	 	 	 fundic	gland	polyp	 	 	 	 1
B9	 F	 30	 clusters	of	SRCs	in	lamina	propria
	 	 	 intra-epithelial	SRCs
	 	 	 vacuolization	of	surface	epithelium
	 	 	 ectopic	gastric	mucosa	in	duodenum	 	 6
B10	 M	 28	 vacuolization	of	surface	epithelium
	 	 	 fundic	gland	polyps
	 	 	 focal	intestinal	metaplasia	 	 	 <5
B11	 M	 29	 no	details	(surgery	in	hospital	abroad)	 	 ?
B12	 F	 28	 clusters	of	SRCs	in	lamina	propria	 	 7						 (continuation on page 38)
Dutch CDH1 mutation families Chapter 2
39
Table 2.
DNA testing and follow-up of carriers
 Fam individuals     mutation carriers*:     GC after mutation    prophylactic age at gastrectomy  prophylactic
 tested for       condition at time         testing (age)             gastrectomy mean (yrs,range)   mastectomy 
 mutation*      of DNA testing
 mut+/total     GC asymptomatic
A 									M	9/21	 	 9	 	 	 												6	
												F	 8/17	 							2	 	6	 											1	(65)	 												3
	 	17/38	 	 	 	 	 												9	 	 35	(18-49)		
B											M		7/11	 	 7	 	 	 												6		
												F	 11/16	 								1	 10	 	 	 												8	
	 18/27	 	 	 	 	 												14	 	 37	(28-61)
	C 									M	1/1	 							1	
													F	 2/3	 	 2	 	 	 												2**		 30	(28,31)	
	 3/4	 	 	 	 	 											2	
D 										M	1/1	 	 1
													F	 3/3	 								2	 	1	
	 4/4	




												F	 4/7	 							1	 3	 	 	 											2	 	 	 																	2	
	 4/9	 	 	 	 	 												2	 	 44	(43,45)	
 G 									M		0/0	
												F	 2/2	 	 	2	 	 	 												2**		 32	(23,40)	
	 2/2	2	
H									M	0/0	
													F	 	2/2	 							1	 1	
	 2/2






total	 58/97	 								12	 	46	 										2	 	 											29	 	 36	(18-61)	 																2	
*			including	obligate	carriers	and	analyzed	archival	tissue	of	deceased	individuals
**	after	detection	of	SRCs	in	endoscopic	random	taken	gastric	mucosal	samples
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Figure 2.
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Continuation Table 3.
Indiv M/F age Histology     (pre)-malignant foci (n)
B13	 F	 28	 clusters	of	SRCs	in	lamina	propria	 	 5
B14	 M	 28	 intra-epithelial	SRCs		 	 	 <5
C1*	 F	 31	 invasive	carcinoma	 	 	 	 1
C2*	 F	 28	 clusters	of	SRCs	in	lamina	propria
	 	 	 parietal	cell	hyperplasia	 	 	 5
F1	 F	 45	 invasive	carcinoma,	8	mm
	 	 	 clusters	of	SRCs	in	lamina	propria		 	 1
	 	 	 vacuolization	of	surface	epithelium	 	 37
F2	 F	 43	 clusters	of	SRCs	in	lamina	propria		 	 1
	 	 	 intra-epithelial	SRCs		 	 	 10
	 	 	 vacuolization	of	surface	epithelium		 	 1
	 	 	 GIST
	 	 	 ectopic	gastric	mucosa	in	duodenum		 	 10
G1*	 F	 23	 clusters	of	SRCs	in	lamina	propria
	 	 	 intestinal	metaplasia	 	 	 10
G2*	 F	 40	 clusters	of	SRCs	in	lamina	propria
	 	 	 intestinal	metaplasia
	 	 	 auto-immune	atrophic	gastritis
	 	 	 G-cell	hyperplasia
	 	 	 neuroendocrine	cell	hyperplasia
	Indiv:	individual
*	after	detection	of	SRCs	in	endoscopic	random	taken	gastric	mucosal	samples
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In contrast to the reported excess of lbcs in some hdgc kindreds4,6,18,20,31, 
we observed lbc/lcis in only 2 patients. This is particularly unexpected 
because of the high bc incidence in the Netherlands (12,5%)32, and 
may be explained by the fact that 18 women died of gc before the 
age of 50 and only a few women with a mutation or at 50% risk of 
being mutation carrier have reached the age of ≥50 years without 
being diagnosed with any type of cancer. The reported prevalence of 
lcis in the general population ranges from 0.5% to 3.6%. In women 
diagnosed with lcis, approximately 30% will develop an invasive car-
cinoma, most often of the ductal type. In the general population, lcis 
is most likely a risk indicator for bc, but it is not itself a true precur-
sor for invasive disease in most patients33. However, the presence of 
multiple foci of lcis in 2 cdh1 mutations carriers, suggest a causative 
relation between the presence of lcis and the development of inva-
sive lbc in women carrying a cdh1 mutation.
A small number of malignancies other than gc and bc were reported. 
None of these cancer types are known to be related to cdh1 mutations.
Finally, the occurrence of cl/p in 7 individuals, all of Caucasian origin, 
in 3 of our 10 families supports the suggested association of clefts and 
cdh1 by Frebourg et al.34 They described 2 Caucasian cdh1 mutation 
families with co-occurrence of cl/p and gc. In an animal model, they 
showed expression of cdh1 at weeks 4-6 of embryogenesis, i.e. the 
critical stage of lip and palate development. However, clefts were 
not reported in 58 other hdgc families with a cdh1 mutation (un-
published data, hdgc consortium Cambridge, 2008), but this may 
be due to reporting bias. Furthermore, in a study population of 500 
individuals with nonsyndromic clefts and 500 controls, Letra et al. 
only observed a borderline association of cl/p with cdh1. No cancer 
data were available for this cohort35. Given the fact that cl/p in the 
general population is relatively rare (1-2/1,000 births), the cl/ps in our 
cohort are considered to be related to the cdh1 mutations, but other 
unknown factors must have been co-contributing to the disruption 
of the lip and palate closure. 
Variable penetrance for gc and bc as well as variable expression of 
cl/p might be influenced by the nature of individual mutations, by 
modifying genes and by environmental risk factors18.
Implications for clinical practice and genetic counseling
The restricted value of current surveillance modalities for cdh1 
mutation carriers was also emphasized in our study and supports 
the need for prophylactic gastrectomy, since most of the malignant 
lesions were not detected at pre-operative gastroscopy. Although 
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Discussion
Five cdh1 mutations in the Dutch families were not reported previ-
ously. The other 5 mutations were previously found in more than 1 
unrelated patients who were reported not to share common haplo-
types, and are therefore not recognized as founder mutations8. The 
findings in all Dutch cdh1 mutation families highlight various known 
and novel aspects that are important as a guideline for care in families 
at risk.
Phenotypic variation
Although the number of patients in this series is too small to define 
a genotype/phenotype correlation, some observations should be 
noted. 
In accordance with described cdh1 families worldwide, the majority 
of gc diagnoses were established before the age of 50 years6. How-
ever, our data showed a wide variability in age at onset (20-72 years) 
between, but also within families, with non-penetrance in supposed 
carriers at an age older than 75 years in families A, G and I. Further-
more, gc was predominantly seen in female patients (m/f: 13/23), 
consistent with the literature on hdgc but in contrast with src cases 
in the general population with predominance in males.
All confirmed gcs were dgcs with the exception of 2 intestinal gcs, 
which, however, also contained typical src-components. igc or 
intestinal components are reported within the histological spectrum 
of hdgc27. A latent, non-proliferative, phase of srcs has been suggested 
previously28 and reasoned recently29, and is now strongly supported 
by the presence of src 10 and 7 years prior to gastrectomy without 
progression to invasive cancer in 2 patients from one family. Re-
markable is the variation in aggressiveness of the disease within this 
family. Another notable point is the finding of only subtle gastric 
abnormalities in 6 prophylactic treated patients and absence of typical 
hdgc-related histological findings in one patient, all from family B. 
The 6 patients showed predominantly superficial vacuolized cells 
without the typical morphology of srcs, as also described by Fitzgerald 
et al.13 and Carneiro et al.30 for which the relation to cdh1 mutation 
carrier status is not fully resolved. Because of the fact that these subtle 
lesions are the most consequent and striking feature in the gast-
rectomy specimens in this family and frequently the only putative 
cdh1-related alteration, it is likely that also these changes fall within 
the spectrum of characteristic alteration in cdh1 mutation carriers. 
(Figure 2) Further study is planned to investigate if this phenotype 
may be characteristic for the type of mutation in this family.
increase of poor pregnancy outcomes after gastrectomies for reasons 
other than cancer, a critical attitude towards the sequence of preg-
nancies and prophylactic surgery is recommended38-40.
In our opinion, there is no reason for informing future parents about 
the risk of cl/p in offspring as integral part of genetic counseling in 
all hdgc families. However, taking a family history in hdgc families 
should include the occurrence of cl/p in relatives. In those families 
positive for cl/p, current knowledge should be carefully communicated 
with counselees, since definite risks of cl/p are not known. 
Finally, the lifelong impact of being cdh1 mutation carrier will be, at 
least for a part of future parents, reason to consider the possibility of 
pgd and referral of these couples to specialized pgd centers may be 
indicated.
Conclusions
The observed wide variability of age at onset and aggressiveness of 
dgc and the longstanding presence of dormant srcs in some patients 
has to be balanced against the limited ability of detecting early 
stages of gc and lbc and the impact of prophylactic surgery, in the 
optimal timing of genetic testing and prophylactic surgery for hdgc 
family members. In case of prophylactic gastrectomy, surgeons and 
pathologists need to be focused on complete eradication of both 
malignant cells and normal gastric mucosa.
Despite the observed low incidence of lbc, we recommend to discuss 
the option of prophylactic mastectomy with female mutation carriers, 
considering the expected higher incidence of lbc in the future.
The observed high incidence of cl/p supports the hypothesis that 
cdh1-mutations are involved in the disturbed lip and palate closure. 
This hypothesis needs to be studied in a larger patient cohort in order 
to inform future parents from hdgc-families adequately.
The reported complexity of counseling topics as well as surgical and 
pathological procedures and the expected high physical and psycho-
social impact of being a mutation carrier and undergoing prophylactic 
interventions emphasize the need for centralized care for cdh1 muta-
tion carriers, provided by experts in this field working in multidisci-
plinary teams. Structured procedures on all aspects of this care are 
warranted.
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prophylactic gastrectomy is expected to be lifesaving, this procedure 
is not without short and long term risks. Postsurgical complications 
that required re-intervention were reported in 4/29 prophylactically 
operated patients. This number is low compared to postoperative 
morbidity rates of therapeutic gastrectomy. In most cases this refers 
to cancer treatment in mainly elder patients with co-morbidity and 
performed with extensive lymfadenectomy with expected higher risk 
for complications.36 Long-term morbidity of prophylactic gastrectomy, 
such as nutritional deficiencies, food intolerance and diarrhea as well 
as impact on psychological functioning is seen in daily practice and 
deserves systematic evaluation. Moreover, long-term study in a larger 
patient population is needed to evaluate the oncological effectiveness 
of prophylactic gastrectomy. This will be largely determined by the 
absence of tumor cells and absence of normal gastric mucosa in the 
resection margins. A frozen section procedure of proximal and distal 
margins is warranted during operation and mentioning of this item 
in pathology reports is important. The Swiss roll technique is the 
designated pathological procedure to enable localization of lesions 
precisely23. Thus far, no recurrent disease or distant metastases were 
observed in our patient group.
Regarding to the lbc risk, the igclc does not recommend prophylactic 
mastectomy for all female cdh1 mutation carriers, because of the 
higher mean age at onset of bc, which could justify a breast surveil-
lance strategy6. Since life prognosis is expected to improve after pro-
phylactic gastrectomy, female mutation carriers must be considered 
to be at high risk for developing bc after gastrectomy. Because the 
value of surveillance is also limited in early detection of lbc, coun-
seling should include the option of prophylactic mastectomy. For 
those who choose not to perform a prophylactic mastectomy, lbc 
surveillance from age 35 year by annual mri and mammography has 
been recommended37. 
In genetic counseling, an important issue is the preferred age to per-
form prophylactic procedures. Regarding gastrectomy, the youngest 
and mean age of occurrence of gc in the own family was the main 
factor in decision making in most of our patients, together with career 
planning. Especially young female mutation carriers have to take 
their possible future pregnancies into account in planning of both 
prophylactic gastrectomy and mastectomy, since postsurgical feeding 
and nutritional deficiencies could complicate pregnancies and breast 
feeding will not be possible. Although Kaurah et al. showed no 
adverse outcomes of 7 pregnancies in 4 women (of whom 3 cdh1 
mutation carriers) after gastrectomy and several studies showed no 
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administrated to patients in high ses neighbour-
hoods. After adjusting for confounding factors, 
the risk of dying was lower for patients with high 
ses (rer 0.89, 95% Confidence Interval 0.81-0.98) 
compared to patients with low ses. 
Conclusion: ses proved to be an independent 
prognostic factor for survival in patients with 
stomach cancer. 
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Abstract
Background: Survival differences in stomach can-
cer are depended on patient, tumour and treat-
ment factors. Some populations are more prone to 
develop stomach cancer, such as people with low 
socio-economic status (ses). The aim of this popula-
tion based study was to assess whether differences 
in ses alone, after adjusting for confounding factors, 
also influence survival. 
Methods: From 1989-2007 all patients with stomach 
cancer were selected from the cancer registry of 
the Comprehensive Cancer Centre North-East. 
Postal code at diagnosis was used to determine ses, 
dividing patients in three groups; low, medium and 
high ses. Associations between age, localization, 
grade, stage, and treatment were determined using 
Chi-square analysis. Relative survival analysis was 
used to estimate relative excess risk (rer) of dying 
according to ses. 
Results: In low ses neighbourhoods diagnosis was 
established at older age. More distal tumours were 
detected in patients with low ses, whereas patho-
logy showed more poorly differentiated tumours 
in patients with high ses. Overall, more resections 
were performed in, and more chemotherapy was 
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The cccne records data on all patients newly diagnosed with cancer 
in the north eastern part of the Netherlands, an area with 3.3 million 
inhabitants. The cancer registry obtains notifications from palga, the 
nationwide network and registry of histo- and cytopathology in the 
Netherlands. Additional sources are the national registry of hospital 
discharge, which accounts for up to 8% of new cases, radiotherapy 
institutions and haematology departments. Information on patient 
characteristics like gender, date of birth, date of diagnosis, primary 
treatment, and tumour characte-ristics such as subsite (International 
Classification of Diseases for Oncology (icd-O-3))13, histology, stage 
(Tumour Lymph Node Metastasis (tnm) classification)14, and grade, 
are obtained routinely from the medical records approximately nine 
months after diagnosis.15 The quality of the data is high, due to tho-
rough training of the administrators and computerized consistency 
checks at regional and national levels. Completeness is estimated to be 
at least 95%.16 Follow-up of vital status of all patients was calculated 
as the time from diagnosis to death or to 1st January 2008. Death 
certificates are not available in an identifiable form to the cancer re-
gistry due to privacy regulations. The information on vital status was 
initially obtained from municipal registries and from 1995 onwards 
from the nationwide municipal population registries network. These 
registries provide virtually complete coverage of all deceased Dutch 
citizens.
Socioeconomic Status Scores 
Postal code at time of diagnosis was used to determine ses. Ses 
scores are available for each of the 3,876 four-digit postal code areas 
in the Netherlands. ses scores were available for the year 2001. The 
mean number of inhabitants was 4907 per postal code area in 2001. 
ses scores are provided by the “Sociaal Cultureel Planbureau” (a 
governmental organization) and based on the following items which 
were collected per six-digit postal code: 1) mean annual income per 
household, 2) the percentage of households with a low income, 3) the 
percentage of households with a low education.17
The ses scores at the six-digit postal code level were aggregated to 
the four-digit level. After aggregation, the variables were merged 
into one score by means of factor analysis (principal components 
analysis). A rank number (1-9) given to each postal code region was 
used as the ses.16 Ses was divided into three groups based on the 
delivered rank numbers: 1=rank number 1-5 ‘low ses’ (ses score lower 
than mean ses score in the Netherlands), 2=rank number 6 ‘medium 
ses’ (mean ses score of the Netherlands) and 3=7-9 ‘high ses’ (ses score 
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Introduction
Like in most countries of the western world, mortality from stomach 
cancer is declining in the Netherlands: from 14.5 in 1989 to 6.7 per 
100,000 person-years in 2007 (eapc -4.1, p<0.0001).1 The decline in 
mortality is related to the declining incidence (16.8 in 1989 and 9.3 in 
2007, eapc -3.3, p<0.0001), but also to some improvements in survival 
rates, due to better treatment options.1 Five year survival in lower 
stage disease (stage ia) is 74%, which declines rapidly by increasing 
stage, and is 14% in stage iiia and only 2% in stage IV disease.1 Thus, 
stomach cancer remains a very lethal disease with overall five year 
survival rates of 21% in the period 2003-2007 in the Netherlands.1 
Stomach cancer incidence has very often been found to be inversely 
related to socioeconomic status (ses), with a higher incidence in 
the lower ses group.2-4 The pathways through which ses influences 
stomach cancer risk are not established, but are likely to reflect 
differences in risk factors for stomach cancer: tobacco smoking, 
diet and infection with H. pylori.5-7 However, on the relationship 
between ses and stomach cancer survival, only few studies are 
available.8-10 The association between ses and survival of cancer at 
various sites has been examined by several epidemiologic studies and 
most studies found improved cancer survival by increasing ses.10-12 
Tumour characteristics as morphology and stage of disease, but also 
treatment have been claimed to contribute to these ses variations 
in cancer survival. People living in socio-economically disadvantaged 
areas may have poorer access to health care, which may result in 
delayed diagnosis and inferior treatment. However, we would not 
expect this to be the case in the Netherlands, as the obligatory 
insurance coverage should prevent inequalities in health care access.
Since 1989, the cancer registry of the Comprehensive Cancer Centre 
North East (ccne) collects data from all cancer patients in the North-
eastern part of the Netherlands. Next to data about patient and 
tumour characteristics, detailed data about the treatment of cancer 
patients is also available. This provides us with the opportunity to 
study the impact of ses on the survival of stomach cancer patients 
in a population-based setting, taking into consideration confounding 
factors like age, stage and treatment.
Material and Methods 
Cancer registration
All cases of stomach cancer diagnosed between 1 January 1989 and 31 
December 2007 (n=9,239) in patients older than 14 years were selected 
from the population-based cancer registry of the cccne. 
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	Table 1.
Distribution of individual characteristics of patients with stomach cancer in North-East Netherlands 
across different socioeconomic groups (%)
    Low SES  medium SES High SES
    %  %  %
     95% CI  95% CI   95% CI p-value*
Gender	 	 male	 	 64	 63-66		 66	 65-68	 67	 64-70	 0,117
	 	 female	 	 36	 34-37	 34	 32-35	 33	 30-36
Age	 	 15-29	 	 0.3	 0.1-0.4	 0.1	 0.0-0.2	 0.1	 0.0-0.3	 0.001
	 	 30-44	 	 2.8	 2.3-3.3	 2.9	 2.4-3.5	 3.5	 2.4-4.6	
	 	 45-59	 	 14	 13-15	 16	 14-17	 19	 17-22
	 	 60-74	 	 40	 38-41	 40	 39-42	 41	 38-44
	 	 75+	 	 43	 42-45	 41	 40-43	 37	 34-40
Tumour
localization	 proximal	 	 27	 26-28	 28	 27-30	 28	 26-31	 0.019
	 	 distal	 	 45	 44-47	 45	 43-46	 42	 39-45
	 	 overlapping	lesion	 20	 18-21	 20	 19-21	 23	 20-25
	 	 not	otherwise	
	 	 specified	 	 9	 8-9	 7	 6-8	 8		 7-10
Histological grade	 well	 	 3.5	 3.0-4.1	 3.2	 2.7-3.8	 3.9	 2.7-5.1	 0.024
	 	 medium	 	 20	 19-21	 21	 20-22	 19	 16-21
	 	 poor	 	 40	 38-41	 42	 40-43	 44	 41-47
	 	 undifferentiated	 1.0	 0.7-1.3	 1.4	 1.0-1.7	 1.7	 0.9-2.4
	 	 unknown		 36	 34-37	 33	 31-34	 32	 29-35	
Stage	 	 I	 	 19	 17-20	 16	 15-18	 19	 17-21	 0.114
	 	 II	 	 13	 12-14	 14	 13-15	 13	 11-15
	 	 III	 	 15	 14-16	 16	 15-17	 17	 15-20
	 	 IV	 	 34	 32-35	 35	 34-37	 34	 31-37
	 	 unknown		 19	 15-20	 19	 18-20	 17	 15-20
Treatment	 resection	 	 44	 43-46	 46	 44-47	 47	 43-50	 0.024
	 	 resection	
	 	 +chemotherapy	 1.0	 0.7-1.3	 1.1	 0.8-1.5	 1.4	 0.7-2.1
	 	 chemotherapy	 4.0	 3.4-4.6	 4.6	 4.0-5.3	 5.7	 4.2-7.1
	 	 none/unknown		 38	 37-40	 35	 33-36	 34	 31-37
	 	 other	 	 13	 12-14	 14	 13-15	 12	 10-14	
*p-values <0.05 are considered to be significant
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higher than mean ses score in the Netherlands). This ses measure is 
assumed to be valid for 10 years before and after the base year (2001) 
and is therefore applicable from 1991 to 2011.
Statistical analyses
Associations between ses of neighbourhood, age at diagnosis, gender 
stage of disease, localization of the tumour, histological grade of the 
tumour and treatment were analyzed by Chi-square analysis and 
calculating 95% confidence intervals (ci). Treatment was classified as 
resection, resection combined with chemotherapy, chemotherapy, 
none/unknown and ‘other’. The group ‘other’ consists of all (combi-
nations) of treatment procedures except the above mentioned.
Relative survival was used as an estimation of disease-specific survival. 
It reflects survival of cancer patients, adjusted for survival in the 
general population with the same structure for age and gender. 
Relative survival is calculated as the ratio of the observed rates in 
cancer patients to the expected rates in the general population. 
Multivariable survival analyses were conducted to discriminate inde-
pendent risk factors for death, expressed in Relative Excess Risk (rer). 
Patients with unknown stage of disease were excluded from survival 
analyses (n=1,732). Statistical analysis was performed with Stata version 10.
Results
In the period 1989-2007 9,239 patients were diagnosed with primary 
stomach cancer in the region of the ccne. Most patients were men 
(66%). The mean age at diagnosis was 71 years (range 18 to 100 years). 
The majority of the patients were diagnosed with stage IV disease (34%).
Analysis of ses revealed that patients living in neighbourhoods with 
lower ses levels were diagnosed on average at older age and more 
often with distal tumours than those living in higher ses neighbour-
hoods. Furthermore, patients living in neighbourhoods with the highest 
ses scores were diagnosed more often with a poor histological grade. 
For the patients living in high ses neighbourhoods the resection rate 
was higher as was the administration rate of chemotherapy (table 1). 
The median survival time was 7.5 months and the mean survival time 
was 27.4 months. 
Table 2 shows the multivariable relative survival for patients in 
different ses groups. As expected, clinical and pathological factors 
appeared to be important prognostic factors. After adjustment for 
age, gender, histological grade, tumour localization, stage and type 
of treatment, the risk of dying was decreased independently for 
patients with high ses (rer 0.89, 95% CI 0.81-0.98 95%) compared to 
patients with low ses. 
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	Discussion
Somewhat unexpectedly we found an association between duration 
of survival of stomach cancer and social economic status. This result 
is robust in the statistical analysis and seems convincing even if 
some inherent theoretical problems of data collection and analysis 
are considered: first we used an ecological measure of ses, which was 
assigned to each individual patient according to the postal code of 
residence at the time of diagnosis. Theoretically it is possible that in-
dividual people are misclassified and that inferences at the area level 
do not directly transfer to individuals. In practice, validation studies, 
however have found that an area-based measure of ses is a good indi-
cator of ses for individuals.18-20 Secondly, we could not use ses-specific 
life tables, because these are not available in the Netherlands. This 
may have resulted in an overestimation of the rer of dying for lower 
ses and underestimation of the rer for higher ses.21
Survival from stomach cancer can be expected to depend on a
number of variables. Among them would be the medical intervention, 
yes or no, and if yes, its quality. Two kinds of intervention deserve 
attention in that respect. Still, the only potentially curative intervention 
is surgery, if it is omitted the patient will die within 6-8 months.22 
The second intervention is the use of chemotherapy in an advanced 
stage of disease. Although long considered to be of limited value, 
later studies found that a survival advantage of approximately 6 
months can be the result of instituting so called palliative chemo-
therapy. In addition it can have real palliative value, among others in 
situations were the primary tumour is symptomatic.22
Is it conceivable that the ses advantage that we found has anything 
to do with treatment? At first sight it would be expected that in 
the Dutch society, that does not know individual financial barriers 
for medical care, this would be an unlikely explanation. The Dutch 
health care system, financially based on an obligatory insurance 
coverage, is designed to provide essential health care to all citizens. 
However a clear sign that nevertheless there are differences between 
different ses groups can be found in the higher resection and chemo-
therapy rates in high ses regions. Even so this is not necessarily by 
choice of the medical profession and indeed it is unlikely to be so.
The most likely reason not to operate can be found in patient aspects 
and tumour characteristics. Patient characteristics can be summarized 
as “frailty” and this is correlated with age.23 Age at diagnosis was 
found to be higher in the low ses group. In addition a ses gradient 
for the presence of co-morbidity has been observed, which could 
have influenced treatment decisions (Dr. M.W.J. Louwman, Erasmus 
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Table 2.
Multivariable relative 5-year survival analyses for stomach cancer patients with different SES scores in 
the North-East Netherlands, period 1989-2007
      Multivariate 
      RER   95% CI
SES	 	 	 Low	 	 	 1	 	 Reference
	 	 	 Medium	 	 	 0.95	 	 0.89-1.00
	 	 	 High	 	 	 0.89	 	 0.81-0.98
Age	 	 	 15-29	 	 	 1	 	 Reference
	 	 	 30-44	 	 	 1.46	 	 0.74-2.86
	 	 	 45-59	 	 	 1.54	 	 0.80-3.00
	 	 	 60-74	 	 	 1.59	 	 0.82-3.08
	 	 	 75+	 	 	 1.76	 	 0.91-3.40
Gender	 	 	 Men	 	 	 1	 	 Reference
	 	 	 Women	 	 	 0.96	 	 0.91-1.02
Localization	 	 proximal	 	 	 1	 	 Reference
	 	 	 distal	 	 	 0.98	 	 0.92-1.05
	 	 	 overlapping	lesion	 	 1.12	 	 1.03-1.21
	 	 	 not	otherwise	specified	 1.23	 	 1.09-1.37
Histological	grade	 	 well	 	 	 1	 	 Reference
	 	 	 medium	 	 	 0.88	 	 0.74-1.05
	 	 	 poor	 	 	 1.10	 	 0.93-1.30
	 	 	 undifferentiated	 	 1.37	 	 1.04-1.81
	 	 	 unknown		 	 0.94	 	 0.79-1.11
Stage		 	 	 I	 	 	 1	 	 Reference
	 	 	 II	 	 	 2.16	 	 1.92-2.43
	 	 	 III	 	 	 3.01	 	 2.70-3.36
	 	 	 IV	 	 	 4.36	 	 3.91-4.86
Therapy	 	 	 Resection		 	 1	 	 Reference
	 	 	 Resection+	chemotherapy	 0.96	 	 0.73-1.25
	 	 	 Chemotherapy	 	 1.56	 	 1.37-1.77
	 	 	 None/unknown	 	 3.38	 	 3.12-3.67
	 	 	 Other	 	 	 2.43	 	 2.22-2.67
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University Medical Centre Rotterdam). The other factor that gives 
rise to abstaining from surgery is advanced tumour growth. In our 
study we did not find any difference in stage between the groups. 
Nevertheless changes in stage can only be identified when large dif-
ferences exist; delay in diagnosis will almost certainly lead to a larger 
tumour bulk. The older age at diagnosis may signify longer delay.
Another factor that could be of importance is the difference in health 
consciousness between high and low ses groups that is apparent in 
differences in adherence to screening procedures.24-27 Such attitude 
differences could well extend into recognizing fairly common upper 
digestive tract complaints as requiring attention or ignoring them 
leading to patient delay. 
Finally patient attitude could impact the use of chemotherapy in 
end stage disease. While surgery is a curative option, chemotherapy 
is palliative at that stage and prolongation of life is limited as is its 
quality. The choice to treat or not, will in that situation far oftener 
be determined by the patients attitude towards health matters, and 
in that respect its age. 
The statistical analysis shows that not one of these factors alone is 
responsible for the survival advantage, but the interrelation surpris-
ingly is strong enough to level off the advantage of distal cancer 
prevailing in the low ses group, and the disadvantage of high grade 
tumours in the high ses group.
Probably the most important observation made in this study is the 
possible under utilization of surgery. If this is the result of an age 
difference alone, recent information suggests that provided careful 
selection is done, successful surgery for stomach cancer is possible 
up to an advanced age.28,29 Moreover, this study underscores the 
potential importance of preventive measures such as eradication 
of Helicobacter Pylori especially aimed at groups at risk such as low ses.30 
In conclusion, ses is an independent prognostic factor for survival in 
patients with stomach cancer. The worse survival in low ses neigh-
bourhoods is considered to be the result of an interrelation between 
patient, tumour and treatment related factors.
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Introduction
The Dutch health care system, financially based on an obligatory 
insurance coverage, is designed to provide essential health care to all 
citizens. However, groups that might be at risk for suboptimal care 
are those who are isolated; for example in a social, cultural, religious 
and/or communicative way1. A group that would fit these characte-
ristics are first generation immigrants from non-western origin due 
to factors related to the migration process, such as health status, 
self perceived needs, health seeking behaviour, language barriers, or 
other cultural or religious differences, which might increase patient 
delay and influence outcome of care.
Accessibility of health care is particularly of interest in diseases, like 
stomach cancer, in which care and outcome are highly dependent on 
early detection. Therefore stomach cancer provides the unique op-
portunity of using survival as an endpoint, as delayed diagnosis and 
under-treatment would influence survival.
For this purpose we analysed data on survival of stomach cancer in 
the north east of the Netherlands for first generation non-western 




All cases of stomach cancer (icd-10 code C16) diagnosed between 
January 1st 1989 and December 31 2007 (n=9,239) were selected from 
the population-based cancer registry of the Comprehensive Cancer 
Centre North East (cccne: 3.3 million inhabitants). First notifications 
are obtained from the nation wide network and registry of histo- 
and cytopathology in the Netherlands (palga) and the national 
registry of hospital discharge, radiotherapy institutions and haema-
tology departments. Information on patient characteristics and 
tumour characteristics such as sub-site (International Classification 
of Diseases for Oncology (icd-O-3)2, histology, stage (Tumor Lymph 
Node Metastasis (tnm) classification3), and grade, are obtained 
routinely from the medical records approximately nine months after 
diagnosis4. The quality of the data is high, completeness is estimated 
to be at least 95%5. Follow-up of vital status of all patients was 
initially obtained from municipal registries and from 1995 onwards 
from the nationwide municipal population registries network and 
was calculated as the time from diagnosis to death or to January 1st 
2008.
Abstract
Background: Isolated groups, like first generation 
non-western immigrants, are at risk for suboptimal 
utilisation of the health care system resulting in a 
worse outcome. 
Methods: From 1989-2007 all patients with stomach 
cancer were selected from the Comprehensive 
Cancer Centre North-East cancer registry.  
Results: After adjusting for confounding factors 
(patient, tumour and treatment related), the risk of 
dying was lower for first generation non-western 
immigrants (Relative Excess Risk 0.55, 95% Confi-
dence Interval 0.43-0.70) compared to western 
patients. 
Conclusion: The better survival of first generation 
non-western immigrants with stomach cancer 
argues against accessibility problems of the Dutch 
health care system.
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Table 1.
Distribution of origin of non-western patients with stomach cancer
	Country of birth    Number of patients
Africa	 	 	 	 	 7
South	America	 	 	 	 2
Middle	East	 	 	 	 58
Surinam/Netherland	Antilles	and	Aruba	 	 18
Far	East	 	 	 	 	 26
Russia	 	 	 	 	 6
Total	 	 	 	 	 117
67
Registration of immigrants and autochthonic patients with stomach cancer
The cancer registry obtains country of birth from the patient files in 
the hospitals. When a hospital does not collect this information the 
country of birth is coded as ‘unknown’. An unknown country of birth 
therefore depends on the hospital in which the patient is diagnosed 
and is not dependent on the patient. Of the 9,239 patients, 1,863 had 
an unknown country of birth and were excluded from the analyses. 
Of the remaining 7,376 patients, 7,259 patients were born in Europe 
(excluding Turkey), North America, Australia and New Zealand and 
were coded as western immigrants or autochthonic patient. Patients 
born in other countries were coded as non-western immigrants 
(Table 1, n=117).
Statistical analysis
Associations between country of birth, age at diagnosis, stage of disease, 
localisation of the tumour, histological grade of the tumour and 
treatment were analysed by Chi-square analysis and calculating 95% 
confidence intervals (ci). 
Localisation of the tumour was divided in proximal (C16.0 and C16.1), 
distal (C16.2, C16.3, C16.4, C16.5 and C16.6), overlapping lesions (C16.8) 
and not otherwise specified (C16.9).
Because information on cause of death is not available in the cancer 
registry, relative survival was used as an estimation of disease-specific 
survival. It reflects survival of cancer patients, adjusted for survival in 
the general population with the same structure for age and gender. 
Relative survival is calculated as the ratio of the observed rates in 
cancer patients to the expected rates in the general population6. 
Multivariable five-year survival analyses were conducted to discrimi-
nate independent risk factors for death, expressed in Relative Excess 
Risk of dying (rer). Year of diagnosis was divided into categories 
and put into the multivariable model to see if there were changes 
in survival over time. Patients with unknown stage of disease were 
excluded from the survival analyses (n=1,415). Statistical analysis was 
performed with Stata version 10.
Results
The majority of the 7,376 patients were male (66%). The mean age 
at diagnosis was 71 years (range 18 to 99 years). Most patients were 
diagnosed in stage IV (35%). The proportion of patients from non-
western origin did not change over time (data not shown).
Table 2 shows the distribution of individual patient and tumour 
characteristics per group. Non-western immigrants were diagnosed 
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Table 3. 
Univariate and multivariate relative 5-year survival analyses for western versus non-western patients 
with stomach cancer in the Netherlands, period 1989-2007
	
     Univariate  Multivariate 
     RER* 95% CI**  RER* 95% CI**
Country of birth western	 	 	 1	 Reference		 1	 Reference
	 	 non-western	 	 0.68	 0.54-0.87	 	 0.55	 0.43-0.70
Age	 	 	 	 	 1.00		 0.99-1.00		 	 1.00	 0.99-1.00
Gender 	 men	 	 	 1	 Reference		 1	 Reference
	 	 women	 	 	 0.98	 0.92-1.04	 	 0.94	 0.88-1.00
Localisation	 proximal	 	 	 1	 Reference		 1	 Reference
	 	 distal	 	 	 0.74	 0.69-0.80	 	 1.00	 0.93-1.08
	 	 overlapping	lesion	 	 1.26	 1.16-1.37	 	 1.23	 1.13-1.34
	 	 not	otherwise	specified	 1.35	 1.19-1.53	 	 1.24	 1.09-1.41
Histological grade	 well	 	 	 1	 Reference		 1	 Reference
	 	 medium	 	 	 1.38	 1.12-1.72	 	 1.00	 0.81-1.23
	 	 poor	 	 	 1.93	 1.57-2.37	 	 1.21	 0.98-1.48
	 	 undifferentiated	 	 1.77	 1.23-2.56	 	 1.06	 0.73-1.52
	 	 unknown		 	 2.42	 1.96-2.98	 	 1.03	 0.83-1.27
Stage 	 	 I	 	 	 1	 Reference		 1	 Reference
	 	 II	 	 	 2.21	 1.95-2.52	 	 2.20	 1.94-2.49
	 	 III	 	 	 3.55	 3.14-4.00	 	 3.12	 2.77-3.51
	 	 IV	 	 	 9.05	 8.09-10.11	 	 4.93	 4.38-5.54
Therapy 	 Resection		 	 1	 Reference		 1	 Reference
	 	 Resection+	chemotherapy	 1.58	 1.22-2.03	 	 1.29	 0.99-1.67
	 	 Chemotherapy	 	 2.3.09	 2.73-3.48	 	 1.61	 1.40-1.84
	 	 None/unknown	 	 6.28	 5.84-6.75	 	 3.68	 3.37-4.03
	 	 Other	 	 	 4.26	 3.90-4.66	 	 2.75	 2.48-3.05	
* adjusted for age, gender, localisation, histological grade, stage and treatment, ** CI= Confidence Interval
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Table 2.
Comparison of characteristics of western immigrants and autochthonic patients
 with non -western patients with stomach cancer in North East Netherlands 
    western immigrants  non-western
    and autochthonic patients immigrants
    %   %    p-Value
     95% CI    95% CI 
Gender  male	 	 66	 65-67	 	 62	 53-70	 	 0.314
	 	 female	 	 34	 33-35	 	 38	 30-47
Age	 	 0-14	 	 -	 -	 	 -	 -	 	 <0.001
	 	 15-29	 	 0.1	 0.1-0.2	 	 4.3	 0.6-7.9
	 	 30-44	 	 2.5	 2.1-2.8	 	 21	 13-28
	 	 45-59	 	 15	 14-16	 	 17	 19-35
	 	 60-74	 	 40	 39-41	 	 35	 26-44
	 	 75+	 	 43	 42-44	 	 13	 7-19
Tumour 	 	 Proximal	 	 29		 28-30		 	 21		 14-29		 	 0.402
localisation	 Distal		 	 44	 43-45	 	 50	 41-59
	 	 overlapping	lesion	 20	 19-21	 	 22	 15-30
	 	 not	otherwise	
	 	 specified	 	 7	 7-8	 	 7	 2-11
	 	
Histological grade	 poor	 	 2.8	 2.5-3.2	 	 1.7	 0.1-4.1	 	 0.034
	 	 medium	 	 20	 19-20	 	 15	 9-22
	 	 well	 	 41	 40-42	 	 46	 37-55
	 	 undifferentiated	 0.9	 0.7-1.1	 	 3.4	 0.1-6.7
	 	 unknown		 36	 35-37	 	 33	 25-4212
Stage	 	 I	 	 17	 16-18	 	 15	 8-21	 	 0.125
	 	 II	 	 13	 13-14	 	 12	 6-18	 	
	 	 III	 	 16	 15-17	 	 20	 13-27
	 	 IV	 	 35	 34-36	 	 42	 33-51
	 	 unknown		 19	 18-20	 	 12	 6-18
Treatment	 resection	 	 43	 42-45	 	 50	 41-60	 	 0.207
	 	 resection	
	 	 +chemotherapy	 1.0	 0.8-1.3	 	 1.7	 0.01-4.1
	 	 chemotherapy	 5	 4.4-5.3	 	 7	 2-11
	 	 none/unknown		 37	 36-38	 	 31	 22-39
	 	 Other	 	 14	 13-15	 	 10	 5-16
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usa18,19, were people with low ses also often are uninsured. 
All of these factors, especially when occurring together, could have 
been expected to influence the survival of stomach cancer in first 
generation non-western immigrants in the Netherlands adversely. 
On the contrary however, our results unexpectedly suggested the 
opposite, we observed a better outcome of patients with stomach 
cancer from non-western origin (rer 0,55, 0.43-0.70 95% ci) compared 
to those of western origin. 
Differences in outcome of stomach cancer can be explained by diffe-
rences in patient and tumour characteristics in addition to the func-
tioning of the health care system. Non-western immigrants were 
substantially younger when diagnosed with stomach cancer than the 
western immigrants and autochthonic patients. We did not observe 
differences in tumour characteristics which could explain this diffe-
rence. Patients from non-western origin, especially first generation 
immigrants, however are more often born in developing countries 
were the prevalence of Helicobacter Pylori (H. Pylori) is higher and 
acquired at a younger age, compared to developed countries. One 
could postulate that this explains part of the earlier age of diagnosis, 
as H. Pylori is considered a class 1 carcinogen. This however can not 
be the solely explanation for the difference observed. Some populations 
were H. Pylori is prevalent have high incidences of gastric cancer, 
while other highly infected populations do not. This might be attri-
butable to differences in H. Pylori strains, next to not yet clarified 
genetic, dietary and environmental factors20,21.
Although at first one would expect young age to be a favourable 
factor for survival (e.g. sustaining treatment) several studies have 
reported that stomach cancer in younger patients has a biological 
more aggressive behaviour22,23. This could result in presentation 
with a more advanced stage of disease and a worse outcome. How-
ever, in the multivariate analysis the outcome of the disease specific 
survival of stomach cancer of non-western immigrants was better 
also after adjusting for age and stage of disease.
Could the better outcome be explained by other more favourable 
tumour characteristics of non-western immigrants compared to 
western immigrants and autochthonic patients? We observed more 
proximal tumours among the western population (not significant). 
Proximal tumours more resemble esophageal adenocarcinoma and 
tend to have a more aggressive behaviour which might result in a 
worse outcome, compared to distal tumours24,25. Also non-western 
migrants more often had well differentiated tumours, which is a 
favourable tumour characteristic compared to a poorly differentiated 
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on average at a younger age and presented more often with well 
differentiated tumours than western immigrants or autochthonic 
patients. No differences were found in localisation, stage or treatment 
of the tumours. 
Table 3 shows the univariate five-year relative survival, as well as the 
multivariable five-year relative survival related to age, gender, histo-
logical grade, localisation, stage and treatment. Univariaterly, the 
relative five year survival for patients from western origin was 17% 
and 31% from non-western origin. Because year of diagnosis did not 
change the multivariable model, year of diagnosis was not put into 
the model. In general, risk of dying is slightly decreased in the multi-
variable analysis compared to the univariate analysis, which indicates 
that the risks are influenced by the other confounding factors in the 
table. The risk of dying is decreased independently for patients from 
non-western origin: rer 0.55, 0.43-0.70 95% ci. Furthermore, patients 
diagnosed with stage II, III or IV show an increased risk of dying 
compared to patients with tumours diagnosed in stage I.
Discussion
Isolated populations are at risk for experiencing access barriers to 
the health care system which can lead to postponing of diagnosis 
and worsening of outcome.  Stomach cancer is a deadly disease 
unless early diagnosis and treatment, requiring advanced medical 
measures and methods, can be applied7. In the current study stomach 
cancer survival among non-western immigrants did not suggest that 
for them barriers in the utilisation of the health care system existed. 
This observation was in contrary to our expectations as especially 
first generation non-western immigrants are often considered as an 
isolated group. Not only did they not have a social network to rely 
on when they arrived, socially, and culturally they differed markedly 
from the autochthonic population. These factors have been described 
to contribute to isolation8. Especially religious convictions can lead 
to underrepresentation in screening programs when predestina-
tion is an issue. Also other diagnostic measures such as endoscopies 
and mammography’s, can be debated, as are various treatment and 
end of life decisions9,10. A language barrier to some extend also can 
explain differences in access to healthcare and outcome of disease 
11,12,13. Finally the socioeconomic status (ses), correlated with 
the incidence of stomach cancer, on average is lower among non-
western immigrants14,15,16. Moreover ses is also inversely correlated 
with cancer mortality17. Inequalities in ses explain a great amount 
of variability in mortality between ethnic groups especially in the 
tumour. But again in multivariate analysis after adjusting for differen-
tiation grade and sub localisation outcome continued to be better in 
the non-western patients. So no obvious patient or tumour related 
factors could explain the relative survival difference. Overall, patients 
with stomach cancer who were treated with chemotherapy alone 
had a worse survival compared to patients who underwent surgery. 
This can be explained by the fact that in most cases chemotherapy 
was administrated to patients with an advanced stage of disease, 
whereas surgery in most cases was performed with a curative intent 
(data not shown).
With regard to the accessibility of the health care system several 
favourable factors, particularly applicable to the Dutch situation 
of first generation non-western immigrants, could have facilitated 
utilisation of the medical services notwithstanding different degrees 
of isolation. First, the lower ses in immigrant patients would in the 
Netherlands not lead to financial inaccessibility of health care. Due 
to the obligatory insurance system in the Netherlands people from 
all ses are insured, in contrast to the usa were underinsurance or 
no insurance is a major problem in health care influencing therapy 
results26. Immigrants of this generation generally came on a contract 
basis and were often employed by large companies. The better survival 
in this group of labour immigrants might be due to the Dutch ‘arbo-
dienst’, a free health service for employees within every company, 
which could have facilitated access to medical care largely circum-
venting the language barrier. Furthermore a firm social network 
within an otherwise heterogeneous ethnic group could compensate 
possible socioeconomic disadvantages of individuals or sub-groups27. 
Probably these factors; employment, insurance and cohesion alone or 
in combination can explain why first generation non-western immi-
grants did not do worse than the autochthonic population, however 
that they would lead to a survival advantage is unexpected and remains 
unexplained, especially as there is no indication that any form of 
treatment or intervention is applied more often in this group.
In conclusion, first generation non-western immigrants had a better 
survival after stomach cancer than the control population. It is sug-
gested that accessibility of the health care system in the Netherlands 
was not hampered for these immigrants.
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hospitals in the 5-year relative survival in the distal 
tumours; 59.7% in the tu versus 36.4% in the tnu 
and 36% in the nt (p=0.03 univariate), however 
this was not confirmed in the multivariate analysis 
(p=0.184). High referral centres did not perform 
better as far as survival is concerned than low 
referral hospitals. 
In conclusion: the hospital type in our region did 
not significantly influence outcome of surgery for 
gastric cancer.
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Abstract
Background: Surgical resection is an important 
factor in the curative treatment of gastric cancer. 
However a variety of aspects of surgical treatment 
that potentially influence outcome are still not well 
defined. This study aims to assess the influence of 
hospital type, referral pattern and proximal or distal 
location of the tumour on the ultimate survival.
Methods: From January 1994 to January 2007, a 
total of 5245 patients were diagnosed with gastric 
adenocarcinoma in the region of the Comprehensive 
Cancer Centre North-East Netherlands. 
Hospitals in this region were categorized into 
three types: teaching university (tu), teaching non-
university (tnu), and non-teaching hospitals (nt). 
The influence of hospital type, referral for surgery 
and location of the tumour on the relative survival 
of operated patients was studied. 
Results: Of the 5245 patients, 2334 patients under-
went surgery. For operated patients, the 5-year 
relative survival was 42.5% for the tu versus 34.0% 
and 35.5% for respectively tnu and nt hospitals 
(p=0.064), with no difference (p=0.38) in relative 
survival (25.6-31.9%) in the proximal tumours. 
A significant difference was found between the 
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cancer cases are submitted to the regional cancer registry regularly 
through these pathology laboratories. The national hospital discharge 
databank, to which hospitals in the region provide the discharge 
diagnosis of all admitted patients on a yearly basis, further completes 
case ascertainment. 
Data collection
After notification, trained registry clerks abstract all relevant data 
directly from patient records, including pathology and surgery 
reports, within the hospitals. Data collection occurs at a minimum 
of 6 months after cytological or histological diagnosis in order to 
document all aspects of the primary therapy. All patients are staged 
according to the tnm system.7,8
In the Netherlands the municipal population registries contain 
information on the vital status of their inhabitants. Since October 
1994 population data from all Dutch municipalities are collected in 
a national database. Vital status was established through linkage of 
cancer registry data with the national automated population registry. 
Variable definitions and Statistics
The referral rate was calculated as the proportion of all operated 
patients, within the population of patients diagnosed in a given 
hospital, which were operated in another hospital.
Survival time was calculated from the date of diagnosis and ended at 
the date of death or the date of most recent linkage with the national 
automated populated registry, whichever came first. The 5-year 
overall survival rates were estimated using the actuarial method and 
survival was compared with the log rank test. Besides overall survival, 
relative survival rates were estimated. The relative survival is an 
estimate for the disease-specific survival and is calculated by dividing 
the absolute overall survival in our cohort by the expected survival 
based on age, sex and period matched mortality rates from the 
general population. The main advantage of using the relative survival 
is that it does not rely on cause of death information and captures 
both direct and indirect mortality due to gastric cancer and its 
treatment. Multivariate analysis of relative survival was performed 
according to the method described by Dickman et al.9
Results
Patients
In the period January 1994 until January 2007, 5245 patients were 
diagnosed with gastric adenocarcinoma of which 3440 were male. 
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Introduction
Although decreasing in incidence, gastric cancer still is diagnosed in 
more than 2000 patients per year in the Netherlands. In the past 
decades half of them died of their disease within 5 years after diagnosis. 
Currently, gastric cancer ranks as the fourth cause of cancer death in 
the western world.1
It is widely recognised that prognosis depends on factors related 
to tumour and patient. The stage of the tumour is of paramount 
importance, and the patient age and especially co-morbidity are 
highly relevant factors in predicting outcome.2
More recently however, other variables, related to surgeon and 
even hospital characteristics have been recognised to be potentially 
important for the ultimate fate of the patient. These hospital related 
factors might be important, as the overall survival in Japan, were 
patients undergo more extensive curatively intended resection 
methods, is higher.2
Data demonstrating the importance of various structural characteris-
tics including the hospital volume, surgeon volume and hospital type 
where the surgical intervention is performed as well as the experience 
and expertise of the surgical team itself, remain equivocal.3-6
In the population based study described here, we analysed some of 
these aspects in relation to the patient survival. Data were provided 
in a group of gastric cancer patients treated in all hospitals in the 
North-East region of the Netherlands regarding the hospital type 
and the location of the tumour, whether proximal or distal in the 
stomach. The outcome of this study is important in the discussion on 
centralization of surgical cancer care. 
Patients and Methods
Patients
All patients diagnosed with primary invasive gastric cancer from 
January 1994, until January 2007 were selected for entry in the study 
by the regional cancer registry of the Comprehensive Cancer Centre 
North-East Netherlands. 
Comprehensive Cancer Centre North-East Netherlands
This regional cancer registry is a population based registry which 
covers the north-eastern part of the Netherlands, a mainly rural area 
with a population of about 3.3 million. The area is served by 22 com-
munity hospitals, among which 8 teaching hospitals, and one uni-
versity hospital, five radiotherapy departments and nine pathology 
laboratories.  Reports of all new, cytological or histological proven 
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Table 1.
Characteristics of patients diagnosed with gastric adenocarcinoma between 
1994-2006, all patients combined, operated and non-operated patients
				 	 	 	 	 	 Total Operated Not-operated   
      N           N      N  *p-value	
Gender	 	 Men	 	 	 	 3440	 	1555	 	1885	 	 0.157
	 	 Women	 	 	 	 1805	 779	 1026	
Age at diagnosis 	 <50	 	 	 	 364	 189	 175	 	 <0.001
	 	 50-59	 	 	 	 672	 332	 340
	 	 60-69	 	 	 	 1207	 627	 580
	 	 70-79	 	 	 	 1751	 835	 916
	 	 80+	 	 	 	 1251	 351	 900	
Histology  	 Adenocarcinoma,	nos		 	 4,051		 1773	 2278	 	 <0.001	
	 	 Mucinous		 	 	 282		 158	 	124	
	 	 Signet	ring	cell	 	 	 767		 403	 	364	
	 	 No	microscopic	confirmation	 	 145	 0	 145	
Tumour location	 Cardia&fundus			 	 	 1509	 517	 992	 	 	<0.001	
	 	 Body	&	curvature,	nos	 	 886		 464	 422	
	 	 Antrum	&	pylorus	 	 	 1430	 888	 542	
	 	 Overlapping	&	unspecified		 	 1420	 465	 955	
Differentiation	 Good	 	 	 	 144	 99	 45	 	 <0.001	
	 	 Intermediate	 	 	 1031	 633	 	398	
	 	 Poor	 	 	 	 2238		 1231	 1007	
	 	 Unknown		 	 	 1832		 371	 	1461	
Stage	 	 	Stage	1A	 	 	 	 317		 264	 53	 	 <0.001	
	 	 Stage	1B	 	 	 	 562		 464	 	98	
	 	 Stage	2	 	 	 	 	698		 603	 95	
	 	 Stage	3	 	 	 	 807		 598	 209	
	 	 Stage	4	 	 	 	 1907		 386	 1521
	 	 	Unknown/not	applicable		 	 954		 19	 935	
Therapy 	 	 Surgery	 	 	 	 2277	 2277	 0	 	 <0.001
	 	 Surgery&CT	 	 	 	37	 37	 0	
	 	 Neoadjuvant	CT	&	surgery	 	 20	 	20	 0	
	 	 CT	 	 	 	 259	 0	 259
	 	 	CT	&	RT	 	 	 	 15	 0	 15
	 	 	Other/none	 	 	 2637	 	0	 2637	
Total 	 	 	 	 	 	 5245	 2334	 2911
	*	p-value	based	on	Chi-square	or	Fisher’s	exact	test	where	applicable
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The median age was 72.3 (range: 18.5-98.3) years. Patient characteris-
tics are described in Table 1. A large proportion of the patients was 
diagnosed at an advanced stage, 2714 patients were in stage IIIA or 
higher. A further 954 patients were insufficiently staged. One hundred 
ninety-four patients were diagnosed in the university hospital, 2869 
in the non-university teaching hospitals and the remaining 2182 
patients were diagnosed in community hospitals.
As table 1 shows, 2334 patients underwent surgery. Older age (p<0.001), 
advanced or unknown stage (p<0.001) and proximal tumour location 
(p<0.001) resulted in a lower probability of tumour resection. A tumour 
with intermediate or poor differentiation was also associated with 
less surgery, but this was highly correlated with stage. In all, 40.2% of 
the patients diagnosed in non-teaching hospitals were operated on, 
compared to 45.6% and 43.5% for non-university teaching and univer-
sity hospitals, respectively (p=0.162). Only a minority of the operated 
patients received (neo)adjuvant chemotherapy, respectively 57 out of 
2334 patients.
Hospitals characteristics  
A total of twenty-three hospitals participated with fourteen non-
teaching hospitals, eight teaching hospitals and one university hos-
pital. For proximal gastric cancers a difference in stage distribution 
was observed (p=0.039) due to a higher frequency of patients with 
stage III and a lower frequency of stage IV cancers among patients 
operated in the university hospital. For the non-proximal tumours 
there were no meaningful differences in stage and sub-site distribution 
between the three hospital types. There was some imbalance in the 
distribution over the age-groups (p<0.001), with slightly younger 
patients operated in the university hospital although overall the 
age distribution did not appear to differ that much when analysed 
categorical (Table 2).
Referral characteristics
Of all operated patients 6% were referred for surgery. Referral differed 
markedly by tumour sub-site, however. Of the operated patients with 
a tumour located in the proximal part of the stomach 18.0% were 
referred for surgery, while only 2.6% of the operated patients with 
a non-proximal tumour (body or distal part of the stomach) were 
referred for surgery. The non-teaching hospitals referred 10.9% of the 
operated patients diagnosed in their hospitals, 35.2% of the patients 
with proximal and 4.6% of the patients with non-proximal tumours. 
Of the fourteen non-teaching hospitals, seven had a high propensity 
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Table 3.
Hospital type, volume and referral pattern for gastric cancer-surgery for hospitals in the 
North-East Netherlands between 1994 and 2006
	Hospital type  Number of operated patients 
Hospital of diagnosis  Cardia/fundus tumours   Body/distal tumours
(n=number of hospitals;
Operated number of  Operated in     Referral for surgery  Operated in      Referral for surgery
patients/year)  hospital of    hospital of
     diagnosis    diagnosis
   N         N   N                         N 
Hospitals	(n=7;	<5	year)	 42	 								39	 	 	 278																					18	
Hospitals	(n=7;	5-9	year)	 83		 								29	 	 	 443						 									17	
Non-teaching   125          68   721                      35 
Hospitals	(n=1;	5-9	year)	 23	 								1	 	 	 88	 									1	
Hospitals	(n=7;	≥10	year)	 256	 								24	 	 	 903	 									11	
Teaching non-university 279          25   991           12
	Hospital	(n=1;	5-9	year)	 20	 								0	 	 	 58	 									0	
Teaching university  20          0   58                        0 
Total		 	 	 424	 								93	 	 	 1,770																		47	
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Table 2.
Stage and age distribution for operated patients according to hospital type were surgery was 
performed 1994-2006, stratified by tumour subsite
				 	 	 Total     Teaching, Teaching,  Non- teaching   p-value
        university non-university 	
	  Stomach:				 N        N      N     N
	 cardia&fundus
Stage	 Stage	1A	 	 41		 				9	 	 	23	 	 	9	 	 0.039*	
	 Stage	1B	 	 89		 				13	 	 	46	 	 30
	 	Stage	2	 	 171		 				22	 	 100	 	 49	
	 Stage	3	 	 	152		 				35	 	 92	 	 25	
	 Stage	4	 	 	61		 				7	 	 38	 	 16
	 Unknown		 3		 				2	 	 0	 	 1	
Age		 <60	 	 163		 				34	 	 	99	 	 30	 	 0.101	
	 60-69	 	 174		 				23	 	 	100	 	 	51	
	 70+	 	 180		 				31	 	 100	 	 	49	
	 Median		 	 65.4		 				64.4		 	 64.8		 	 66.8	 	 0.169
	 (IQR#)	 	 (57.9-72.5)				(55.8-72.1)		 (57.5-72.5)	 (61.5-73.0)	
Total	 	 	 517	 				88	 	 299	 	 	130	 	 100.0
	 Stomach: other 
Stage	 	Stage	1A	 	 223		 				14	 	 121	 	 	88	 	 0.409*	
	 Stage	1B	 	 375		 				22	 	 192	 	 	161
	 	Stage	2	 	 432		 				17	 	 248	 	 167
	 	Stage	3	 	 446		 					14	 	 	254	 	 178	
	 Stage	4	 	 325		 					13	 	 181	 	 131
	 Unknown		 	16		 				2	 	 	6	 	 	8	
Age		 <60	 	 358		 				23	 	 198	 	 137	 	 0.391	
	 60-69	 	 453		 				18	 	 251	 	 	184	
	 70+	 	 1,006		 				41	 	 553	 	 412	
	 Median		 	 71.7		 				70.1		 	 71.8		 	 71.8
	 (IQR**)	 		 (63.0-78.0)					(58.1-77.6)	 (62.7-77.8)	 (63.8-78.3)	 	<.001	
Tumour		 Body&curvature,	nos	464		 				20	 	 252	 	 192	 	 0.359
location	 	Antrum&pylorus	 888		 				38	 	 478	 	 	372	
	 Overlapping&
	 unspecified		 465		 				24	 	 	272																	 169	
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Table 4.
 Overall and relative 5-year survival and estimated excess risk of death with 95% confidence intervals (95% CI) 
for operated patients with gastric cancer, diagnosed between 1994-2006
      All gastric cancers      Proximal gastric cancer    Distal gastric cancer
      Univariate       Multivariate     Univariate     Multivariate   Univariate     Multivariate 
      5-year   5-year   EMR   95% CI   *p-value   5-year   5-year  EMR   95% CI    *p-value    5-year   5-year EMR   95% CI     *p-value 
      OS         RS      OS         RS     OS         RS
Sex 	 	 	 	 	 	 	 	 																									0.075	 	 	 	 	 	 									0.519	 	 	 	 										 									0.224			
					 male	 	 	 	 	 27.1								34.0	 	1.00	 	 	 	 	 24.7						28.6	 1.00	 	 	 	 28.0						36.0	 1.00			
					 female	 	 	 	 	 30.9						37.4	 0.90				0.79-1.02	 	 	 	 21.4							24.3	 0.91				0.68-1.22	 	 	 32.1							39.1	 0.92				0.80-1.06	
Age	 	 	 	 	 	 	 	 	 										0.055	 	 	 	 	 	 										0.206	 	 	 	 	 									0.050			
					 <	60	(ref)	 	 	 	 	 32.0							32.8	 1.00	 	 	 	 	 	23.8						24.4	 1.00	 	 	 	 35.7						36.5	 	1.00			
					 60-69	 	 	 	 	 31.5							35.0	 1.03				0.89-1.21	 	 	 	 28.8						31.9	 0.85				0.64-1.12	 	 	 	32.6						36.1	 1.13					0.94-1.37			
					 70+	 	 	 	 	 25.1							36.8	 1.17				1.01-1.34	 	 	 	 20.3							27.6	 1.09					0.83-1.44	 	 	 	25.9						38.4	 	1.23					1.04-1.45	
Period 	 	 	 	 	 	 	 	 	 								0.001		 	 	 	 	 	 								0.092	 	 	 	 	 										0.014			
					 1994-1999	 	 	 	 	 26.7						33.8	 	1.00	 	 	 	 	 	21.3							25.2	 1.00	 	 	 	 28.1							36.1	 1.00			
					 2000-2006		 	 	 	 30.0						36.3		 0.83				0.74-0.94	 	 	 	 27.5						30.9	 0.83				0.65-1.04	 	 	 	30.9						38.1	 0.84				0.73-0.96	
Stage	 	 	 	 	 	 	 	 	 									<0.001	 	 	 	 	 	 								 <0.001	 	 	 	 	 									<0.001			
					 stage	1	(ref)	 	 	 	 55.6								70.5	 	1.00	 	 	 	 	 46.1							54.2	 	1.00	 	 	 	 57.6								73.8	 	1.00			
					 stage	2	 	 	 	 	 26.5						32.5	 	2.96					2.44-3.60	 	 	 	 24.5						28.3	 2.12					1.49-2.99	 	 	 27.2							34.1	 3.25				2.57-4.13			
					 stage	3	 	 	 	 	 11.2							13.5	 5.20					4.31-6.27	 	 	 	 	14.0							15.9	 	3.49				2.43-4.99	 	 	 10.3								12.7			 5.99				4.78-7.51			
					 stage	4	 	 	 	 	 5.3								6.3	 8.05				6.61-9.80	 	 	 	 2.0									2.3	 4.93				3.29-7.38	 	 	 5.9								7.1	 9.37				7.43-11.83	
Hospital type** 	 	 	 	 	 	 	 	 									0.112		 	 	 	 		 	 								0.433	 	 	 	 																									0.184			
					 Non-teaching	(ref)	 	 	 	 28.6						35.5	 	1.00	 	 	 	 	 	27.1						31.9	 1.00					 	 	 	 28.9							36.0	 	1.00			
	 Teaching	non-university	 	 	 27.4								34.0	 0.96				0.74-1.25	 	 	 	 22.6							25.6	 0.99				0.62-1.56	 	 	 28.7							36.4	 0.92				0.66-1.29			
	 Teaching	university	 	 	 	 34.7							42.5	 0.76					0.56-1.03	 	 	 	 24.5							29.2	 0.80				0.51-1.26	 	 	 	47.5								59.7	 0.66				0.40-1.07
	Volume hospital***	 	 	 	 	 	 	 	 										0.880	 	 	 	 	 	 								0.778	 	 	 	 	 									0.814			
	 <	5	patients	operated/year	 	 	 28.5							34.6	 1.00					 	 	 	 	 30.5							35.0	 1.00			 	 	 	 27.8							34.5	 1.00			
	 5-9	patients	operated/year	 	 	 28.2							35.5	 1.00				0.81-1.22	 	 	 	 23.4						28.1	 1.15					0.75-1.76	 	 	 29.1							37.1	 0.98					0.77-1.25		
	 ≥	10	patients	operated/year	 	 	 28.4							35.2	 1.06					0.80-1.40	 	 	 	 22.5							25.9	 1.14						0.73-1.78	 	 	 30.1								38.3	 	1.08				0.74-1.55
	
Referral rate hospital****	 	 	 	 	 	 	 								0.377	 	 	 	 	 	 								 	0.627	 	 	 	 	 									0.498			
	 Low	(<	5.0%)	 	 	 	 28.7							34.5	 1.00					 	 	 	 	 24.7						28.4	 	1.00	 	 	 	 	29.8							37.8	 1.00			
	 Intermediate	(5.0-15.0%)	 	 	 28.0							35.3	 0.95				0.77-1.17	 	 	 	 20.7							25.2	 	1.10				0.74-1.63	 	 	 29.7							37.8	 0.91				0.71-1.17			
	 High	(>	15.0%)	 	 	 	 26.0							32.2	 1.12					0.91-1.39	 	 	 	 23.6						27.4	 	1.19				 	0.82-1.72	 	 	 26.7						 33.7	 1.08				0.83-1.40	
OS=Overall survival, RS=relative survival, EMR=Excess Mortality Risk, 
95% CI=95% Confidence Interval	
*			p-values	apply	to	the	multivariate	model,	adjusted	for	time	since	diagnosis		 	 	 	 	 										***			subdivision	based	on	<5	versus		5-9	or	≥	10	patients	operated/	year	based	on	all	gastric	cancers	combined
**		teaching	status	based	on	surgical	subspecialisation	 	 	 	 	 	 	 										****	subdivision	based	on	<5%,	5-15%	and	>15%	referral	of	patients	for	surgery	based	on	all	gastric	cancers	combined
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in lower probability of resection. Moreover in gastric cancer both 
tumour (T) and nodal (N) status are important elements in deter-
mining treatment plans and independent prognostic factors of long-
term survival.12-14
However factors that are neither patient nor tumour related have 
been reported to influence the outcome of curative intended surgery 
in cancer patients. Some of them are related to the experience and 
expertise of the surgical team and the case volume. Others stem 
from non-oncological surgical experience, such as expertise in 
extensive transplantations. Several studies demonstrated hospital 
and surgeon volume to have an important impact on short and long 
term survival in patients with potentially curative resection in 
different cancer types. Better outcome was also found in specialised 
centres.15-18 Verhoef et al. described significantly better outcome in 
oesophageal cancer surgery in the university hospital compared with 
other, non-university teaching and non teaching, hospitals in our 
region.19 As shown in oesophageal cancer, some studies also support 
the impact of hospital and surgeon related factors on short and long-
term results in gastric cancer.20-22
The 5-year overall survival rate in our study reflects reported stage-
specific 5-year survival rates of 10-64%.23 Patients treated in high 
referral hospitals did not have a better long term survival than those 
treated in  low referral hospitals. Survival also seemed independent 
of hospital type for the whole group of surgical patients. Although 
relative survival appeared to be somewhat better in the tu compared 
to tnu and nt hospitals (42.5% versus 34.0% and 35.5% of tnu and nt 
(p=0.064)). This could partly be explained by an imbalance in tumour 
and patient characteristics between the hospital types. On average 
less patients, with lower stages of proximal gastric cancer and 
slightly younger of age were operated in the tu hospital (Table 2). 
With regard to survival and tumour location, there were no hospital 
related differences in outcome in proximal gastric cancer. However 
overall outcome in that location was worse compared to that in the 
distal stomach, an observation also found in the work of others.24-27 
For distal gastric cancer the univariate analysis showed a significant 
difference in the 5 year relative survival regarding hospital type, in 
favour of the university hospital (57.7 % versus 36.4% tnu and  36% 
nt). This difference could not be confirmed in multivariate analysis 
and to some extend might be explained by patient selection; the tu 
hospital operated on average, younger patients. Therefore, hypotheti-
cally maybe the high volume more experienced non-university hospi-
tals (tnu and tu) have balanced the more academic approach of the 
to refer (referral rates 50-83%) patients with proximal gastric cancers 
for surgery and three hospitals rarely (0.0%-10.0%) referred patients. 
The eight non-university teaching hospitals referred 2.8% of the patients 
diagnosed in their hospitals, 8.2% of the patients with proximal and 
1.2% of the patients with non-proximal tumours (Table 3).
Survival in relation to patient, tumour and hospital characteristics 
The 5-year relative survival rate in the period of 1994-2006 for men 
with gastric cancer was 34.0% versus 37.4% for women. Age over 70 
had a detrimental effect on survival compared to age <60 years with 
an excess mortality risk of 1.17 (1.01-1.34; p=0.022). The 5-year relative 
survival markedly decreased with more advanced stage, respectively 
85.0% in stage IA, 62.0% in stage ib, 32.5% in stage II, 13.5% in stage III, 
6.3% in stage IV (p<0.001). Assessing all operated gastric cancers com-
bined; 5-year relative survival did not significantly differ by hospital 
type, referral pattern or volume of the centres. Although relative sur-
vival appeared to be somewhat better in the tu, as the 5-year relative 
survival was 42.5% for the tu versus 34.0% and 35.5% for respectively 
tnu and nt hospitals (p=0.064 univariate). Survival was also analysed 
separately for patients with proximal and non-proximal tumour. For 
proximal tumours outcome was strongly associated with stage, but 
neither hospital volume, nor teaching characteristics were significant 
factors. However in univariate analysis 5-year relative survival of the 
non-proximal tumours was significantly better in the tu compared to 
tnu and non-teaching hospitals (p=0.033 univariate) (Table 4). After 
adjusting for sex, age, period, stage, volume, referral and time since 
diagnosis these differences no longer reached statistical significance. 
Survival with respect to age, stage, volume (< 5, 5-9 and ≥ 10 patients/
year) and referral rate (<5%, 5-15% and>15%) was not different between 
the hospital types (Table 4).
Survival before and after the year 2000, for all types of gastric cancer 
combined did differ. For proximal cancer the results were similar 
between the two periods. However survival for non-proximal cancer 
was better in the later period. This improvement was not related to 
any of the hospital factors (volume teaching academic).
Discussion   
In this population based study patient characteristics such as gender 
and age distribution are comparable to other European countries.10 
Age, subsite and histology type are known factors in explaining 
survival variability.11 In our study older age, advanced or unknown 
stage, poorly differentiated tumours and proximal location resulted 
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tu resulting in no significant difference in survival. With regard to 
long-term survival we also did not observe hospital volume to play 
an important role. Of note, all surgeons in our region are low volume 
surgeons and the subdivision of centres based on volume of <5, 5-9, ≥ 10 
patients operated/year served as a suitable separator between its 23 
centres. Within this small window no striking differences were found 
in relation to survival.  Controversy on the role of surgical volume 
still remains, as is also discussed by other authors.3,5,6,28 This obser-
vation suggests that other factors than sheer number of procedures 
are important for outcome. As in our case, the university hospital is a 
low volume hospital for gastric cancer, it becomes evident that other 
factors than the caseload prevail.  The better outcome for oesopha-
geal cancer surgery that Verhoef et al. described in our region might 
therefore not be attributed to the university hospital on basis of the 
highest volume but other hospital related qualities.19 This might also 
be the case for the benefit described by Bachmann et al., based on 
the difficulty to distinguish this volume aspect from other hospital 
related qualities.22 Quality of initial surgical care, for example exten-
ded lymphadenectomy, not fully reflected by operative mortality 
rates might play a role next to patient care in the follow up period 
after surgery. Enzinger et al. suggested delay in time of recurrence 
because of their observation that survival based on volume differen-
ces appear during the first 3 years after surgery.28
It is interesting that comparison of the two observation periods 
showed an improvement in survival during the later period limited 
to distal cancer. The most likely cause of such differences is stage 
migration due to better diagnostics. However this would not readily 
explain the lack of improvement in proximal cancers. 
In conclusion the hospital type in our region did not significantly 
influence outcome of surgery for gastric cancer. For future conside-
ration however, gastric cancer surgery will require the guaranteed 
availability of multidisciplinary oncological teams experienced in 
multimodality treatments.
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term outcome was acceptable with a median sur-
vival of 17.4 months (95 % Confidence Interval (ci); 
13.5 -21.4 months). The 5-year relative survival was 
41.5% (95% ci; 33.3-50.3%) and the 5-year overall 
survival 16.3% (95% ci; 11.2-22.2%). 
Conclusion: Although long-term survival is accept-
able, the postoperative mortality in octo-and non-
agenarians after gastric cancer surgery is too high.  
Better selection procedures and improved peri-
operative care are needed to reduce surgery related 
mortality, next to studies open for this age group.
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Abstract
Background: In the next decade not only the 
number of octo- and nonagenarians with gastric 
cancer will rise, but this group will also be more 
heterogeneous. Reluctance towards extensive sur-
gery in this age group still is high, although single 
centre studies show a favourable outcome. This 
population based study aims to support decisions in 
this particular age group, by exploring patient and 
treatment related factors important for outcome. 
Methods: From 1994-2006, 1251 patients, 80 years or 
older, were diagnosed with gastric adenocarcinoma 
in the Comprehensive Cancer Centre North-East 
Netherlands region. Information was collected with 
regard to patient, tumour and hospital characteris-
tics. Survival on the short and long-term was 
determined by linkage with the national automated 
population registry. 
Results: Only 351 out of 1251 octo- and nonagenarians 
with gastric cancer were operated. Fewer operations 
were performed in nonagenarians and in case of 
advanced or unknown stage (p<0.001). Postoperative 
mortality (61-days) was only associated with age 
and as high as 38.1% in patients 85 years or older. 
However when patients survived an operation long 
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of the Netherlands. In these patients we have recorded the choice of 
treatment; surgery or not and compared outcome in two periods to 
identify possible changes in patient- and treatment factors.
Patients and Methods
Patients
Information on octo- and nonagenarians with primary invasive gastric 
cancer in the period 1994- 2006 was retrieved from the Comprehensive 
Cancer Centre North-East Netherlands registry. This population based 
registry covers the North-eastern part of the Netherlands, an area 
with 3.3 million inhabitants, that is served by one university hospital 
and 22 community hospitals, among which 8 teaching hospitals.  
The regional cancer registry collects information on all newly diagnosed 
cancer cases submitted by regional pathology laboratories. Trained 
registry clerks complete case ascertainment directly from patient 
records, including pathology and surgery reports. Data collection occurs 
at a minimum of 6 months after diagnosis in order to document all 
aspects of the primary treatment. All patients are staged according to 
the tnm system. Vital status is established through linkage of 
cancer registry data with the national automated population registry. 
Date of initial surgical resection was registered in the Northern 
region in the period of 2002-2006, data from the Eastern region were 
recorded from 2004 onwards. Surgery included all patients, those 
with a curative and palliative intent. 
Variable definitions and Statistics
Postoperative mortality was defined as all deaths occurring within 
61-days after initial surgery. Survival time was calculated from the date 
of diagnosis and ended at the date of death or the date of most recent 
linkage with the national automated populated registry, whichever 
came first. The 5-year overall survival was calculated using the Kaplan 
Meier method. The distribution of overall survival time was compared 
with the log rank test. The cumulative relative survival, the ratio of 
the overall and the expected survival, calculated using age, sex and 
period matched mortality rates from regional life expectancy tables 
(www.statline.cbs.nl/StatWeb), was also calculated. Multivariate analy-
sis of relative survival uses the property that the ratio of two relative 
survival rates can be considered an excess mortality ratio. Excess 
mortality rates are calculated by subtracting the expected number 
from the observed number of deaths and dividing this figure by accu-
mulated person-years. The excess mortality ratio is given by the ratio 
of two excess mortality rates. Multivariate excess mortality ratios were 
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Introduction
The ageing of the general population poses an increasing challenge 
for the health care system. By 2015 a demographic shift will have 
emerged towards old age, with 20% more people aged 65 years and 
over, and 50% more aged 80 years and over1. Today the majority of 
patients treated in hospitals are already in their seventies. In the 
Netherlands 65% of the outpatient clinic population is older than 65 
years (www.cbs.nl). But in the next decade especially the prevalence 
of octo- and nonagenarians will rise dramatically. In 2050 in the 
group over 65 years, 4 out of 10 people will be older than 80 years 
(www.cbs.nl).
Compared to the still somewhat rare very old patients who are 
treated today, this future group of patients is more heterogeneous, 
as improved care allows many more chronically ill patients to reach 
these advanced ages1. Today in the Netherlands 4% of the general 
population is 80 years or older, one in three having more than one 
chronic disease (www.cbs.nl). With advancing age also other factors, 
related to frailty and important for the life expectancy, change. This 
means that in the near future not only the fit elderly, but also more 
frail patients, with more co morbidities, will require treatment. 
Because of the different structure of the elderly population over the 
next years, the established treatment paradigms for the ailments 
particular to this age group need to be reviewed regularly. 
As the incidence of solid tumours increases with age a considerable 
fraction of those octo- and nonagenarians will present with a diagnosis 
of a malignancy. In our region already 18% percent of all cancers are 
diagnosed in patients 80 years or older. In this older age group gas-
tric cancer is prevalent. Due to the demographic developments the 
absolute number of newly diagnosed gastric cancers in the Nether-
lands is expected to rise with 44% between 2005 and 2025 (www.cbs.
nl). Current treatment strategies for gastric cancer often incorporate 
chemo- and/or radiotherapy next to surgery. A few decades ago curative 
surgical treatment for especially the very old was considered highly 
unusual. Today, with advanced surgical techniques and improved 
postoperative care it is questionable whether this is still the correct 
approach.  Several recent, mostly single centre, studies suggest that 
curative surgery can be performed at an acceptable risk and with 
reasonable good outcome in this age group3-5. More informative, 
compared to single centre studies, are data on outcome from popu-
lation based studies. To support decisions about the best treatment 
options for octo-or nonagenarians we have analysed retrospectively a 
large cohort of patients with gastric cancer in the North-east region 
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Table 1.
Characteristics of patients diagnosed with gastric adenocarcinoma between 1994-2006, 
aged 80 years or over, all patients combined, operated and non-operated patients
				 	 	 	 	 Total	 Operated			 Not	operated	
	 	 	 	 	 N							 N	 %		 N	 	 	p-Value*
Gender	 	 Men	 	 	 646	 	185	 28.6	 461	 	 0.637	
	 	 Women	 	 	 605	 	166	 27.4	 439	
Age at diagnosis 	 80-84	 	 	 717	 	249	 34.7	 468	 	 	<0.001	
(years)  	 	 	85-89	 	 	 386	 89	 23.1	 	297	
	 	 90-94	 	 	 128	 	11	 8.6	 117
	 	 95+	 	 	 20	 2	 10.0	 18	
Histology 	 Adenocarcinoma,	nos		 1019	 	285	 28.0	 734	 	 <0.001	
	 	 Mucinous		 	 60	 33	 	55.0	 	27	
	 	 Signet	ring	cell	 	 	107	 	33	 30.8	 74	
	 	 No	microscopic	confirmation	 65	 	0	 0.0	 	65	
	 	
Tumour location	 Cardia&fundus			 	 260	 	23	 	8.9	 237	 	 <0.001
	 	 Body&curvature,	nos	 210	 	71	 	33.8	 	139	
	 	 Antrum&pylorus	 	 417	 	195	 	46.8	 222	
	 	 Overlapping	&	unspecified		 364	 	62	 17.0	 302	
Differentiation 	 Good	 	 	 39	 20	 51.3	 	19	 	 <0.001
	 	 	Intermediate	 	 252	 106	 	42.1	 146
	 	 	Poor	 	 	 435	 	179	 	41.2	 256
	 	 	Unknown		 	 	525	 	46	 8.8	 479	
Stage 	 Stage	IA	 	 	 	70	 42	 	60.0	 28	 	 <0.001	
	 	 Stage	IB	 	 	 	142	 	90	 63.4	 52	
	 	 Stage	II	 	 	 114	 89	 78.1	 25
	 	 	Stage	III	 	 	 122	 	73	 59.8	 49
	 	 	Stage	IV	 	 	 294	 	55	 18.7	 	239
	 	 	Unknown		 	 509	 2	 0.4	 	507
Therapy 	 Surgery	 	 	 351	 	351	 100.0	 	0	 	 <0.001	
	 	 Chemotherapy	 	 	1	 0	 0.0	 1	
	 	 Radiotherapy	 	 49	 0	 0.0	 49	
	 	 Other/none	 	 	850	 0	 0.0	 850	
Total     1.251 351 100.0 900
	*	p-Values	apply	to	Chi-square	or	Fischer’s	exact	test	where	applicable
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estimated in a generalized linear model with a Poisson error structure 
based on collapsed relative survival data6.
Results
Patient and hospital characteristics
In the period of 1994-2006 a total of 1251 patients, 80 years or older 
were diagnosed with gastric cancer of which 646 patients were male. 
The number of established diagnosis declined with age, with 148/1251 
patients presenting at age 90 years or older. An operation was rarely 
performed in these nonagenarians compared to the octogenarians, 
respectively 13/148 versus 338/1103 (p<0.001). 
A small part of the adenocarcinoma histology showed signet ring 
cells (107/1251). Differentiation grade in most cases was poor (435/1251) 
or unknown (525/1251).
Most tumours were located in the antrum and pylorus region (417/1251). 
These distal tumours were much more operated on compared to 
proximal tumours (46.8% versus 8.9%, p<0.001). 
In many cases (509/1251) no stage classification was available and in 
this group an operation was rarely performed (2/509). Furthermore 
when patients were staged, often advanced disease was diagnosed, 
with 416/1251 tumours in stage III or higher. With advanced stage 
less operations were performed, respectively 61.7% in stage I, 78.1% 
in stage II, 59.8% in stage III and 18.7% in case of stage IV disease 
(p<0.001). In the very small minority of patients who received chemo- or 
radiotherapy (respectively 1/1251 and 49/1251) an operation was never 
performed (Table 1).
There were no differences in age and stage distribution or tumour 
location for operated patient between the teaching and non-teaching 
hospitals (Table 2).
Post-operative mortality
Table 3 shows postoperative mortality of the patients according to 
patient, tumour and hospital characteristics from 2002 onwards. In 
total 17 out of 91 patients died within 61 days after surgery. Only 
patient age was associated with postoperative mortality. Patients 
aged 85 years or over had a markedly increased probability of post-
operative death, 8/23 versus 9/68 in patients of 80-84 years. 
There was no difference in postoperative mortality between teaching 
and nonteaching hospitals, respectively 11/48 versus 6/43 of the 
operated patients died within 61 days after surgery.
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Post-operative (61-day) mortality for patients aged 80 years or over, operated in the period 2002-2006
				 	 	 	 	 Patients Post-operative mortality p-Value*
     N N %
All patients    91	 17	 18.7
Age (years)	 	 	 	 	 	 	
	 	 80-84		 	 	 68	 9	 13.2		 	 0.054
	 	 85-89	 	 	 21	 8	 38.1
	 	 90+	 	 	 2	 0	 0.0
Tumour location	 Cardia	&	fundus			 	 4	 0	 0.0		 	 0.685
	 	 Body	&	curvature,	nos	 24	 3	 12.5
	 	 Antrum	&	pylorus	 	 40	 9	 22.5
	 	 Overlapping	&	unspecified		 23	 5	 21.7
	 	
Stage	 	 Stage	I**	 	 	 36	 4	 11.1		 	 0.454
	 	 Stage	II	 	 	 17	 4	 23.5
	 	 Stage	III	 	 	 19	 5	 26.3
	 	 Stage	IV	 	 	 19	 4	 21.1
Hospital type***	 Non-teaching**		 	 43	 6	 14.0		 	 0.297
	 	 Teaching	 	 	 48	 11	 22.9
* p-Values based on Fisher’s exact test, ** Reference group, 
*** Teaching status based on surgical subspecialisation
Figure 1b.
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Stage and age distribution for operated patients aged 80 years or over, 
according to hospital type were surgery was performed 1994-2006, stratified by tumour subsite
				 	 	 	 Total  Teaching  Non-teaching p-Value*
     N  N  N 
Stage	 	 	Stage	IA	 	 42	 	 29	 	 	13	 	 0.162**		
	 	 Stage	IB	 	 90	 	 48	 	 42	
	 	 Stage	II	 	 89	 	 52	 	 37
	 	 	Stage	III	 	 73	 	 50	 	 23
	 	 	Stage	IV	 	 55	 	 29	 	 26	
	 	 Unknown		 2	 	 1	 	 1	
Age (yrs)	 	 80-84	 	 249	 	 151	 	 98	 	 0.280**
	 	 	85-89	 	 891	 	 53	 	 36	
	 	 90+	 	 13	 	 5	 	 8	
	 	 Median		 	 82.9	 	 83.0	 	 82.8	 	 0.548
	 	 (IQR***	)		 	 (81.4-85.5)		 (81.4-85.4)		 (81.4-85.8)		
Tumour location	 Cardia	&	fundus			 23	 	 16	 	 7	 	 0.597**		
	 	 Body	&	curvature,	
	 	 nos	 	 71	 	 43	 	 	28	
	 	 Antrum	&	pylorus	 195	 	 113	 	 	82	
	 	 Overlapping	&	
	 	 unspecified		 	62	 	 37	 	 25 
Total    351  209  142
	
* p-Values apply to Chi-square tests, ** excluding stage unknown, *** IQR=Inter Quartile Range
Figure 1a.
Relative survival for gastric cancer patients aged 80 years or over
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The median overall and relative survival (in months) and estimated excess risk of death with 95% confidence 
intervals (95% CI) for not-operated gastric cancer patients aged 80 years or over, diagnosed 1994-2006
				 	 	 All  not-operated gastric cancer patients
   Univariate   Multivariate
   Median OS Median RS EMR 95% CI  p-Value* 
Sex Males	 	 3.4	 	 3.7	 	 1.00		 	 	 0.688
	 Females	 	 2.7	 	 2.8	 	 1.03	 0.88-1.20
Age		 80-84**		 	 3.4	 	 3.6		 	 1.00		 	 	 0.286
(years)	 85-89	 	 2.8	 	 3.1	 	 1.07	 0.90-1.20
	 90+		 	 2.0	 	 2.8	 	 1.20	 0.95-1.51
Period	 1994-2000		 2.9	 	 3.0	 	 1.00		 	 	 0.790
	 2001-2006		 3.3	 	 3.5	 	 0.98	 0.84-1.14
Tumour 	 Cardia	&	fundus		 4.1	 	 4.4	 	 1.00	 	 	 0.006
location	 Body	&	curvature,	
	 nos	 	 3.8	 	 4.1	 	 0.94	 0.74-1.21
	 Antrum	&	pylorus	 2.8	 	 3.2	 	 1.03	 0.83-1.28
	 Overlapping	&		
	 unspecified		 2.2	 	 2.3	 	 1.31	 1.07-1.59
Stage	 Stage	I**	 	 3.9	 	 4.4	 	 1.00	 	 	 <0.001
	 Stage	II	 	 5.8	 	 7.1	 	 0.99	 0.58-1.68
	 Stage	III	 	 4.2	 	 4.4	 	 1.35	 0.89-2.03
	 Stage	IV	 	 2.2	 	 2.3	 	 2.15	 1.60-2.89
	 Stage	unknown	 2.9	 	 3.7	 	 1.27	 0.96-1.67
OS=Overall Survival, RS=Relative Survival, EMR=Excess Mortality Risk, 95% CI=95% Confidence Interval;
* p-Values apply to multivariate model,  adjusted for time since diagnosis** Reference group
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Table 4.
Overall and relative 5-year survival and estimated excess risk of death with 95% confidence intervals (95% CI) 
for operated gastric cancer patients aged 80 years or over, diagnosed 1994-2006
				 	 	 All  operated gastric cancer patients
   Univariate   Multivariate
   5-year OS  5-year RS  EMR 95% CI  p-Value*	
Sex Males	 	 16.3	 	 38.3	 	 1.00		 	 	 0.536
	 Females	 	 26.1	 	 44.8	 	 0.89	 0.62-1.28
Age		 80-84**		 	 24.8		 	 42.7		 	 1.00		 	 	 0.070
(years)	 85-89	 	 11.7	 	 31.8	 	 1.57	 1.05-2.35
	 90+		 	 7.7		 	 24.5		 	 1.72		 0.64-4.64
Period	 1994-2000		 21.0	 	 41.1	 	 1.00		 	 	 0.351
	 2001-2006		 20.0	 	 40.1	 	 0.83	 0.56-1.23
Tumour 	 Cardia	&	fundus		 19.6		 	 35.6	 	 1.00	 	 	 0.339
location	 Body	&	curvature,	
	 nos	 	 22.5	 	 43.2	 	 0.92	 0.39-2.11
	 Antrum	&	pylorus	 22.5	 	 45.2	 	 0.83	 0.38-1.79
	 Overlapping	&		
	 unspecified		 13.6	 	 26.1	 	 1.25	 0.55-2.82
Stage	 Stage	I**	 	 35.7	 	 70.3	 	 1.00	 	 	 <0.001
	 Stage	II	 	 20.2	 	 38.8	 	 2.35	 1.30-4.24
	 Stage	III	 	 9.2	 	 17.6	 	 3.92	 2.21-6.94
	 Stage	IV	 	 2.3	 	 3.8	 	 7.11	 3.97-12.72
Hospital		 Non-teaching**		 19.2		 	 38.1		 	 1.00		 	 	 0.665
type***	 Teaching	 	 22.0	 	 43.5	 	 0.93	 0.65-1.32
	
OS=Overall Survival, RS=Relative Survival, EMR=Excess Mortality Risk, 95% CI=95% Confidence Interval; 
* p-Values apply to multivariate model,  adjusted for time since diagnosis, ** Reference group,
*** Teaching status based on surgical subspecialisation
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one in three patients died within two months after surgery. However 
some recent retrospective single centre studies provide evidence 
that operation is indeed feasibel also in octogenarians. These studies 
showed a postoperative mortality between 3.8-11.6%4,5,13. Japanese 
series even reported zero postoperative deaths14,15. Identifying the 
clues to this contradiction might help to recognise patient and surgical 
selection procedures that would improve results in the general popu-
lation.
The single centre studies do provide some evidence that excluding 
octo- and nonagenarians with co morbidity could improve postope-
rative morbidity results4,13,16. Another factor emerging from these 
single centre studies as being important in the deselection of the 
very old is advanced disease17. Higher mortality rates are reported in 
case of locally advanced disease leading to non-curative surgery or 
the presence of distant metastasis13. Marrelli et al even observed a 
fatality rate of complications 5 times higher in case of non-curative 
surgery (50%) compared to curative procedures (10%)4. 
The extend of the surgery can also be an important factor in explain-
ing the differences in short-term outcome between single centre and 
population based studies. The surgical approach most often chosen 
in the single centre studies in octo- and nonagenarians is subtotal 
gastrectomy (65-80%) instead of total gastrectomy4,5,13,15. In the 
elderly population total gastrectomy has been reported to be associ-
ated with a higher postoperative mortality risk around 10%18. This 
association was confirmed in a recent survey on gastric cancer in 1611 
patients in 18 population based cancer registries within Europe. In 
this survey in the general population postoperative mortality after 
total gastrectomy (12.4%) was nearly twice as high as that after sub-
total gastrectomy (6.6%)19. 
Finally, some single centre studies reported a more than three times 
higher number of operations performed in the very old per year 
compared to the centres in our study4,5,13. In the Japanese studies 
not only a large number of octo- and nonagenarians was operated 
on, but the total number of gastric cancers operation per year (range 
71-440) was impressive5,14,15,20. Therefore these centres are very high 
volume hospitals. High surgical volume has in many but not in all 
studies21 been reported to be associated with better post-operative 
survival. Especially the Japanese studies therefore might serve as 
arguments for centralization of gastric cancer surgery at least in this 
advanced age group. A confounding factor remains that most studies 
that report favourable post-operative survival do not report on the 
percentage of deselection for surgery. 
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Survival
In the patients who underwent an operation median survival was 
17.4 months (95% Confidence Interval (ci); 13.5 -21.4 months) and the 
5-year relative survival was 41.5% (95% ci; 33.3-50.3%) with a 5-year 
overall survival of 16.3% (95% ci; 11.2-22.2%) (Figure Ia and Ib). The 
5-year relative survival was 38.3% for men compared to 44.8% for 
women. Although survival decreased with age, after multivariate 
analyses relative survival in the operated group was not statistically 
significantly different when comparing octogenarians (80-84 yrs 
42.7%, 85-89 yrs 31.8%) and nonagenarians (24.5%) (p=0.070).
Patients who presented with stage I disease and were operated on 
had a 5-year overall survival of 35.7% and a 5-year relative survival of 
70.3%. However relative survival decreased rapidly with more ad-
vanced stage, and was respectively 38.8% in stage II, 17.6% in stage III 
and 3.8% in stage IV disease (p<0.001). Survival for operated gastric 
cancer patients did not improve during the study period, with re-
spectively a 5 year relative survival of 41.1 in the period of 1994-2000 
and of 40.1 in the period of 2001- 2006 (Table 4). Neither the location 
of the tumour, proximal or distal, nor the type of hospitals where 
the operation was performed influenced outcome in this particular 
age group.  
In those patients in whom no operation was performed median 
survival was 3.0 months (95% ci 2.6-3.6 months) with a 5-year relative 
survival close to zero (Table 5).
Discussion
Until the beginning of the last decade of the previous century, 
reluctance towards gastric cancer surgery in patients older than 70 
years was high, as advanced age was considered to be one of the 
highest risk factors for postoperative morbidity and mortality7.  In 
the late nineties it was recognized that it was save to perform these 
operations in septuagenarians, as far as morbidity and mortality were 
concerned, through studies from Bittner and Msika8,9. However in 
the near future due to demographic shifts, not only septuagenarians 
but also increased numbers of octo- and nonagenarians are going 
to develop gastric cancer. Reluctance towards operation for this 
particular group is still high. 
Recent population based studies indeed showed a high risk of post-
operative death after gastric cancer surgery in the very old. A post-
operative mortality rate as high as 24% in octogenarians and 44% in 
nonagenarians was observed in these studies10-12. Our results are in 
line with these data, especially in the group 85 years and older, as 
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not improve in the later years compared to the earlier period. This 
was also observed by a French population-based study that found a 
short lived improvement in long term survival, among patients aged 
80 years or over, in the last decade of the previous century, that 
halted in later years27. Recently, advances in long-term survival have 
been described by the use of neoadjuvant chemotherapy28. However 
these studies did not include or report the percentage of patients 
older than 80 years27 and its careful application should therefore be 
awaited. 
Selection could mitigate the impact of surgery on patients; however 
it will not lessen the number of deselected patients. For these patients 
and for those who relapse, measures to improve all aspects, quality 
and duration, of life are needed. Evidence suggests that palliative 
chemotherapy in advanced gastric cancer can prolong survival com-
pared to best supportive care (bsc)29 and improve Qol30. In these 
trials, age 75 years or older, was an exclusion criterion. In the general 
population, compared to bsc, the months gained with single agent 
chemotherapy is about 6 months, or 10% of the natural life span in 
our particular age group, more toxic combination chemotherapy 
might even increase the survival further29. As for pre-operative 
chemotherapy, advantages of palliative chemotherapy in the very 
old are yet not clear. A recent review of the International Society of 
Geriatric Oncology chemotherapy Taskforce (siog) however showed 
that excessive toxicity of chemotherapy agents often used in gastric 
cancer such as fluoropyrimidines, platinum compounds and taxanes 
could not be attributed to age, but was related to organ dysfunction 
such as renal capacity or co morbidity31. In the new era, effects of 
biologicals such as trastuzumab, might outbalance that of cardiac 
complications.
In conclusion, this study confirms that successfully operated octo– 
and nonagenarians with gastric cancer have a satisfactory survival. 
The post-operative mortality was however high and independent 
of hospital type. Better selection procedures, assessing frailty, 
and improved peri-operative care are needed to reduce surgery 
related mortality. For improvement in long term outcome and better 
palliative care, appropriate studies open to patients from this age 
group, employing chemotherapy and biological response modifiers 
are eagerly awaited.
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Selection for surgery takes into account the biological age that refers 
to the human functional capacity. The functional decline in an elderly 
patient is a highly individualized multidimensional process. The value 
of calendar age in octo- and nonagenarians as a selection criterion 
for adverse events after surgery and as predictor of life expectancy 
is therefore limited.   In the process of ageing, in addition to co 
morbidity, other domains such as cognitive, social and psychological 
capabilities are especially important. This loss of resources in several 
domains of functioning is captured in the term frailty. According to 
Schuurmans et al using frailty as the criterion to select older patients 
instead of calendar age leads to better selection of patients at risk for 
interventions22. Such criteria can be found in selection instruments 
such as the multidimensional Comprehensive Geriatric Assessment 
(cga)23. Other practical or investigational instruments in this area 
have been described24. Hopefully it might therefore be possible by 
using those assessments to improve postoperative survival rates, 
whether by deselection for surgery or optimizing the patient’s condi-
tion preoperative, like nutrition status.25 Improving surgical and 
post-operative care could further optimize outcome on the short-term. 
Minimally invasive surgical procedures, such as laparoscopic gastrec-
tomy, have been advocated to improve peri operative morbidity and 
mortality26. However definitive results of randomised trials, in which 
frailty is also recorded, have to be awaited to substantiate that both 
short term and long term oncological results offer hope for the future 
treatment of this advanced age group.
The long-term survival of the operated octo- and nonagenarians in 
our population-based study was acceptable and comparable to out-
come in the general population. Due to a possible selection bias, i.e 
selection of more fit elderly with stage I and II disease for an opera-
tion, relative survival might overestimate disease specific survival for 
this group of patients, because the expected survival for this patient 
group is based on the survival in the complete population of, say, 
patients aged 85-89. This would give too optimistic expectation for 
the survival gain, in terms of gastric cancer specific survival, for the 
operated patients. Although even overall survival will be biased due 
to selection of the less frail patients for surgery, it is clear that life 
expectancy is much better for patients who underwent surgery, espe-
cially those with stage I or II disease, when we compare survival for 
operated with that of non-operated patients.  
The 5-year survival rate of 41.5% which we observed overlapped 
with that reported by others4,13, again Japanese series reporting the 
best 5 year survival14,20. In our study the long term outcome did 
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Introduction
At the end of the last decade of the twentieth century a multitude of 
chemotherapy regimens were investigated for the treatment of surgi-
cally incurable gastric cancer1. Differences between regimens were 
especially at the level of toxicity rather than the antitumor activity 
was concerned. Cascinu reported in 1997 on an active intensive weekly 
regimen with a high response rate2. Essentially the compounds used 
in this regimen were by that time emerging to become the standard 
of care for incurable gastric cancer. In the previous years 5-fluorour-
acil (5-fu) had been the mainstay of treatment as it had demonstrat-
ed that its use improved overall survival and quality of life compared 
to best supportive care (bsc) in several randomized trials3,4,5. Sub-
sequently, from all drugs added to 5fu especially cisplatin and epiru-
bicin or adriamycin seemed to improve on the results of 5-fu alone. 
The 3 weekly regimens were most commonly used in these compari-
sons till today, but it was not yet standard when the current weekly 
regimen was tested. Based on those data we performed a study of 
Cascinu regimen with a modification of the platinum compound 
in order to improve the feasibility and tolerability of this intensive 
weekly regimen. Triggered by the long-term clinical results we report 
on the mature data.  
Material and Methods
In august 1998, we initiated this phase I dose finding study in chemo-
therapy naive patients with metastatic and/or surgically incurable 
locally advanced gastric carcinoma in the university hospital in 
Groningen, the Netherlands. 
Eligibility criteria
All patients had to have histological proven, measurable gastric carci-
noma, either surgically incurable locally advanced disease or meta-
static disease. Age was 18 – 60 years, with an ambulatory performance 
status of 0-1 on the Eastern Cooperative Oncology Group (ecog) scale 
and a life expectancy of > 3 months. Laboratory acceptance parameters 
included a white blood cell count ≥ 4.0 x 109/L, platelet count ≥ 150 
x 109/L, serum bilirubin ≤ 1,5 x upper limit of normal, and calculated 
creatinine clearance of ≥ 80 ml/min. 
Additional eligibility criteria included the absence of clinical signs of 
myocardial ischemia, no serious active infections requiring antibiotics, 
no clinical signs of brain metastasis, no concurrent radiotherapy 
and no previous chemotherapy. Pregnant or lactating women were 
not eligible as were patients with previous or current malignancy 
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Abstract
A dose escalation study of carboplatin in combina-
tion with 5fu and epirubicin in surgically incurable 
gastric cancer. Carboplatin was combined with a 
fixed dose epirubicin 35 mg/m2, leucovorin 250 mg/m2 
and 5-fu 500 mg/m2 (celf). The starting dose of 
carboplatin was 100 mg/m2, which was escalated to 
150 mg/m2. This celf regimen was repeated every 
week, for a maximum of 14 cycles. Primary prophy-
laxis against leukopenia with filgrastim was given. 
Twelve chemotherapy naive patients were enrolled, 
9 with metastatic disease and 3 with locally 
advanced surgically incurable disease. The major 
toxicities of the celf regimen were uncomplicated 
leukopenia and thrombopenia. Nausea and muco-
sitis were the most common non-haematological 
toxicities. The dose-limiting toxicity was grade 3 
leukopenia, observed at a dose of 150 mg/m2/week. 
The objective response rate was 58% (95% ci 31%-85%). 
From the three patients, with localized but surgically 
incurable disease, two remained alive without 
disease progression and without symptoms after 6 
and 9 years after chemotherapy without any other 
treatment. 
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non-haematological toxicity.  Toxicity was evaluated according to 
the National Cancer Institute Common Toxicity Criteria (nci ctc), 
version 2.0. 
Statistical analysis
The analysis of this phase 1 study is primarily descriptive. Values are 
presented as median with ranges unless stated otherwise. Pearson’s 




During the study period a total of 12 patients, 8 men and 4 females, 
with a median age of 55 years (range 32-62) were enrolled. Nine pa-
tients had stage IV disease and three had locally advanced surgically 
incurable disease. (Table 1) 
Treatment characteristics
The first four patients were treated at the 100 mg/m2 carboplatin 
level, without dose-limiting toxicity during the first three cycles. 
Subsequently the next four patients were treated at the 150 mg/m2 
carboplatin dose level. In this dose level, one patient had grade 3 
leukopenia in the third cycle and one grade 4 with septicaemia in 
the fifth cycle. As defined by protocol the following patients were 
treated at a dose of 100 mg/m2 carboplatin. 121 Treatment cycles were 
applied in this study. The median number of cycles administered was 
10 per patient (range 4-14). Dose reductions and delayed administra-
tion of cycles resulted in a dose intensity of respectively 81% in the 
100 mg/m2 carboplatin dose level, at the 150 mg/m2 carboplatin dose 
level the dose intensity was 67%, and 85% of this reduced intensity 
was due to delayed administration. Since we expected that frequent 
dosing, dose density, is one of the features to increase the therapeu-
tic index, the frequent delays and even a delay of 3 weeks in the 150 
mg/m2 carboplatin dose level, combined with a complicated grade IV 
leukopenia in the fifth cycle, led to the conclusion that 100 mg/m2 
carboplatin was the mtd.
Toxicity
All patients were assessable for toxicity (Table 2). Haematological 
toxicity, diarrhoea and nausea were the major toxic effects of celf 
chemotherapy. One patient with evidence of response based on 
reduction of a supraclavicular lymph node, had a gastric perforation, 
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at other sites with the exception of squamous cell carcinoma of the 
skin or in situ carcinoma of the cervix uteri. All patients gave written 
informed consent before entering this study. The study protocol was 
approved by the institutional review board.
Study design
Before study entrance, patients underwent a complete history and 
physical examination, including performance status and weight. 
Base line imaging studies were obtained to define the extent of the 
disease. Laboratory tests included a complete blood cell count with 
differential and platelet count, blood chemistry studies and urine 
analysis. 
In order to define the maximum tolerated dose (mtd) of carboplatin 
in combination with epirubicin, 5fu and leucovorin, escalating doses 
of carboplatin were added to fixed doses of epirubicin, 5-fu and leu-
covorin. The starting dose of carboplatin was 100 mg/m2/week in the 
first four patients. In the absence of toxicity exceeding who grade 2 
on leucocytes and platelets in the first three weeks of treatment, the 
next cohort of four patients were planned to receive carboplatin 
150 mg/m2/week. In case of no haematological toxicity exceeding 
who grade 2 in this cohort, the next dose level was 200 mg/m2/week. 
In case of toxicity who grade 3 or 4 on leucocytes and or platelets 
during the first three weeks of treatment, this was considered dose-
limiting toxicity. In case of 2 patients with dose-limiting toxicity on 
a given dose level the level below this level was considered to be 
the maximum tolerated dose. The carboplatin dose was de-escalated 
to the prior dose level for the following courses. Planned doses of 
chemotherapy were given if white blood cells count ≥ 4.0 x 109/L and 
platelets ≥ 100 x 109/L, otherwise treatment was delayed for one week 
until full recovery. In the case of grade 2 or 3 mucositis or diarrhoea 
treatment was also delayed for one week until recovery. 
The outpatient chemotherapeutic regimen consisted of a 1-day per 
week (day 1) administration of Carboplatin as a 30-min i.v. infusion; 
epirubicin 35 mg/m2 as an i.v. bolus infusion; leucovorin 250 mg/
m2 as a 60 min split i.v. infusion before and after 5-fu; 5 fu 500 mg/
m2 as a 15 min i.v. infusion. From day 2 till day 6 patients received 
g-csf 5 µg/kg subcutaneous. As anti-emetic therapy patients received 
ondansetron before and after chemotherapy administration. After 
8 weeks of treatment tumour re-evaluation was performed and 
patients with a tumour response or stable disease, according to who 
criteria were planned to have a further 6 weeks of treatment. 
Treatment was stopped in case of progression or any grade 4 
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Table 1.
Patient and tumour characteristics
				 	 	 	 	 	 	 Total  %			
	 	 	 	 	 	
Number entered     12
Median age in years     55 (Range 32-62)
Sex
	 	 	 Male	 	 	 	 8	 	 (67)
	 	 	 Female	 	 	 	 4	 	 (33)
WHO performance status
	 	 	 0	 	 	 	 3	 	 (25)
	 	 	 1	 	 	 	 9	 	 (75)
Gastric cancer stage (AJCC)
	 	 	 IIIb	 	 	 	 3	 	 (25)
	 	 	 IV	 	 	 	 9	 	 (75)
Histology
	 	 	 Diffuse	 	 	 	 3	 	 (25)
	 	 	 Intestinal		 	 	 9	 	 (75)
Differentiation grade
	 	 	 Well	differentiated	 	 	 3	 	 (25)
	 	 	 Moderately	differentiated	 	 4	 	 (33)
	 	 	 Poorly	differentiated	 	 5	 	 (42)
Table 2.
Toxicity of chemotherapy
				 	 Carboplatin dose level 100 mg/m2   Carboplatin dose level 150 mg/m2
  (n=8, cycles 81)     (n=4, cycles 40)
  WHO grade    WHO grade		
  I II III  IV   I II III IV 
Mucositis   5	 1	 1	
Nausea  4	 2	 	 	 	 3	 1	
Diarrhoea 	 	 1	 	 	 	 2	
Leukopenia 9	 4	 3	 	 	 9	 4	 1	 1	
Thrombopenia 25	 	6	 2	 	 	 10	 5	 1	 1	
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possibly due to the tumour response. This was considered grade IV 
toxicity so treatment was stopped, and the patient died 5 months 
later. The median dose of carboplatin based on auc using the Calvert 
formula, was 1.63 mg/ml*min (range 1.41 to 1.94) in the 100 mg/m2 
group, and respectively 2.60 mg/ml*min (range 2.29-3.0) in the 150 
mg/m2 group. We did not find a relation with relative platelet count 
reductions in the first 3 cycles and carboplatin target auc (R=0,24)
Tumour response
All patients had measurable lesions. Eight patients completed 8 
weeks of treatment until the first planned response evaluation; 
so four patients were lost for response evaluation and considered 
non-responders. Of these four patients one patient had probably 
progressive disease, based on clinical findings. Two patients refused 
further treatment after respectively 4 and 6 cycles; one of them was 
evaluated and had stable disease. In one patient the treatment was 
stopped after 5 cycles due to gastric perforation, however clinical 
findings indicated response. Of the 8 evaluated patients after 8 weeks 
of treatment, 6 patients had a partial response (pr). In none of these 
patients additional surgical intervention was feasible. Two patients 
had a stable disease (sd), resulting in an objective response rate of 
50% (95% ci 22%-78%) after 8 cycles. 
One patient with pr refused further treatment after the first response 
evaluation; she had a complete response on a repeated tumour evalu-
ation after 2 years. The remaining 7 patients had a second evaluation 
after the planned total of 14 cycles. One patient had a pr after a sd 
in the first evaluation. Two patients with a pr in the first evaluation 
had evidence of ongoing pr at the time of the second evaluation. 
For the other 4 patients the situation between the first and second 
evaluation was unchanged. Thus the overall objective response rate 
was 58% (95% ci 31%-85%) after 14 weeks. The median survival was 
11.25 months (range 1.5 –100+months). 
Of the 3 patients with locally advanced surgically irresectable disease 
one died of tumour progression after 24 months. However the other 
two patients are currently still alive with no clinical evidence of 
disease at respectively 9 and 6 years post treatment. The first patient 
had a stage IIIb, intestinal type adenocarcinoma and was treated at 
the 150 mg/m2 dose-level (7 cycles) with an actual dose intensity of 
77%, the second patient had a stage IIIb, undifferentiated adenocar-
cinoma and was treated at the 100 mg/m2 dose-level with an actual 
dose intensity of 71% (13 cycles). Both long-term survivors received no 
additional treatment. 
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in an outpatient setting with an acceptable toxicity at a carboplatin 
dose of 100 mg/m2. Toxicity in the first three cycles of chemotherapy, 
limiting the dose dense intention of the schedule, was observed at a 
dose level of 150 mg/m2. The mtd of 100 mg/m2, induced in three 
cycles who grade III leukopenia and in two cycles grade III throm-
bopenia, during later cycles. Grade 3-4 toxicity data reported for the 
pelf regimen are comparable to the data reported here. The celf 
regimen showed a promising response rate of 58% (95% ci 31%-85%) 
comparable to the objective response rate of 62% in the phase 2 
study of weekly pelf. 
The mature data on this weekly regimen show interesting and not 
expected long-term event free survival of two patients in this study 
of respectively 9 and 6 years. Both patients had locally advanced sur-
gically incurable disease, one patient received 7 courses (150 mg/m2 
carboplatin) and one patient received 13 courses (100 mg/m2 carbo-
platin) of celf. Both had a partial response after chemotherapy, and 
at that time it was judged that curative resection was still not feasible. 
The fate of patients deemed surgically incurable is usually considered 
to be grim. In the era of best supportive care all patients die within 
1 year after diagnosis3,4,5. Subsequently in the western world this 
group has been entered in chemotherapy studies, sometime recog-
nizable in stratified subgroups; one or more metastasis or locally 
advanced disease2,14-18. In such patients an interesting 55.6 -68% 4-5 
years survival have been reported in patients who were considered 
to be resectable after chemotherapy2,14,19. Especially in Japanese 
studies local treatments (extended surgery, local chemotherapy) have 
been added tot these regimens20. In this study only 3 long-term sur-
vivors, after only chemotherapy, out of 643 patients were described. 
One of them survived more than 5 years; two others ultimately 
succumbed to their disease20. 
In view of our results it seems not unlikely that a subgroup of 
patients with especially surgically incurable, but still limited disease, 
not only will have palliative benefit, but may even find cure from 
chemotherapeutic intervention. 
Conclusion
Long-term follow-up of this feasible phase I trial, with promising 
response rates, uncovered two long-term survivors. Late evaluations 
of studies in gastric cancer patients are uncommon however for 
some subgroups of patients such analyses might be worthwhile. 
Based on our results we therefore would like to encourage other 
researchers to perform late analysis of data in order to help to discover 
patient and tumour characteristics resulting in long-term survivorship. 
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Discussion
Although the incidence of gastric cancer declines it is still the world’s 
second leading cause of cancer related death. The mainstay of treat-
ment remains a radical surgical resection, which seems feasible in 
about 40 % of the patients (American Joint Committee on Cancer 
staging (ajcc) stage I-III). This results in a 5 year survival of approxi-
mately 58-95% in stage I, 34-54% stage II, 20-37% stage IIIa and 8-11% 
stage IIIb disease6,7. Even after apparent curative resections, local 
recurrences or distant metastasis occur in up to 60% of the patients. 
Unfortunately, most patients present with an advanced stage of 
disease with a dismal outcome. This group consists of patients with 
locally advanced surgically incurable disease (±30%) and patients with 
metastatic disease (±30%). In that situation the prognosis is worse 
with a median survival in case of locally advanced disease of 12-15 
months and 7-10 months in case of relapsed or metastatic disease8,9. 
The last decade a lot of effort has been put into the development of 
more effective systemic therapies for those patients with advanced 
gastric cancer to improve quality of life and prolongate survival. At 
first multiple single agent regimens were tested, later much effort 
has been put in combination chemotherapy in order to improve 
response rate and survival. In these regimens 5-fu was combined 
with either etoposide and leucovorin (elf), doxorubicin and metho-
trexate (famtx) or epirubicin and methotrexate (femtx). These treat-
ments resulted in response rates of approximately 50% objective 
responses and 10% complete responses with median survival rates of 
8 to 11 months, but essentially no long term survivors were repor-
ted2,3,5,10,11. Two randomized controlled trials were conducted using 
these 5-fu based regimens versus cisplatin and 5-fu based schedules. 
One study compared elf or famtx versus cisplatin and 5-fu, with 
no significant differences in either response or survival12. The other 
study showed higher response rates for epirubicin, cisplatin and 
5-fu versus famtx, with comparable survival rates11. The favourable 
response rate of the combination of epirubicin, cisplatin and 5-fu 
(pelf) was confirmed in a phase II trial in a weekly schedule2. 
Although high response rates do not necessarily translate into pro-
longed survival, they might be valuable in the neo-adjuvant setting 
and in the situation where a rapid palliation, for instance of obstruc-
tion problems, is required. A few years later the value of perioperative 
chemotherapy on survival in resectable gastric cancer was confirmed 
in the magic trial13. 
At the moment that the weekly regimen caught our attention, 
the 3 weekly regimen was not yet considered standard treatment.  
The current study showed that the weekly celf regimen was feasible 
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Background
Gastric cancer is one of the most common and fatal cancers, affecting 
more males than females. Large differences exist in the incidence of 
gastric cancers between various geographic regions. In North America, 
Africa, Oceania 4-10 /100.000 people per year are affected, 
in northeast Asia up to 69 cases per 100.000 people per year1. 
It is now known that this cancer is generally the aftermath of Heli-
cobacter Pylori (H. Pylori) infection. The risk for adenocarcinoma is 
6-fold increased in those infected with H. Pylori. H. Pylori are a bac-
terium which can lead to chronic gastritis. However only a minority 
of patients infected with this organism develop cancer, concerting 
risk factors are high salt intake, low intake of vegetables or fruit, 
obesity and smoking2.
Although the incidence of gastric cancer is declining due to preventive 
strategies, such as treatment of H. Pylori and better food preservation 
methods, it remains the second leading cause of cancer related death 
worldwide. Symptomatic patients often have complaints like weight 
loss, abdominal pain or dysphagia. Diagnosis is established by endo-
scopy, which is insertion of a flexible tube through the mouth1. Once 
the diagnosis is established by obtaining tissue scored by the patho-
logist as being malignant, therapy can be aimed at cure or be limited 
to some prolongation of life and mitigation of symptoms.
The only way to cure gastric cancer is by surgery. Because of the 
high recurrence rate after surgery alone most patients are also 
treated with some form of adjuvant (postoperative) or neoadjuvant 
(preoperative) chemotherapy, in the United States combined with 
radiotherapy. If surgery can be done requires ct scanning and often 
ultrasound1. Sometimes it is only during surgery that it becomes 
clear that the cancer has progressed beyond the surgeon’s domain. In 
such advanced stages of gastric cancer, when the tumour has become 
irresectable, attention has to be focused on palliative measures. The 
emphasis in this phase is based on prolonging survival with preser-
vation or improving quality of life. Care is then largely determined 
by the expectancy of approaching death. Although still a demanding 
clinical task, much literature and guidance is available for the clinician 
on giving optimal support. Compared to best supportive care several 
studies have described a beneficial effect of chemotherapy on quality 
of life, next to achievement of survival benefit. Compared to mono 
chemotherapy agents, combination chemotherapy gives additional 
survival benefit of some weeks to months, at the expense of more 
toxicity3. With the development of targeted agents against molecular 
signalling pathways a larger survival benefit might be accomplished. 
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Abstract
Worldwide, gastric cancer is one of the most 
common and fatal cancers. The majority of patients 
present with an advanced stage of disease. Even 
with use of palliative chemotherapy most patients 
die within one year after diagnosis. Medical psycho-
logical attention after a diagnosis of incurable 
cancer is focused on end of life support.
The case is presented of a patient treated with 
palliative intent with chemotherapy for an 
irresectable histologically confirmed gastric cancer. 
When, unexpectedly prolonged symptom free 
survival followed, the reaction of the patient came 
as a surprise to the attending medical team. In this 
case history we urge those who care for incurable 
cancer patients, that the rare patient who survives 
against all odds may require special psychological 
care.   
In conclusion, unexpected developments, in this 
case prolonged survival, culminating in likely cure, 
require intensive efforts in adaptation of care.
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against painful or threatening information. Depending on the situ-
ation this can be maladaptive, e.g. leading to treatment delay, or 
adaptive, e.g. enabling the patient to cope with this life-threatening 
disease. A recent review on denial in cancer patients distinguished 
four types of denial: denial of diagnosis, denial of impact, denial of 
affect, and behavioural escape2. Denial of diagnosis mostly takes 
place early in the process of diagnosis, and decreases over time, 
although it sometimes increases during the terminal phase7. 
Our patient, however, seems to be cured and denying having had 
cancer at first sight seems incomprehensible. Insight in this denial 
can be obtained from available knowledge on how people try to 
explain unpredictable life events. In general, people make different 
causal attributions for positive and negative events. Positive events 
mostly are considered to be the result of internal causes: people tend 
to ascribe success in life to themselves. Negative events are mostly 
attributed to external causes: failure due to circumstances. So, we 
could expect that our patient would refer being a survivor of cancer 
to these internal causes, such as a fighting spirit, or a healthy life 
style. Most patients will make causal attributions to external sources 
for the fact that they get cancer, clearly a negative event, in such a 
way that self-esteem is preserved6.
When our patient stayed alive longer than expected, external rather 
than internal attributions were sought. Given the fact that the 
doctors were wrong about dying soon they could be wrong in other 
aspects of the disease too. If the patient did not believe in divine 
intervention, how could this unexpected outcome be explained? 
The thought of not having cancer in the first place is in accordance 
with this unexpected outcome. Moreover, this conviction serves 
well to reduce anxiety and uncertainty about recurrence of cancer: 
a predominant preoccupation in most survivors of cancer4,5. There 
was no reason to be afraid that the cancer could come back if it had 
never been there! Although denial in this case is not a logical solu-
tion, it certainly is a psychological one. Thus for the patient the past 
experiences with life-threatening disease and the unexpected positive 
outcome are explained, and the fear of a recurrence of cancer is 
superfluous.
As a medical team we were unable to help the patient on the path 
from the certainty of death to unexpected survival. Whether the 
adaptation through denial of the patient to the new situation is the 
most desirable one is doubtful. Realization by us that good news 
may be as difficult to cope with as bad news might have provided a 
guideline for earlier psychological intervention.
Targeted therapy is a type of medication which blocks the growth of 
cancer cells by interfering with specific targeted molecules needed 
for tumour growth rather than interfering with rapidly dividing 
cells in case of traditional chemotherapy1.
Next to chemotherapy or local palliative measurements physicians 
get trained in guiding patients on their way to approaching death, 
by listening to their complaints, desires and fears. Surprisingly little 
is known about the psychological consequences for the rare patient 
with unexpected long-term survival or cure against all odds, as de-
scribed here.
Case Report
A middle-aged patient was referred after explorative laparotomy only 
because of irresectabel adenocarcinoma of the stomach. 
Chemotherapy was instituted, but stopped because of excessive 
toxicity. The message communicated at that moment was gloomy 
based on the initial diagnosis and the residual lesions on ct-scan after 
chemotherapy. Even more than before the start of chemotherapy, 
the patient expected to die from this cancer and seemed to adapt to 
this situation, the more since a second opinion, confirmed the initial 
diagnosis and did not provide alternatives. However the patient 
remained in an excellent condition throughout the following years. 
Although one could assume that a patient would be relieved by being 
an exceptional long-term survivor, 9 years by now, the opposite 
occurred. Survival became a considerable psychological problem. 
Finally some form of equilibrium was found in a state of denial of 
ever having had cancer.
Discussion
The median survival of patients with advanced gastric cancer is 7 to 
10 months. Chemotherapy can lead to palliation and prolongs survival 
with a few months. However long-term survival or cure after only 
a partial tumour remission on chemotherapy without surgery has 
rarely been described3.
Apart from these medical considerations the most remarkable reac-
tion of our patient was the psychological one. At first the patient 
accepted the diagnosis of irresectable gastric cancer and agreed to 
palliative chemotherapy. However, after remaining alive longer than 
expected without evidence of disease our patient reacted with a rare 
type of denial namely retrospective denial of the diagnosis.
Denial in cancer patients is a well recognized phenomenon in clinical 
practice4-7. Denial is the process by which the mind defends itself 
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was told that this disease was fatal and treated invasively for a 
disease which was not there.
Drs. Siemerink: So, the retrospective denial of the diagnosis is a way 
of coping with this unexpected positive course of the disease?
Dr. Jaspers: Cancer is a disease that brings much uncertainty and loss 
of control for patients. In general there is little they can do, except 
rely on medical treatment and hope for the best. Loss of control is 
hard to deal with, and research on coping with cancer shows that at 
least half of the surviving patients experience positive effects (post-
traumatic growth) of having cancer. Some consider these positive 
effects as a way of coping to regulate feelings of anxiety and depres-
sion (illusionary growth), others consider these positive experiences 
as real growth.8 Retrospective denial of the diagnosis is an effective 
way to regain control and at the same time eliminate anxiety and 
uncertainty about recurrence of cancer.
Professor Mulder: At the other hand, denial as a way of coping seems 
unrealistic. Can denial be an effective coping method?
Dr. Jaspers: Denial is the process by which the mind defends itself 
against painful or threatening information. Mostly denial does not 
last long, because it is only temporarily necessary to regulate and 
control negative emotions. In the long run denial is often inadequate, 
because it hampers adaptation to the altered situation, for instance 
having cancer. So, it depends on the circumstances whether denial 
can be an adequate or inadequate coping strategy. In the case of this 
patient denial not only explains the unexpected cure of cancer, but 
also seems to have positive effects on the long run (reduce anxiety 
about recurrence of cancer). So, may be in this case denial is not a 
bad strategy for the patient as long as this strategy has no evident 
disadvantages for the patient. There may be another reason for this 
unexpected attribution. In general, people have a strong urge to seek 
causal attributions for their behaviour or for the events they experience. 
The cure of irresectable gastric cancer cannot be explained. It is hard 
for people to live with such events of vital importance that cannot 
be explained. So, retrospective denial of the diagnosis makes sense, 
because it explains the inexplicable: it is better to have an improb-
able explanation than no explanation at all.
Drs. Siemerink: What can we learn from this case? The reaction of the 
patient resulted in premature loss of contact with the patient. We 
realized too late that the good news was difficult to cope with.
Dr. Jaspers: Indeed, the first lesson to learn from this case is that 
good news may be as difficult to cope with as bad news. To realize 
this and to speak with the patient about this unexpected progress 
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Dialogue between Drs. Siemerink (junior Medical Oncologist), 
Dr. Jaspers (Psychologist) and Professor Mulder (senior Medical 
Oncologist) regarding the case:
Drs. Siemerink: Professor Mulder, how often did you observe unexpected 
prolonged survival among patients with advanced disease? And was 
there in your opinion a common reaction in your patients to that 
situation? 
Professor Mulder: There are various levels of unexpected survival, 
most often reported in the context of some form of alternative 
medicine. In a review in our country some 400 reports of that kind 
were analyzed and only 2 could be accepted as undoubtful. If we 
give a prognosis of 8-12 months for a patient as described here we 
would expect an occasional patient to live for 2 years, some patients 
with breast cancer may survive for decades with metastatic disease. 
However for a patient treated in a palliative context to be cured, as 
in this situation, I can remember three in a period of some thirty 
years, all of them were extremely grateful, if not to me at least to 
their good fortune. 
Professor Mulder: Dr. Jaspers, the reaction of our patient to survival, 
retrospective denial of the diagnosis of cancer, came as a complete 
surprise for the medical team. Is this reaction common in cancer 
patients?
Dr. Jaspers: Denial in cancer patients is a well recognized phenomenon 
in clinical practice, especially denial of diagnosis. However, it mostly 
takes place early in the process of diagnosis, and decreases over time. 
Sometimes it increases during the terminal phase. So, denial is a 
common reaction to bad news. What makes denial exceptionally in 
this case, is that it is a reaction to the good news of survival. Other 
causal attributions for this positive event could be 
expected. People normally attribute positive events to internal 
causes, in the case of cancer survival for instance to their fighting 
spirit or to their change of lifestyle. When a patient attributes his 
survival to his own behaviour or characteristics, there is no need to 
deny the fact that he had cancer.   
Drs. Siemerink: At first we did not understand the reaction of the 
patient who was very angry at us and was convinced that we had 
failed as doctors and caused much sorrow.
Dr. Jaspers: Indeed, at first sight it seems incomprehensible that a 
positive progress of the disease made the patient react this way. But 
from the point of view of the patient, if it would be true that cancer 
had never been there the emotions can be understood. The patient 
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answer, the psychologist can explain that it is our human nature to 
attribute causes to all important events that we experience, also the 
events that perhaps are inexplicable. So, it may be difficult to realize 
that certainty about the cause of progress of the patient’s disease 
cannot be found. But, if the patient is already convinced that the 
doctor was wrong in his diagnosis, I think it would be wise to 
respect this opinion, given the psychological function that we 
discussed before. This does not mean the psychologist has to agree 
with the patient: he can state that – just like the medical team – he 
cannot give an explanation for this unexpected development. What 
the psychologist can do for the patient is to sort out how to adapt to 
this new situation, prevent obsessive preoccupation and rumination, 
and how to get on with life, leaving this stressful period of illness 
behind. When the patient succeeds in this respect, the urgency to 
blame the physicians for the alleged faults they made will be less, 
and the conclusion that the patient was very lucky in the end can be 
acceptable.
Drs. Siemerink: Finally a question that, perhaps, cannot be answered: 
should this extraordinary case change the information we give an 
incurable patient or if there is no statistical hope should we still 
provide it?
Dr. Jaspers: In the last decades there has been a major change in 
the way we talk about cancer and in our view how to inform the 
patient. Although the patient has the (legal) right to be informed 
fully, sometimes the truth and nothing but the truth can be too 
much to handle for the patient. Appraisal of the state of mind of the 
patient can be difficult and to bring the bad news of approaching 
death remains a demanding clinical task, but in general the informa-
tion available should be given. Timing, choosing the right words and 
opportunity are important in telling the unwelcome truth, but this 
truth gives the patient and his beloved ones the opportunity to deal 
with it. So, when there is no (statistical) hope, no false hope should 
be given. When the patient needs hope to endure his situation, he 
will find it anyway, holding the truth is not a good way to provide 
hope.
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and the possible confusing impact of it can be the first step. To share 
feelings with the patient over this positive, but unlikely development 
can give the physician the opportunity to consider whether psycho-
logical intervention is indicated. Doubts about the diagnosis can be 
discussed earlier by the patient when he feels he is free to do so 
without direct rejection of this possibility. I think, physicians should 
respect this opinion of the patient, bearing in mind that this attri-
bution has a psychological function. Direct attempts to refute this 
opinion only increases resistance to chance or reconsider this 
opinion and hinders to discuss other issues for example how to 
adapt to the fact that life is not over yet and the patient can plan for 
the future again. Perhaps, for some physicians the conviction of the 
patient that the diagnosis was wrong is a difficult one, because their 
expertise is called in question. Of course, the patient has the right to 
be informed about all aspects of his disease, but sometimes the truth 
of the medical team is not the truth of the patient.
Dr. Jaspers: how are you as a young oncologist trained in dealing 
with these difficult situations of providing information about the 
fatal course of a disease in general but also staying focused on the 
individual patient?
Drs. Siemerink: In our traineeship much attention is paid to commu-
nication of bad news and the different ways a patient can react to 
this news at diagnosis, for example by patient simulation and 
watching video’s. However this specific situation of sustained denial 
was not something I was prepared for.
Professor Mulder: If we had recognized the problem earlier, and had 
consulted a psychologist, would he have tried to reverse this process? 
In other words, given that the patient has reached some form of 
equilibrium, can we consider this to be a satisfactory situation? Not 
quite unconnected is the question if it is likely that at some time the 
patient will realize that cancer indeed had occurred.
Dr. Jaspers: I don’t think the reason for consulting a psychologist 
should be to convince the patient of the correctness of the diagnosis 
of cancer, but to explore with the patient what contrary to all ex-
pectations, this unexpected survival means for the patient. I think it 
is important for the patient to express (mixed) emotions and to talk 
about the reactions to this confusing course of the disease. Undoub-
tedly, in talking about the situation the question will arise: ‘How can 
this be?’ It is hard to speculate whether this patient would have 
considered other answers than the conviction that cancer never had 
occurred, but I suppose that earlier in the process this idea is still 
more open for discussion. When the patient is still looking for an 










Hartgerink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. 
Lancet 2009;374:477-490. 
Helicobacter and cancer Collaborative Group. Gastric cancer and Helico-
bacter pylori: a combined analysis of 12 case control studies nested within 
prospective cohorts. Gut 2001;49:347-353.
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy 
in advanced gastric cancer: a systematic review and meta-analysis based on 
aggregate data. J Clin Oncol 2006;24:2903-9.
Vos MS, de Haes JC. Denial in cancer patients, an explorative review. 
Psychooncology 2007;16:12-25.
Rabinowitz T, Peirson R. “Nothing is wrong, doctor”: understanding and 
managing denial in patients with cancer. Cancer Invest 2006;24:68-76.
Sharf BF, Stelljes LA, Gordon HS. ‘A little bitty spot and I’m a big man’: 
patients’ perspectives on refusing diagnosis or treatment for lung cancer. 
Psychooncology 2005;14:636-46.
Heim E, Augustiny KF, Schaffner L, Valach L. Coping with breast cancer over 
time and situation. J Psychosom Res 1993;37:523-42.
Zoellner T, Maercker A. Posttraumatic growth in clinical psychology – 
A critical review and introduction of a two component model. Clinical 
Psychology Review 2006;26:626-53.
Chapter 7a Retrospective denial as a coping method
134
Chapter 8
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gastric cancer
Ester J.M. Siemerinka, Annemieke F.J. Drenthb, Nanno H. Muldera,  
John T.M. Plukkerb, Geke A.P. Hospersa,
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Medical Center Groningen and University of Groningen, Groningen, the Netherlands 
3 patients. No hand-foot syndrome (hfs) occurred. 
Conclusions Oxaliplatin is an effective drug in 
gastric cancer, but, as previously reported, its 
feasibility in combination with capecitabine is ham-
pered due to combined hand-foot-based toxicity. 
The present phase II study of a combination of 
oxaliplatin with uft and leucovorin appears to have 
efficacy and tolerability comparable to other two 
drug regimens used in gastric cancer, without the 
hfs problem.
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Abstract
Background The present study evaluated the 
efficacy and safety of oxaliplatin, uft, and 
leucovorin in metastatic gastric cancer. 
Methods Patients received intravenous oxaliplatin 
130 mg/m2 on day 1, followed by oral uft capsules 
(350 mg/m2 per day) and leucovorin tablets (90 mg/
day), every 8 h, for 14 days, in a 3-week cycle.
Results Twenty-three patients (61% with ≥ 2 meta-
static sites), median age of 60 years (range, 36-69 
years) were entered. Based on intention-to-treat 
analysis, one complete response and seven partial 
responses were found, resulting in an overall 
response rate (rr) of 35% (95% confidence interval 
(ci), 16-54), a median time to progression of 4 
months (95% ci, 0.5-7.5) and a median overall 
survival (os) of 8 months (95% ci, 4.5-11.5). The 1-year 
survival rate was 26%. Three patients did 
not complete the first course of 2 weeks; 1 died 
suddenly on day 16 with fatal lung embolism, 1 had 
rapid progressive disease and 1 experienced gastric 
haemorrhage on day 15 - both these patients with-
drew. In the 20 patients assessable for toxicity no 
grade 4 toxicity occurred, grade 3 toxicity consisted 
of anaemia in 1, diarrhoea in 2 and neurotoxicity in 
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gastric cancer. In comparison with cisplatin it has a more favourable 
toxicity profile, with substantially lower rates of myelosuppression, 
nefrotoxicity and ototoxicity, but with at least equivalent activity21-24. 
The duration of intravenous hydration required with cisplatin use is 
not required for oxaliplatin, hereby facilitating outpatient administra-
tion. In combination with other chemotherapeutic agents, the uft/
lv schedules that are often used are uft doses of 300-400 mg/m2/d, 
and lv doses of 25-500 mg, for 1-14 treatment days per 21 days or 1-28 
treatment days per 35 days11. In combination with a fluoropyrimidine, 
oxaliplatin is given in a 2- or 3-weekly schedule with an intravenous 
(i.v.) dose of respectively, 85 and 130 mg/m2 25-27. 
Based on these promising data of two different active agents with 
little overlap in terms of key side effects, we conducted a phase II 
study with oxaliplatin (130 mg/m2 on day 1), uft capsules (350 mg/m2 
day), lv tablets (90 mg/day), every 8 h, for 14 days, in a 3-week cycle 
in patients with metastatic gastric cancer, in an outpatient setting, 




Between February 2004 and September 2008, patients with histologi-
cally confirmed metastatic gastric cancer with at least one measur-
able lesion according to the response evaluation criteria in solid 
tumours (recist) criteria were considered to be eligible in this open, 
non-comparative phase II study.
All patients were age > 18 years with an ambulatory performance 
status of 0-1 on the Eastern Cooperative Oncology Group (ecog) scale 
and a life expectancy of more than 3 months. Laboratory accept-
ance parameters included adequate haematological (white blood 
cell count 4.0 x 109/L), hepatic (serum bilirubin < 1,5 x upper limit of 
normal), and renal (calculated creatinine clearance of > 50 ml/ min) 
function. Exclusion criteria consisted of: bone metastasis or effusions 
as only manifestation of disease; clinical signs of brain metastasis; 
concurrent radiation therapy or previous chemotherapy; previous 
or current malignancies at other sites; evidence of serious active 
infections; severe cardiac and/or pulmonary failure, and pregnant or 
lactating women. 
The study was approved by the ethics review board of our hospital 
(metc 2004.016) and carried out in accordance with the Declaration 
of Helsinki principles. Written informed consent was obtained from 
all patients with a 7-day interval after thorough information had 
been given about the study.
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Introduction
Gastric cancer is the world’s second leading cause of cancer related 
death. Unfortunately, most patients present with an advanced stage 
of disease, with a dismal outcome. Even after apparently curative 
resections, local recurrences or distant metastasis occur in up to 60% 
of the patients1,2. 
In this palliative situation patients do benefit from combination 
chemotherapy compared to best supportive care, as it shows modest 
survival benefit, with improvement of quality of life3-6. 5-Fluorour-
acil (5-fu) is still one of the main chemotherapeutic agents used in 
advanced gastric cancer with a response rate (rr) as mono-agent of 
21% and a median survival of 6-7 months, while at the same time epi-
rubicin, cisplatin and 5-fu (ecf) is the most widely used combination 
regimen. With an overall rr of ecf of 40-45% and a median survival 
around 8-10 months it is considered a reference regimen especially 
in Europe2,7-10. In the context of quality of life, the observed toxicity, 
prolonged hospital time due cisplatin infusion and risks of central 
venous access devices and ambulatory infusion pumps, the use of the 
combination regimes instead of mono chemotherapy is debatable. 
There is a need for an effective chemotherapy combination which is 
less toxic and can be easily administrated in an outpatient setting. In 
order to improve convenience and tolerability three oral fluoropyri-
midines have been developed11,12. One of them is uft, a combination 
of Tegafur, an oral prodrug of 5-fu which is slowly metabolized in 
the liver into the active drug 5-fu and Uracil, a competitive antago-
nist for dihydropyrimidine dehydrogenase (dpd), in a 1:4 M ratio. 
Uracil inhibits degradation of 5-fu because it competes with 5-fu for 
dpd, leading to higher intra-tumoural 5-fu levels. This combination 
drug has a rr of about 16-57 % and an median overall survival (os) of 
5.8 to 15 months and is less toxic as far as myelosuppression, stoma-
titis, diarrhoea, and Hand-foot syndrome (hfs) are concerned11-16. 
Clinical studies in metastatic colon cancer have shown that uft has 
a comparable efficacy profile compared to intravenous bolus admin-
istration of 5-fu17,18. Capecitabine, the oral fluoropyrimidine most 
often used worldwide, has a toxicity and efficacy profile similar to 
uft, except that hfs, which is rarely observed in uft, occurs in more 
than half of all patients treated with capecitabine19,20. The third 
oral fluoropyrimidine S-1 has not been registered in Europe, and is 
licensed in Korea and Japan11.
Oxaliplatin is a third generation platinum derivative, which inhibits 
replication and transcription by formation of dna adducts. It has 
shown anti-tumour activity as a mono-therapy or in combination 
with 5-fu and leucovorin (lv) in various solid tumours, including 
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Figure 1.
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Pre-treatment evaluation
Pre study assessment consisted of full medical history, vital signs and 
physical examination. Further investigations included haematological 
and blood chemistry testing, electrocardiogram, chest X-ray and a 
computed tomography (ct) scan of the abdomen.   
Treatment schedule 
Oxaliplatin (130 mg/m2) was administrated by a 2 h i.v. infusion 
on day 1 followed by oral uft capsules (350 mg/m2 per day) and lv 
tablets (90 mg/day) taken simultaneously every 8 h from the evening 
of day 1 to the morning of day 15, followed by a 7-day treatment free 
interval in a 3-week cycle. After two and four cycles, patients with 
a tumour response or stable disease continued on chemotherapy, 
receiving a maximum of 6 cycles.
Dose modifications
In patients with non haematological toxicity of grade 2 or greater, 
treatment was postponed until toxicity resolved to grade 1 or less; 
the next uft dose was reduced by 25% in patients with grade 3-4 
toxicity. With haematological toxicity of grade 2 or greater, treat-
ment was withheld until the white blood cell count was 3.0 x 109/L 
or greater and the platelet count was 100 x 109/L or greater. The 
oxaliplatin dose was reduced by 25% in case of persistent (≥14 days) 
paresthesia or temporary painful paresthesia or functional impair-
ment. Treatment was discontinued in case of grade 4 non haema-
tological toxicity or non-recovery of persistent paresthesia, and in 
those with non haematological toxicity of grade 1 or greater despite 
a 2-week delay.
Treatment response and toxicity
Tumour response was evaluated on a ct-scan after cycles 2 and 4, 
and after the treatment was finished. The tumour responses were 
classified according to the recist. All patients were examined on days 
1 and 15 of each cycle for vital signs, including physical examination, 
ecog performance status and complete blood counts and biochemi-
cal tests. Toxicity was evaluated according to the National Cancer 
Institute Common Toxicity Criteria (nci ctc), version 2.0.
Statistical analyses 
For the determination of the number of patients required in a pre-
liminary and follow-up trial of a new chemotherapeutic agent, the 
Gehan’s two-stage design was used28. We expected a response rate 
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Toxicity
The patients received a total number of 86 cycles (median, 3.5 cycles; 
range, 1-6). Nine patients received the maximum of 6 cycles. The 
most common reported toxicity was oxaliplatin-related sensory 
neuropathy, in 11 patients. Usually this was mild and reversible, with 
a need for dose reduction of oxaliplatin in only 3 patients. Other non 
haematological toxicity consisted of diarrhoea in 6 patients (2 with 
grade 3 toxicity), grade 1/2 nausea in 7 patients, and grade 1 weight 
loss in 5 patients. Haematological toxicity observed were grade 2 
anaemia in 1 patient and grade 2 thrombocytopenia in 8 patients, 
and grade 3 anaemia in 1 patient. No grade 4 haematological or non-
haematological toxicity was reported (Table 1). Eventually, treatment-
related reasons for discontinuation were: persistent thrombopenia 
after 2 weeks of postponing the next cycle in 3 patients (after cycle 
3,4,5, respectively), grade 3 diarrhoea in 2 patients, with need for 
hospitalization and clinical worsening in 1 patient and recurrent diar-
rhoea after dose reduction in the previous cycle in the other patient. 
The gastric haemorrhage that occurred on day 15 might have been 
treatment-related. The fatal lung embolism that occurred in cycle 
one did not seem to be treatment-related.
Treatment was also discontinued due to clinical tumour progression 
in four patients, and due to tumour progression on ct-scan in three 
patients. After discontinuation because of prolonged thrombocytopenia, 
two patients continued off study on mono uft/lv. 
Discussion
There is currently no universal standard regimen for the treatment 
of advanced gastric cancer. Two drug regimens often consist of a 
cisplatin and fluorouracil combination. In a palliative situation this 
regimen is not very patient-friendly, as hospitalization is often re-
quired, as is the use of continuously intravenous infusion.
Compared with the overall rr in the literature, with ecf and epiru-
bicin, oxaliplatin, capecitabine (eox) regimens showing rr of 38-47% 
and a median survival around 8-11 months, the results of our study 
showing an overall rr of 35% and median os of 8.0 months, are simi-
lar but on the lower boundary2,7-10. This may be due to a relatively 
large number of patients showing early progression in our study 
who could not complete the first course. Our study also included 
patients with a relative high stage of advanced disease, as 61% of the 
patients had two or more metastatic sites, compared with 36-40% of 
the patients in the randomized ecf for advanced and locally advanced 
esophagogastric cancer 2 (real-2) study7. Based on the remaining
of 30% or greater. If no objective response was seen in the first 12 
patients, then the probability of a response rate of 30% or greater 
would be below 5% and no additional patients would be entered. If, 
in the first 12 patients more than four responses occurred, 8 addi-
tional patients were required for the evaluability of response. With a 
dropout frequency of 10%, 23 patients had to be included to estimate 
the 95% confidence interval (ci) for a true response rate with a maxi-
mum width of 38%.
Results
Patient Characteristics 
During the study period a total of 23 patients, 21 men and two 
women, with a median age of 60 years (range, 39-69) were enrolled. 
Eighty percent of these patients had a performance score up to 1 at 
the start of treatment. Most patients (21/23) had a metastatic disease 
at time of diagnosis, while 2 patients developed metastatic disease 
after surgical resection of the primary tumour. The most common 
metastatic sites were liver, lung, bone, or peritoneum (83% of the 
patients), while 17% of the patients had only lymph nodes metastasis. 
Two or more metastatic sites occurred in 61% of the patients.  At the 
evaluation in November 2009 all 23 patients had died.
Eff i cacy and survival
Twenty of 23 patients were assessable for toxicity, while the remain-
ing 3 did not complete the first course of 3 weeks. One patient died 
suddenly on day 16 with a clinical diagnosis of fatal lung embolism, 
and a second patient had rapid progression of pulmonary metastasis 
and withdrew. The third patient who still had his primary tumour in 
situ, experienced a gastric haemorrhage on day 15 and withdrew. 
All efficacy data are reported using the intention-to treat patient 
population.
The overall rr was 35% (95% ci,16-54); one patient had a complete 
remission, seven patients had a partial response, eight patients had 
stable disease and four patients had progressive disease. The median 
time to progression was 4 months (95% ci, 0.5-7.5) and the median 
os was 8 months (95% ci, 4.5-11.5); see Figs. 1 and 2. The 1-year sur-
vival rate was 26%. Three initially responding patients in this study 
received second-line chemotherapy. One patient progressed after 1.5 
year and was treated with irinotecan because of disease progression; 
however, this treatment was without an objective response. The two 
other patients progressed, after 6 and 8 months, respectively, and 
were treated with the oral fluoropyrimidine capecitabine; however, 
this treatment was also without an objective response. 
144
Phase II study of Oxaliplatin, UFT, and Leucovorin Chapter 8
147
evaluable 20 patients in the present study, our combination chemo-
therapy of oxaliplatin, uft, and lv showed an acceptable antitumor 
activity with an RR of 40% and a median os of 9 months, and could 
be safely administrated on an outpatient basis. 
Several phase II-III studies have already indicated that oxaliplatin-based 
doublets may represent an effective and well-tolerated treatment 
option, compared to cisplatin, for patients with advanced gastric 
cancer7,29-32. In a study by Cunningham, oxaliplatin, compared to 
cisplatin, showed significantly less grade 3/4 neutropenia, alopecia, 
and thromboembolism, with significantly more grade 3/4 diarrhoea 
and peripheral neuropathy. This prompted these authors to the 
conclusion that oxaliplatin could replace cisplatin7. The results of 
a study by Al-Batran et al. are consistent with the real-2 data that 
oxaliplatin is at least as effective as cisplatin in patients with advanced 
gastric cancer33. The results of these two studies are comparable 
regarding neurotoxicity with the generally mild and reversible neuro-
toxicity observed in our study; in which all patients with grade 3 
neurotoxicity could continue on treatment after dose reduction. As 
patients prefer oral to iv therapy provided that no more side effects 
occur and efficacy is not compromised, uft and lv are a logical 
alternative for intravenous 5-fu15. Different phase II studies have 
investigated the efficacy of uft with lv in combination with another 
agent11,34-36. These efficacy results are comparable with the rr of 
35% and confidence interval of 16-54% in our study. 
More often studies in patients with advanced gastric cancer use the 
oral fluoropyrimidine capecitabine. The real-2 data and the study of 
Okines et al. showed at least similar efficacy of intravenous fluorouracil 
and the oral fluoropyrimidine capecitabine7,37. The all-grade hfs was 
high in all groups (ecf 29.8%; epirubicin, cisplatin, capecitabine (ecx) 
45.9%; epirubicin, oxaliplatin, 5-fu (eof) 28.9%; eox 39.3%). Moreover 
in the patients receiving capecitabine with epirubicin and cisplatin, 
significantly more grade 3/4 hfs was observed (grade 3/4; 10.3%) than 
in the ecf group (grade 3/4; 4.3%)7. Another recently published phase 
II study also emphasized the problem of hfs, which occurred in 39% 
of the patient population receiving capecitabine and oxaliplatin32. 
The problem of hand-foot-based toxicity, interfering with quality of 
life in a palliative situation is disturbing. In our study, as in many 
other studies with uft-based combinations, patients hardly reported 
any hfs (< 0.01%). This observation forms the basis for replacing the 
oral fluoropyrimidine capecitabine by uft. The efficacies of two-drug 
combinations with uft are comparable with those of other capeci-
tabine-based regimens, with reported overall rrs of 35-49% and 
Table 1.
Toxicity
NCI-CTC grade  1 2 3 4
Hand foot syndrome	 -	 -	 -	 -
Neuropathy	 	 2	 6	 3	 -
Diarrhoea 	 1	 3	 2	 -
Nausea	 	 	 4	 3	 -	 -
Weight loss	 	 5	 -	 -	 -
Thrombocytopenia	 	 -	 8	 -	 -
Leukopenia	 	 1	 -	 -	 -
Anaemia			 	 1	 1	 1	 -																																							
ASAT	 	 	 2	 1	 -	 -
ALAT	 	 	 2	 3	 -	 -
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median os rates of 6 -11 months2,11,30,38.  
For the future new promising targeted biologic agents, often combined 
with chemotherapeutic drugs, are investigated.  Although biologic 
agents are seemingly less toxic, epidermal growth factor receptor 
(egfr) inhibitors can cause severe paronychia, and more commonly, 
acneiform rash39. Based on the toxicity profiles of uft and capecit-
abine, it seems to be more logical to combine uft with these new 
targeted biologicals. 
In conclusion, based on the real-2 data, oxaliplatin has an important 
place in the first-line treatment of advanced gastric cancer7. However, 
the use of oxaliplatin in combination with capecitabine has led to an 
increasing number of patients with hand-foot problems. Therefore, 
combining an uft/lv-based regimen with oxaliplatin in patients with 
advanced gastric cancer has the advantage of a good tolerability pro-
file, with no hfs, and the regimen can be easily administered in an 
outpatient setting. For future studies with the new targeted agents, 
a combination of such agents with uft would seem to be superior in 
dealing with the problem of hand-foot toxicity.
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more widely recognized environmental risk factors for gastric cancer, 
but also obesity and gastro oesophageal reflux are prevalent. The risk 
of developing gastric cancer is also increased in patient with low 
socioeconomic status (ses). In chapter 3 we described the influence 
of ses on survival of gastric cancer in the North East region of the 
Netherlands. ses proved to be an independent prognostic factor for 
survival, with a lower risk of dying of gastric cancer in the higher ses 
group. For the patients living in high ses neighbourhoods the resection 
rate was higher as was the administration rate of chemotherapy. 
Moreover in the low ses group patient’s diagnosis was established 
at older age. Nevertheless the statistical analysis showed neither type 
of treatment nor age, gender, histological grade, tumour localisation 
and stage alone were, as single factors responsible for the survival 
advantage. Obviously the interrelation of patient, tumour and 
treatment factors surprisingly was strong enough to level off the 
advantage of distal cancer prevailing in the low ses group, and the 
disadvantage of high grade tumours in the high ses group. 
The purpose of the Dutch health care system, financially based on an 
obligatory insurance coverage, is to provide high quality health care 
and make it available to all citizens. Still disparities in health care 
access and outcome can develop in groups that are isolated in some 
way; social, cultural, religious and or communicative. To monitor the 
equality or difference in the care system a disease like gastric cancer 
can serve as a surrogate marker, as outcome is highly dependent on 
early detection. In this thesis, in chapter 4, we analyzed survival of 
a group at risk of receiving suboptimal care; first generations non-
western immigrants in the North East region of the Netherlands. 
Surprisingly outcome of gastric cancer in this group was better 
compared to western immigrants and autochthonic patients, also 
after adjusting for confounding factors. This difference could not 
directly be explained, but we could conclude that accessibility of the 
health care system does not seem to be hampered for this group of 
immigrants. We hypothesized that possible favourable factors were 
the social cohesion within this group of immigrants and the typical 
Dutch professional network (“the arbodienst”).
Factors that are neither patient nor tumour related can also contrib-
ute to the outcome of curatively intended surgery in cancer patients. 
For example the influences of hospital volume and type as well as 
the surgical experience on the ultimate survival remain indetermi-
nate. In chapter 5 we reported data on outcome of gastric cancer 
in our region with regard to hospital characteristics. Between the 15 




Worldwide, gastric cancer is still the fifth most frequent cancer, and 
the second most frequent cause of cancer related death. The persis-
ting high fatality rate of this disease is an interplay of multiple factors, 
patient, tumour and treatment related. 
This thesis focussed on three issues regarding outcome of gastric 
cancer. Firstly, differences in patient characteristics which could lead 
to disparities in diagnosis, treatment and ultimately survival. 
Secondly, differences in hospital variables influencing outcome. Thirdly, 
two chapters were dedicated to the majority of patients, those with 
an advanced stage of disease, who can not be cured, and their treat-
ment options and restrictions.
In chapter 1 we presented an overview of the current perspectives 
on gastric cancer, regarding aetiology, diagnostic modalities and 
treatment options in curative and palliative setting. The risk of 
developing gastric cancer is considered an interaction between 
a bacterial risk factor as in Helicobacter Pylori next to host and 
environmental risk factors. 
A genetic predisposition for gastric cancer has been described in 
families with atrophic gastritis, hereditary nonpolyposis colorectal 
cancer or in families who fulfill the criteria of hereditary diffuse 
gastric cancer (hdgc). The lifetime risk of deve-loping gastric cancer 
within hdgc families, in patients with a cdh1 mutation is high and 
is estimated >80%. In chapter 2 we reported the geno-/phenotypical 
data of all, in total 10, Dutch families with cdh1 mutations. We 
observed a variable penetrance of gastric cancer between and within 
the Dutch families. Most carriers underwent prophylactic gastrectomy, 
revealing in most cases multiple foci of intramucosal carcinoma, with 
diffuse spread signet ring cells, that were not detected at screening. In 
cdh1 families females are also at risk of developing lobular breast 
cancer (lbc). The incidence of lbc was remarkable low in the Dutch 
families. As it is expected that due to prophylactic gastrectomy morta-
lity of gastric cancer can be prevented, the incidence of lbc probably 
will rise. Also because of the diff iculty to detect lbc with screening, 
we recommended discussing prophylactic mastectomy as an option 
with female cdh1 mutation carriers. Finally we observed a high 
incidence of cleft lip/palate, which supports the hypothesis that cdh1 
mutations are involved in the disturbed lip and palate closure. 
To establish the true impact of this observation further research 
is warranted in a larger patient cohort, in order to inform future 
parents from hdgc-families at genetic counselling.
High salt intake, smoking and Helicobacter Pylori infection are the 
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survival of two patients, of respectively 6 and 9 years after diagnosis. 
This could implicate that a subgroup of patients with a surgically 
incurable disease, not only will have palliative benefit, but may even find 
cure from chemotherapeutic interventions. In chapter 7a we presented 
a case history of a patient included in the celf study described above, 
which illustrated how doctors could misinterpreted the effect of 
such an unexpected event as possible cure on patients. Although the 
medical team assumed that the patient would be relieved by being 
an exceptional long-term survivor, the opposite occurred. The patient 
reacted with a rare type of denial, namely retrospective denial of the 
diagnosis. This conviction was in accordance with the unexpected 
outcome and probably served well to reduce anxiety and uncertainty 
about recurrence of cancer; a pre-dominant preoccupation in most 
survivors of cancer. Most physicians are trained in guiding patients 
on their way to approaching death. However we concluded from this 
case history that for patients both negative as positive unexpected 
developments, in this case prolonged survival culminating in likely 
cure, requires intensive efforts in adaptation of care. In chapter 8 we 
reported data of a more recent phase II study of a 3- weekly chemo-
therapy regimen with oxaliplatin, leucovorin and Tegafur/Uracil (uft) 
in a palliative setting. This two drug regimen showed a response rate 
of 35% (95% ci; 16-54%) and median overall survival of 8 months 
(95% ci; 4.5 – 11.5 months), which is comparable to other two drug 
regimens used in gastric cancer. The benefit of the current regimen 
however is the applicability in an outpatient setting with no hand 
foot syndrome problems, which develop in the majority of patients 
who are treated with capecitabine. For future studies with the 
new targeted agents, especially in the context of skin toxicity, a 
combination of such agents with uft therefore seems to be superior 
in dealing with the hand foot syndrome.
Summary Chapter 9
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centre we did not observed a role of teaching status or referral pattern 
on long term outcome. Within the small window of number of 
operations performed per year in our region no striking differences 
were found of hospital volume in relation to survival. In univariate 
analysis the 5-year relative survival of distal cancers seemed better 
in the academic hospital but this was not confirmed in multivariate 
analysis. This might be explained therefore by selection bias, because 
on average younger patients were operated on in the academic centre.
This issue of patient selection was highlighted in chapter 6, with the 
emphasis on the elderly population. In the next decade not only the 
number of octo- and nonagenarians with gastric cancer will rise, but 
this group will also be more heterogeneous with respect to frailty. 
Reluctance towards extensive surgery in this age group still is high 
although some single centre studies show a favourable outcome. In 
this thesis we described outcome in a population based study of 
gastric cancer in octo- and nonagenarians in the North East part of 
the Netherlands in order to support decisions with regard to surgery. 
Although long term relative survival after surgery was comparable to 
the general population, the postoperative mortality was too high. 
Especially in the group 85 years and older, where one in three patients 
died within two months after surgery. We concluded that better 
selection procedures are required and improved peri-operative care is 
needed in order to reduce surgery related mortality. 
As a consequence of better selection the group of octo- and nonage-
narians not fit for surgery will rise. Appropriate studies in a palliatieve 
setting open to patients of this age group are rare, but with respect 
to our data are highly recommended so that the increasing demand 
for patient tailored therapy in this particular age group can be fulfilled.
For the general population of patients with advanced gastric cancer 
many chemotherapeutic regimens have been explored but yet no 
standard treatment has evolved and prognosis is still grim. Various 
single- and combination chemotherapy regimens were tested in order 
to prolong survival, often at the expense of increased toxicity in case 
of combination therapy. We conducted a weekly dose escalation 
study of carboplatin, with epirubicin, leucovorin and 5-fluororouracil 
(celf) and filgrastim in 12 patients with surgically incurable gastric 
cancer, described in chapter 7. This regimen, in an outpatient setting, 
proved feasible with an acceptable toxicity, and a response rate of 58% 
(95 % Confidence Interval (ci); 31-85 %). We therefore concluded that 
this might be a suitable regimen for further study. We also recom-
mended performing late evaluations of studies, as our mature data 
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als optie ook te bespreken met cdh1 mutatie draagsters. Ten slotte 
vonden wij een hoge incidentie van gespleten lip/gehemelte, dat de 
hypothese dat cdh1 mutaties betrokken zijn bij verstoorde lip en 
gehemelte sluiting ondersteunt. Om de echte impact van deze ob-
servatie vast te stellen is verder onderzoek noodzakelijk in een groter 
patiënten cohort, om zo toekomstige ouders uit hdgc families raad te 
kunnen geven. Een hoog zoutgebruik, roken en een Helicobacter 
Pylori infectie zijn de meer algemeen erkende omgevingsrisicofactoren 
voor maagkanker, maar ook overgewicht en gastrooesophageale reflux 
komen veel voor. Het risico op het ontwikkelen van maagkanker is 
tevens verhoogd in patiënten met een lage socio-economische status 
(ses). In hoofdstuk 3 hebben we de invloed beschreven van ses op 
de overleving van maagkanker in de Noordoostelijke regio van 
Nederland. ses bleek een onafhankelijke prognostische factor voor 
overleving, met een lager risico op sterfte ten gevolge van maagkanker 
in de hoge ses groep. Bij patiënten die leefden in een hoge ses buurt 
werden meer resecties uitgevoerd en werd vaker chemotherapie 
toegediend. Daarbij werd in de lage ses groep de diagnose op oudere 
leeftijd vastgesteld. Desondanks bleken bij statistische analyse noch 
soort behandeling danwel leeftijd, geslacht, histologische gradering, 
tumor lokalisatie en stadium alleen, als enkelvoudige factoren, verant-
woordelijk voor dit verschil in overleving. Duidelijk werd wel dat de 
onderlinge relatie tussen patiënt, tumor en behandeling factoren ver-
rassend genoeg voldoende sterk was om het voordeel te niet te doen 
van distale kankers voornamelijk voorkomend in de lage ses groep, 
en het nadeel van hooggradige tumoren in de hoge ses groep. 
Het doel van het Nederlandse gezondheidssysteem, financieel 
gebaseerd op een verplichte verzekeringsdekking, is om kwalitatief 
hoge medische zorg te verlenen en dit beschikbaar te maken voor 
alle inwoners. Echter verschillen in toegankelijkheid van medische 
zorg en de uitkomst hiervan kunnen ontstaan in groepen die op een 
of andere manier geïsoleerd zijn; sociaal, cultureel, religieus en/of 
communicatief. Om de gelijkheid danwel verschillen in het zorg-
systeem te monitoren kan maagkanker dienen als een surrogaat 
marker, aangezien de uitkomst erg afhankelijk is van vroege detectie. 
In dit proefschrift, in hoofdstuk 4, analyseerden wij de overleving 
van een risicogroep voor het ontvangen van suboptimale zorg; eerste 
generatie niet westerse immigranten in de Noordoostelijke regio van 
Nederland. De uitkomst van maagkanker in deze groep bleek verrassend 
beter in vergelijking met westerse immigranten en autochtone 
patiënten, ook na correctie voor verstorende variabelen. Dit verschil 
kon niet direct worden verklaard, echter we konden concluderen dat 
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Maagkanker is wereldwijd nog steeds de vijfde meest voorkomende 
vorm van kanker en de tweede meest voorkomende oorzaak van 
sterfte ten gevolge van kanker. De persisterende hoge sterfte ten 
gevolge van deze ziekte wordt veroorzaakt door multipele factoren; 
die aan patiënt, tumor en behandeling gerelateerd zijn. In dit proef-
schrift werd de aandacht gevestigd op drie aspecten in relatie tot 
de overleving van maagkanker. Ten eerste, verschillen in patiënten 
karakteristieken die verschillen in diagnose, behandeling en uiteindelijk 
overleving zouden kunnen veroorzaken. Ten tweede, verschillen in 
ziekenhuisvariabelen die de overleving kunnen beïnvloeden. Ten 
derde, werden 2 hoofdstukken gewijd aan de meerderheid van de 
patiënten, diegenen met een vergevorderd stadium, die niet meer 
kunnen genezen, en aan hun behandelopties en de beperkingen 
daarvan.
In hoofdstuk 1 presenteerden we een overzicht van de perspectieven 
voor maagkanker ten aanzien van etiologie, diagnostische modali-
teiten en behandelopties in curatieve en palliatieve setting. Het 
risico op het ontwikkelen van maagkanker wordt beschouwd als een 
interactie tussen een bacteriële risicofactor zoals Helicobacter Pylori 
en risico-factoren vanuit gastheer danwel omgeving. 
Een genetische predispositie voor maagkanker is beschreven in 
families met atrofische gastritis, hereditair nonpolyposis colorectale 
kanker of in families die voldoen aan de criteria van erfelijk diffuus 
maagkanker (hdgc). Het risico gedurende het leven op het ontwikkelen 
van maagkanker in hdgc families, in patiënten met een cdh1 mutatie 
is hoog en wordt geschat op >80%. 
In hoofdstuk 2 rapporteerden we de geno-/phenotypische data van 
alle 10 Nederlandse families met cdh1 mutaties. We observeerden 
een variabele penetrantie van maagkanker tussen en binnen de 
Nederlandse families. De meeste dragers ondergingen een profylactische 
maagresectie, waarbij in de meeste gevallen multipele foci van intra-
mucosaal carcinoom met diffuus verspreide zegelringcellen werden 
gezien, welke niet gedetecteerd waren bij screening. In families met 
cdh1 mutaties hebben vrouwen ook een verhoogd risico op het 
ontwikkelen van een lobulair mammacarcinoom (lbc). De incidentie 
van lbc was opmerkelijk laag in de Nederlandse families, in tegen-
stelling tot gegevens uit andere studies. Aangezien het de verwachting 
is dat door profylactische maagresecties de sterfte ten gevolge van 
maagkanker kan worden voorkomen, zal de incidentie van lbc waar-
schijnlijk toenemen. Mede gezien de moeilijkheid om lbc te detecteren 
bij screening adviseerden wij om een profylactische mastectomie 
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leeftijdscategorie includeren zijn zeldzaam. Op grond van onze data 
is het sterk aan te bevelen dit onderzoeksgebied uit te breiden, om te 
kunnen voldoen aan de toenemende behoefte van patiënt gerichte 
behandeling in deze specifieke leeftijdsgroep. 
Voor de algemene populatie van patiënten met een vergevorderd 
stadium van maagkanker zijn meerdere chemotherapeutische regiems 
onderzocht, maar tot op heden heeft dit niet geleid tot een standaard 
behandeling en de prognose is nog steeds somber. Verschillende 
enkele danwel combinatie chemotherapie regiems zijn getest met 
als doel de overleving te verbeteren, echter ten koste van toegenomen 
toxiciteit in het geval van combinatie therapie. Wij hebben een 
wekelijks dosis escalatie studie uitgevoerd van carboplatin met epiru-
bicine, leucovorine en 5-fluorouracil (celf) en filgrastim in 12 patiënten 
met chirurgisch incurabel maagkanker, beschreven in hoofdstuk 7. 
Dit regiem, in een poliklinische setting, bleek uitvoerbaar met een 
acceptabele toxiciteit, en een responsepercentage van 58% (95% be-
trouwbaarheidsinterval (ci); 31-85%). Wij concludeerden daarom dat 
dit wellicht een geschikt regiem was voor verder onderzoek. Tevens 
raadden we aan om late evaluaties van studies uit te voeren, aangezien 
onze mature data een interessante en niet verwachte lange termijn 
symptoomvrije overleving liet zien bij twee patiënten, respectievelijk 6 
en 9 jaar na diagnose. Dit zou kunnen betekenen dat een subgroep 
van patiënten met chirurgisch incurabele ziekte, niet alleen in 
palliatief opzicht voordeel heeft van chemotherapeutische interventies 
maar dat wellicht ook genezing haalbaar is. In hoofdstuk 7a presen-
teerden wij de ziektegeschiedenis van een patiënt die geïncludeerd 
was in de celf studie hierboven beschreven, welke illustreert hoe 
artsen het effect van een onverwachte gebeurtenis zoals mogelijk 
genezing voor een patiënt verkeerd konden interpreteren. Hoewel 
het medische team veronderstelde dat de patiënt opgelucht zou zijn 
door een uitzonderlijk lange overleving, gebeurde het omgekeerde. 
De patiënt reageerde met een vreemde vorm van ontkenning, namel-
ijk retrospectieve ontkenning van diagnose. Deze overtuiging was in 
overeenstemming met de onverwachte uitkomst en kon waarschijn-
lijk goed de angst reduceren en de onzekerheid over terugkeer van 
kanker; een overheersende gedachte bij de meeste overlevenden van 
kanker. De meeste artsen zijn getraind in het begeleiden van patiënten 
op hun weg naar de dood. Echter wij concludeerden van deze 
casus dat voor patiënten zowel negatieve als positieve onverwachte 
ontwikkelingen, in dit geval toegenomen overleving waarschijnlijk 
resulterend in genezing, intensieve aandacht vereist in aanpassing 
van zorg. In hoofdstuk 8 rapporteerden wij de data van een meer 
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de toegankelijkheid van het gezondheidssysteem voor deze groep 
van immigranten niet leek belemmerd. We hypothetiseerden dat de 
sociale cohesie binnen de groep van immigranten en het typische 
Nederlandse dienstverleningssysteem voor werkgevers en werknemers 
(“de arbodienst”) wellicht positieve bijdragende factoren waren.
Factoren die noch patiënt noch tumor gerelateerd zijn kunnen ook 
bijdragen aan de uitkomst van in opzet curatieve chirurgie bij kanker 
patiënten. 
Wat echter precies bijvoorbeeld de invloed van ziekenhuis volume en 
type en van de chirurgische ervaring op de uiteindelijke overleving is, 
is nog steeds niet geheel duidelijk. In hoofdstuk 5 rapporteerden wij 
de overlevingsdata van maagkanker in onze regio met betrekking tot 
ziekenhuis karakteristieken. Tussen de 15 niet opleidingsziekenhuizen, 
8 opleidingsziekenhuizen en het enige academische centrum vonden 
wij geen invloed van opleidingsstatus danwel verwijsgedrag op de 
lange termijn overleving. Binnen de geringe variatie in aantal 
operaties per jaar in onze regio werden geen opvallende verschillen 
gevonden van ziekenhuis volume in relatie tot overleving. In univariant 
analyse leek de 5-jaars relatieve overleving van distale kankers beter 
in het academische ziekenhuis, echter dit werd niet bevestigd in multi-
variant analyse. Dit werd daarom wellicht verklaard door selectie 
bias, omdat gemiddeld genomen jongere patiënten werden geopereerd 
in het academische centrum. 
Het onderwerp patiëntenselectie speelde een hoofdrol in hoofdstuk 6, 
waarbij de nadruk lag op de populatie ouderen. In het komend 
decennium stijgt niet alleen het aantal tachtig- en negentigjarigen 
met maagkanker, maar zal deze groep ook meer heterogeen zijn met 
betrekking tot frailty. Weerstand tegen uitgebreide operaties in deze 
leeftijdscategorie is nog steeds groot, hoewel sommige studies een 
gunstige overleving beschrijven. 
In dit proefschrift hebben wij de overleving onderzocht onder 
tachtig- en negentigjarigen met maagkanker in Noordoost Nederland 
met als doel besluitvorming ten aanzien van operaties te ondersteunen. 
Hoewel de lange termijn relatieve overleving na een operatie verge-
lijkbaar was met de algemene populatie was de postoperatieve 
sterfte te hoog. Dit was vooral het geval in de groep 85 jaar en ouder, 
waar een op de drie patiënten overleed binnen twee maanden na de 
operatie. Wij concludeerden dat betere selectie procedures en betere 
perioperatieve zorg nodig is om sterfte ten gevolge van chirurgie te 
reduceren. Ten gevolge van betere selectie zal het aantal tachtig- en 
negentigjarigen die niet geschikt zijn voor chirurgie toenemen. 
Geschikte studies in een palliatieve setting die patiënten uit deze 
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recente fase II studie van een 3 wekelijkse chemotherapie regiem 
met oxaliplatine, leucovorine en Tegafur/Uracil (uft) in een palliatieve 
setting. Dit twee drug regiem toonde een response rate van 35% 
(95% ci; 16-54%) en een mediane overall overleving van 8 maanden 
(95% ci; 4.5-11.5 maanden), welke vergelijkbaar zijn met andere twee 
drug regiems die gebruikt worden bij maagkanker. Het voordeel van 
het huidige regiem echter is de toepasbaarheid in een poliklinische 
setting zonder handvoet syndroom problemen, welke zich voordoen 
bij de meerderheid van de patiënten die behandeld worden met 
capecitabine. Voor toekomstige studies met de nieuwe doelgerichte 
middelen, vooral in de context van huidtoxiciteit, lijkt daarom een 
combinatie van zulke middelen met uft superieur om te kunnen 
omgaan met het handvoet syndroom.




reizend bestaan toch een promotietraject af te kunnen ronden, jullie 
betrokkenheid maakte mede dat Groningen voelt als een tweede 
thuis. De fellows; Sabine, Jan Willem en Janine, bedankt voor jullie 
praktische hulp en gezelligheid.
Lieve Gretha, Bianca, Sylvia en Gerry, zonder jullie hulp had ik infor-
matie niet zo accuraat verzameld en artikelen niet zo snel gesubmit, 
maar bovenal niet zo heerlijk kunnen kletsen over mijn prachtige 
zoon.
Als oncoloog kan je je vak alleen samen met anderen goed uitvoeren, 
dus overige collega’s, ook vanuit andere disciplines, het lab medische 
oncologie, personeel van D2 en dagcentrum, en de medewerkers van 
de poli, bedankt voor jullie bijdrage aan mijn werkplezier!
Op het moment dat je kiest voor een promotietraject, in de omstan-
digheid van je man en later je zoon op afstand, dan bereid je je voor 
op een pittige tijd. Dat de afgelopen jaren voorbij zijn gevlogen met 
heel veel vrolijke, gezellige maar ook ontroerende momenten komt 
door een geweldig netwerk van vrienden en familie. In het bijzonder 
wil ik graag een aantal mensen bedanken.
Lieve paranimfen, hier vandaag met jullie naast mij kan me niets 
gebeuren. Lieve Maaike, vriendinnen zijn we al sinds onze middelbare 
schooltijd. We deelden destijds soms klein nu soms groter verdriet, 
maar de hoofdtoon voert het genieten van het leven. Afstanden doen 
er niet toe, wij zijn altijd heel dichtbij elkaar. Lieve Monique, de on-
bevangenheid waarmee wij tweetjes destijds het Zuid-Afrika avontuur 
aangingen verbaast ons beide nog steeds. Dat ik zo’n soulmate eraan 
over zou houden, later ook nog collega-oncoloog, ervaar ik als een 
groot geschenk.
Lieve Cari, Jut, mijn pseudo-echtgenoot in het hoge noorden. Bedankt 
voor je vriendschap, je gezelligheid, je ontbijt op bed enige weken 
lang, en je dagelijkse versgeperste jus d’orange gedurende meer dan 
twee jaar. De basis voor een dierbare vriendschap is in Groningen 
gelegd!
Jaarclubgenoten, meiden van Danté. Jullie oprechte interesse in mijn 
werk en privé leven voelde als een enorme steun. De Duitse snelwe-
gen vlogen voorbij door de vele telefoongesprekken. Feestjes organ-
iseren en vieren, de afgelopen jaren heb ik het vaak moeten laten bij 
de jaarlijkse barbecue bij ons thuis, bedankt dat jullie mij desondanks 
steeds enthousiast welkom heetten als ik wel op een clubdate arriveerde. 
Lieve familie, wat fijn dat jullie hier vandaag zijn, wat verdrietig dat 
we sommigen moeten missen. 




Beste Nanno, ik heb het altijd als een voorrecht ervaren dat je mijn 
promotor wilde zijn. Tijdens onze gesprekken over het proefschrift 
leerde ik zowel veel van de door jou zorgvuldig gekozen woorden, 
als van de stiltes, hoe moeilijk dat ook soms was voor een praatgraag 
zoals ik. Zonder jouw hulp was dit proefschrift in dit tempo er niet 
gekomen, daar ben ik mij terdege van bewust. Bedankt voor de  ver-
heldering die je bracht tijdens de discussies, voor je geduld,  voor je 
hulp in de vorming van mij als doctor, bedankt ook voor je humor 
welke alles relativeerde.
Beste John, een chirurg als promotor gaf een extra dimensie aan het 
schrijven van dit proefschrift. Jouw passie voor je vak, je geloof in 
ons vakmanschap werkte enthousiastmerend. Je schouderklopje bij 
tijd en wijle gaf vertrouwen in een goede afronding van mijn proef-
schrift.
Lieve Geke, in jou herken ik veel van mijzelf; van de liefde voor je 
patiënt tot ons looptempo over de gang. Mede doordat jij altijd zo 
dicht bij jezelf blijft ben je voor mij de afgelopen jaren een grote 
steun geweest, als co-promotor, collega en mens. Bedankt hiervoor! 
Ik ga je de komende jaren nog vaak raadplegen voor je vakinhoudelijke- 
en mensenkennis.
Prof. H.J. Hoekstra, Prof. J.H. Kleibeuker, Prof. D.T. Sleijfer wil ik 
bedanken voor hun bereidheid plaats te nemen in de leescommisie. 
Beste Harold, Jan en Dirk bedankt voor de tijd die jullie vrij hebben 
gemaakt om mijn proefschrift te beoordelen.
Beste medeauteurs, jullie wil ik allemaal bedanken voor de prettige 
manier waarop ik met jullie heb samengewerkt. 
Rolf, bedankt dat jij mij hebt geïntroduceerd bij de Werkgroep erfe-
lijk maagkanker. Irma, onze zoektocht in de statussen van families 
met een cdh1 mutatie bracht naast veel informatie vooral ook veel 
gezelligheid. Het was erg fijn om een lief persoon zoals jij beter te 
leren kennen.
Mijn persoonlijke fusie tussen het oosten en het noorden van het 
land werd tijdens mijn promotietijd gevolgd door de fusie van het 
Integraal Kankercentrum Noord en Oost, de ultieme samensmelting. 
Michael, Maaike en Sabine, ontzettend bedankt voor de tijd die jullie 
geïnvesteerd hebben in het uitpluizen van de ikno database en het 
mij wegwijs maken in de wereld van de epidemiologie.
Mijn promotietraject had ik niet zo snel kunnen afronden zonder 
de steun van al mijn collega’s. Beste Liesbeth, bedankt dat jij mij 
dit hebt gegund. Lieve An, Annemiek, Carolien, Dirk, Jourik, Pax en 
Sjoukje, jullie collegialiteit maakte het mogelijk om ondanks een 
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kinderen en kleinkinderen is groot en voelt als een warm nest waar 
ik mij erg thuis voel. Dit boekje was er niet gekomen zonder de hulp 
die jullie John en mij hebben geboden de afgelopen jaren.
Lieve Tanja, voor altijd zusje, bedankt voor je rotsvaste vertrouwen in 
mijn kunnen. Bedankt ook voor het bij tijd en wijle mij weer vertellen 
waar het om draait in het leven!
Mam en Pap, jullie zijn de wortels van datgene wat mij in het leven 
drijft om te presteren, maar ook om te genieten. Jullie onvoorwaar-
delijke bereidheid om ons de afgelopen jaren te helpen maakte dat ik 
hier vandaag kan staan. 
Lieve Florian, wat kan jij genieten van het leven! Dit ondanks de soms 
onconventionele manier waarop dit plaatsvindt. Jouw komst is mijn 
mooiste cadeau. We genieten allemaal volop met je mee. Ik hoop dat 
dit geluk op je pad blijft komen.
Liefste John, zonder jou was niets van dit alles hierboven geschreven 
over genieten van het leven, passie in je werk & liefde zo intens 
en prachtig geweest. Wij wandelen op dezelfde weg, soms via 
ongebruikelijke zijwegen, maar altijd samen!
       
        Ester
